Deprecated: The each() function is deprecated. This message will be suppressed on further calls in /home/zhenxiangba/zhenxiangba.com/public_html/phproxy-improved-master/index.php on line 456
AU2002303078B2 - Aniline derivatives useful as phosphodiesterase 4 inhibitors - Google Patents
[go: Go Back, main page]

AU2002303078B2 - Aniline derivatives useful as phosphodiesterase 4 inhibitors - Google Patents

Aniline derivatives useful as phosphodiesterase 4 inhibitors Download PDF

Info

Publication number
AU2002303078B2
AU2002303078B2 AU2002303078A AU2002303078A AU2002303078B2 AU 2002303078 B2 AU2002303078 B2 AU 2002303078B2 AU 2002303078 A AU2002303078 A AU 2002303078A AU 2002303078 A AU2002303078 A AU 2002303078A AU 2002303078 B2 AU2002303078 B2 AU 2002303078B2
Authority
AU
Australia
Prior art keywords
pyridylmethyl
methoxy
cyclopentyloxy
diphenylamine
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2002303078A
Other versions
AU2002303078A1 (en
Inventor
William Frederick Brubaker Jr.
Michael De Vivo
Hans-Jurgen Ernst Hess
Allen Hopper
Ruiping Liu
Richard A. Schumacher
Ashok Tehim
Axel Unterbeck
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Memory Pharmaceuticals Corp
Original Assignee
Memory Pharmaceuticals Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Memory Pharmaceuticals Corp filed Critical Memory Pharmaceuticals Corp
Publication of AU2002303078A1 publication Critical patent/AU2002303078A1/en
Application granted granted Critical
Publication of AU2002303078B2 publication Critical patent/AU2002303078B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/73—Unsubstituted amino or imino radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/78—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
    • C07C217/80—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of non-condensed six-membered aromatic rings
    • C07C217/82—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of non-condensed six-membered aromatic rings of the same non-condensed six-membered aromatic ring
    • C07C217/84—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of non-condensed six-membered aromatic rings of the same non-condensed six-membered aromatic ring the oxygen atom of at least one of the etherified hydroxy groups being further bound to an acyclic carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/78—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
    • C07C217/80—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of non-condensed six-membered aromatic rings
    • C07C217/82—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of non-condensed six-membered aromatic rings of the same non-condensed six-membered aromatic ring
    • C07C217/88—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of non-condensed six-membered aromatic rings of the same non-condensed six-membered aromatic ring the oxygen atom of at least one of the etherified hydroxy groups being further bound to a carbon atom of a ring other than a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/78—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
    • C07C217/80—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of non-condensed six-membered aromatic rings
    • C07C217/82—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of non-condensed six-membered aromatic rings of the same non-condensed six-membered aromatic ring
    • C07C217/92—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of non-condensed six-membered aromatic rings of the same non-condensed six-membered aromatic ring the nitrogen atom of at least one of the amino groups being further bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/16—Radicals substituted by singly bound hetero atoms other than halogen by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/30—Hetero atoms other than halogen
    • C07D333/32—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/16—Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
  • AIDS & HIV (AREA)
  • Vascular Medicine (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)

Description

WO 02/074726 PCT/US02/01508 PHOSPHODIESTERASE 4 INHIBITORS This application claims benefit of U.S. Provisional application Serial No.
60/262,651, filed January 22, 2001, U.S. provisional application Serial No. 60/267,196, filed February 8, 2001, and U.S. Provisional application Serial No. 60/306,140, filed July 14, 2001.
FIELD OF THE INVENTION The present invention relates generally to the field ofphosphodiesterase 4 (PDE4) enzyme inhibition. More specifically this invention relates to selective PDE4 inhibition by novel compounds, N-substituted aniline and diphenylamine analogs, methods of preparing such compounds, compositions containing such compounds, and methods of use thereof.
BACKGROUND OF THE INVENTION The cyclic nucleotide specific phosphodiesterases (PDEs) represent a family of enzymes that catalyze the hydrolysis of various, cyclic nucleoside monophosphates (including cAMP and cGMP). These cyclic nucleotides act as second messengers within cells, and as messengers, carry impulses from cell surface receptors having bound various hormones and neurotransmitters. PDEs act to regulate the level of cyclic nucleotides within cells and maintain cyclic nucleotide homeostasis by degrading such cyclic mononucleotides resulting in termination of their messenger role.
PDE enzymes can be grouped into eleven families according to their specificity toward hydrolysis ofcAMP or cGMP, their sensitivity to regulation by calcium, calmodulin or cGMP, and their selective inhibition by various compounds. For example, PDE 1 is stimulated by Ca 2 /calmodulin. PDE 2 is cGMP-dependent, and is found in the heart and adrenals. PDE 3 is cGMP-dependent, and inhibition of this enzyme creates positive inotropic activity. PDE 4 is cAMP specific, and its inhibition causes airway relaxation, antiinflammatory and antidepressant activity. PDE 5 appears to be important WO 02/074726 PCT/US02/01508 in regulating cGMP content in vascular smooth muscle, and therefore PDE 5 inhibitors may have cardiovascular activity. Since the PDEs possess distinct biochemical properties, it is likely that they are subject to a variety of different forms of regulation.
PDE4 is distinguished by various kinetic properties including low Michaelis constant for cAMP and sensitivity to certain drugs. The PDE4 enzyme family consists of four genes, which produce 4 isoforms of the PDE4 enzyme designated PDE4A, PDE4B, PDE4C, and PDE4D [See: Wang et al., Expression, Purification, and Characterization of human cAMP-Specific Phosphodiesterase (PDE4) Subtypes A, B, C, and D, Biochem.
Biophys. Res. Comm., 234, 320-324 (1997)] In addition, various splice variants of each PDE4 isoform have been identified.
PDE4 isoenzymes are localized in the cytosol of cells and are unassociated with any known membranous structures. PDE4 isoenzymes specifically inactivate cAMP by catalyzing its hydrolysis to adenosine 5'-monophosphate (AMP). Regulation of cAMP activity is important in many biological processes, including inflammation and memory.
Inhibitors ofPDE4 isoenzymes such as rolipram, piclamilast, CDP-840 and ariflo are powerful antiinflammatory agents and therefore may be'useful in treating diseases where inflammation is problematic such as asthma or arthritis. Further, rolipram improves the cognitive performance of rats and mice in learning paradigms.
0/ rolipram piclamilast P \WPDCSMDTSpm)7R925153 d.3 I )7/2(00 -3- In addition to such compounds as rolipram, xanthine derivatives such as pentoxifylline, denbufylline, and theophylline inhibit PDE4 and have received considerable attention of late for their cognition enhancing effects. cAMP and cGMP are 00 second messengers that mediate cellular responses to many different hormones and 0neurotransmitters. Thus, therapeutically significant effects may result from PDE Sinhibition and the resulting increase in intracellular cAMP or cGMP in key cells, such as N those located in the nervous system and elsewhere in the body.
Rolipram, previously in development as an anti-depressant, selectively inhibits the PDE4 enzyme and has become a standard agent in the classification of PDE enzyme subtypes. Early work in the PDE4 field focused on depression and inflammation, and has subsequently been extended to include indications such as dementia. [see "The PDE IV Family Of Calcium-Phosphodiesterases Enzymes," John A. Lowe, III, et al., Drugs of the Future 1992, 17(9):799-807 for a general review). Further clinical developments of rolipram and other first-generation PDE4 inhibitors were terminated due to the side effect profile of these compounds. The primary side effect in primates is emesis, while the primary side effects in rodents are testicular degranulation, weakening of vascular smooth muscle, psychotrophic effects, increased gastric acid secretion and stomach erosion.
SUMMARY OF THE INVENTION The present invention relates to novel compounds, novel N-substituted aniline and diphenylamine compounds, that inhibit PDE4 enzymes, and especially have improved side effect profiles, are relatively non-emetic, as compared to the previously discussed prior art compounds). Preferably, the compounds selectively inhibit PDE4 enzymes. The compounds of this invention at the same time facilitate entry into cells, especially cells of the nervous system.
The present invention also relates to methods for synthesizing compounds with such activity and selectivity as well as methods of (and corresponding pharmaceutical compositions for) treating a patient, mammals, including humans, requiring PDE inhibition, especially PDE4 inhibition, for a disease state that involves elevated P XWPDOCS\MDT\Sp$\8255153 doM.IA)7I2(X17 -4intracellular PDE4 levels or decreased cAMP levels, involving neurological syndromes, especially those states associated with memory impairment, most especially long term memory impairment, as where such memory impairment is due in part to 0 catabolism of intracellular cAMP levels by PDE 4 enzymes, or where such memory impairment may be improved by effectively inhibiting PDE4 enzyme activity.
CIn a preferred aspect, the compounds of the invention improve such diseases by Sinhibiting PDE4 enzymes at doses which do not induce emesis.
In a first aspect, the present invention provides compounds of the Formula I: R1 O N R 3
R
2
R
4 wherein: R' is alkyl having 1 to 4 carbon atoms, which is branched or unbranched and which is unsubstituted or substituted one or more times by halogen CH 3
CHF
2
CF
3 etc.);
R
2 is alkyl having 1 to 12, preferably 1 to 8 carbon atoms, which is branched or unbranched and which is unsubstituted or substituted one or more times by halogen, hydroxy, cyano, Ci- 4 -alkoxy, oxo or combinations thereof, and wherein optionally one or more -CH 2
CH
2 groups are replaced in each case by -CH=CH or CH 3
CHF
2
CF
3 methoxyethyl, etc.), WO 02/074726 PCT/US02/01508 cycloalkyl having 3 to 10, preferably 3 to 8 carbon atoms, which is unsubstituted or substituted one or more times by halogen, hydroxy, oxo, cyano, alkyl having 1 to 4 carbon atoms, alkoxy having 1 to 4 carbon atoms, or combinations thereof cyclopentyl), cycloalkylalkyl having 4 to 16, preferably 4 to 12 carbon atoms, which is unsubstituted or substituted in the cycloalkyl portion and/or the alkyl portion one or more times by halogen, oxo, cyano, hydroxy, Ci- 4 -alkyl, C 4 -alkoxy or combinations thereof cyclopentylmethyl, cyclopropylmethyl, etc.), aryl having 6 to 14 carbon atoms, which is unsubstituted or substituted one or more times by halogen, CF3, OCF 3 alkyl, hydroxy, alkoxy, nitro, methylenedioxy, ethylenedioxy, cyano, or combinations thereof methylphenyl, methoxyphenyl, chlorophenyl, etc.), arylalkyl in which the aryl portion has 6 to 14 carbon atoms and the alkyl portion, which is branched or unbranched, has 1 to 5 carbon atoms, which the arylalkyl radical is unsubstituted or is substituted in the aryl portion one or more times by halogen, CF 3
OCF
3 alkyl, hydroxy, alkoxy, nitro, cyano, methylenedioxy, ethylenedioxy, or combinations thereof, and wherein in the alkyl portion one or more -CH 2
CH
2 groups are each optionally replaced by -CH=CH- or and one or more -CH 2 groups WO 02/074726 PCT/US02/01508 are each optionallyreplaced by or -NH- and/or the alkyl portion is optionally substituted by halogen, oxo, hydroxy, cyano, or combinations thereof phenylethyl, phenylpropyl, phenylbutyl, methoxyphenylethyl, methoxyphenylpropyl, chlorophenylethyl, chlorophenylpropyl, phenylethenyl, phenoxyethyl, phenoxybutyl, chlorophenoxyethyl, chlorophenylaminoethyl, etc.), a partially unsaturated carbocyclic group having 5 to 14 carbon atoms, which is unsubstituted or substituted one or more times by halogen, alkyl, alkoxy, hydroxy, nitro, cyano, oxo, or combinations thereof cyclohexenyl, cyclohexadienyl, indanyl, tetrahydronaphthenyl, etc.), a heterocyclic group, which is saturated, partially saturated or unsaturated, having 5 to 10 ring atoms in which at least 1 ring atom is a N, O or S atom, which is unsubstituted or substituted one or more times by halogen, hydroxy, aryl, alkyl, alkoxy, cyano, trifluoromethyl, nitro, oxo, or combinations thereof 3-thienyl, 3-tetrahydrofuranyl, 3-pyrrolyl, etc.), or a heterocycle-alkyl group, wherein the heterocyclic portion is saturated, partially saturated or unsaturated, and has 5 to 10 ring atoms in which at least 1 ring atom is a N, O or S atom, and the alkyl portion is branched or unbranched and has 1 to 5 carbon atoms, the heterocycle-alkyl group is P \WPDOCS\MDT'Spcs\78255153 doc-3 I)7/20i)7 0 -7unsubstituted or substituted one or more times in the heterocyclic portion Sby halogen, OCF 3 hydroxy, aryl, alkyl, alkoxy, cyano, trifluoromethyl, 00 nitro, oxo, or combinations thereof, wherein in the alkyl portion one or 0 more -CH 2
CH
2 groups are each optionally replaced by -CH=CH- or and one or more -CH 2 groups are each optionally replaced by -0or -NH- and/or the alkyl portion is optionally substituted by halogen, oxo, hydroxy, cyano, or combinations thereof pyridylethyl, pydridylpropyl, methylpiperazinylethyl, etc.); R is alkyl having 1 to 8, preferably 1 to 4 carbon atoms, which is branched or unbranched and which is unsubstituted or substituted one or more times with halogen, cyano, Ci- 4 -alkoxy, or combinations thereof methyl, ethyl, propyl, etc.), a partially unsaturated carbocycle-alkyl group wherein the carbocyclic portion has 5 to 14 carbon atoms and the alkyl portion which is branched or unbranched has 1 to 5 carbon atoms, and which is unsubstituted or substituted in the carbocyclic portion one or more times by halogen, alkyl, alkoxy, nitro, cyano, oxo, or combinations thereof, and the alkyl portion is optionally substituted by halogen, CI- 4 -alkoxy, cyano or combinations thereof cyclohexenylmethyl, etc.), arylalkyl having 7 to 19 carbon atoms, wherein the aryl portion has 6 to 14 carbon atoms and the alkyl portion, which is branched or unbranched, has 1 to 5 carbon atoms,-arylalkyl radical is unsubstituted or substituted, in the aryl portion, one or more times by halogen, trifluoromethyl, CF 3 0, nitro, P NWPDOCS\MDTSpe\7825Si 53 dm- I AfS/21)7 -8amino, alkyl, alkoxy, alkylamino, dialkylamino and/or substituted in the alkyl portion by halogen, cyano, or methyl benzyl, phenethyl, phenpropyl, methylbenzyl, methoxybenzyl, trfluoromethyl, benzyl, 00 methylenedioxobenzyl, etc.), or heteroarylalkyl group, wherein the heteroaryl portion has 5 to 10 ring atoms in which at least 1 ring atom is a N, 0 or S atom, the alkyl portion, which is branched or unbranched, has 1 to 5 carbon atoms, the heteroarylalkyl group is N 5 unsubstituted or substituted one or more times in the heteroaryl portion by halogen, alkyl, alkoxy, cyano, trifluoromethyl, CF 3 0, nitro, oxo, amino, alkylamino, dialkylamino, or combinations thereof and/or substituted in the alkyl portion by halogen, cyano, or methyl or combinations thereof pyridylmethyl, pyridylpropyl, methylpyridylmethyl, chioropyridylmethyl, dichloropyridylmethyl, thienylmethyl, thiazolylmethyl, quinolinylmethyl, isoquinolinylmethyl, prperidinylmethyl, furanylmethyl, imidazolylmethyl, methylimidazolylmethyl, pyrrolylmethyl, etc.); R' is aryl having 6 to 14 carbon atoms and which is unsubstituted or substituted one or Is more times by halogen, alkyl, alkenyl, alkynyl, hydroxy, alkoxy, alkoxyalkoxy, nitro, methylenedioxy, ethylenedioxy, trifluoromethyl, OCF 3 amino, aminoalkyl, aminoalkoxy, dialkylamino, hydroxyalkyl hydroxymethyl), hydroxamic acid, 2-(tetrahydropyranyl)-tetrazo I e-5-yl, hydroxyalkoxy, carboxy, alkoxycarbonyl tert-butyloxycarbonyl, ethoxycarbonyl), cyano, acyl, alkylthio, alkylsulfinyl, alkylsulfonyl, phenoxy, trialkylsilyloxy (eg. terbutyldimethylsilyloxy), R or combinations thereof substituted or unsubstituted phenyl, naphthyl, and biphenyl, such as phenyl, P MPDOCSW).D7Sp-,\7S235 I53 de.31U7/(X)7 -9methylphenyl,.chlorophenyl, fluorophenyl, vinyiphenyl, cyanophenyl, methylenedioxophenyl, ethyiphenyl, dichiorophenyl, carboxyphenyl, ethoxy carbonyiphenyl, dimethyiphenyl, hydroxymethyiphenyl, 00 nitrophenyl, aminophenyl, etc.), or heteroaryl having 5 to 10 ring atoms in which at least 1 ring atom is a hieteroatom, which is unsubstituted or substituted one or more times by halogen, alkyl, hydroxy, alkoxy, alkoxyalkoxy, nitro, methylenedioxy, ethylencdioxy, trifluoromethyl, amino, aminomethyl, arninoalkyl, aminoalkoxy dialkylamino, hydroxyalkyl hydroxymethyl), hydroxamic acid, tetrazole-5-yl, hydroxyalkoxy, carboxy, alkoxycarbonyl tert-butyloxycarbonyl, ethoxycarbonyl), cyano, acyl, alkylthio, alkylsulfinyl, alkylsulfonyl, phenoxy, trialkylsilyloxy (eg. tertbutyldimethylsilyloxy), or combinations thereof pyridyl, thienyl, pyrazinyl, quinolinyl, isoquinolinyl, pyrimidinyl, imidazolyl, thiazolyl, etc.); R' is H, alkyl having 1 to 8, preferably 1 to 4 carbon atoms, which is unsubstituted or substituted one or more times with halogen, C 1 4 -alkyl, CI- 4 -alkoxy, oxo, or combinations thereof methyl, ethyl, propyl, etc.), alkylamino or dialkylamino wherein each alkyl portion has independently I to 8, preferaby I to 4 carbon atoms dimethylamino, etc.), a partially unsaturated carbocycle-alkyl group wherein the carbocyclic portion has 5 to 14 carbon atoms and the alkyl portion has I to 5 carbon atoms, which is unsubstituted or substituted, preferably in the carbocyclic portion, one or more times by halogen, alkyl, alkoxy, nitro, cyano, oxo, or combinations thereof cyclohexenylmethyl, etc.), WO 02/074726 PCT/US02/01508 cycloalkyl having 3 to 10, preferably 3 to 8 carbon atoms, which is unsubstituted or substituted one or more times by halogen, hydroxy, oxo, cyano, alkoxy, alkyl having 1 to 4 carbon atoms, or combinations thereof cyclopentyl), cycloalkylalkyl having 4 to 16, preferably 4 to 12 carbon atoms, which is unsubstituted or substituted in the cycloalkyl portion and/or the alkyl portion one or more times by halogen, oxo, cyano, hydroxy, alkyl, alkoxy or combinations thereof cyclopentylmethyl, cyclopropylmethyl, etc.), aryl having 6 to 14 carbon atoms and which is unsubstituted or substituted one or more times by halogen, alkyl, hydroxy, alkoxy, alkoxyalkoxy, nitro, methylenedioxy, ethylenedioxy, trifluoromethyl, amino, aminomethyl, aminoalkyl, aminoalkoxy dialkylamino, hydroxyalkyl (eg., hydroxymethyl), hydroxamic acid, tetrazole-5-yl, hydroxyalkoxy, carboxy, alkoxycarbonyl tert-but'loxycarbonyl, ethoxycarbonyl), cyano, acyl, alkylthio, alkylsulfinyl, alkylsulfonyl, substituted or unsubstituted phenyl and naphthyl, methylphenyl, chlorophenyl, fluorophenyl, vinylphenyl, cyanophenyl, methylenedioxophenyl, ethylphenyl, dichlorophenyl, carboxyphenyl, ethoxycarbonylphenyl, dimethylphenyl, hydroxymethylphenyl, nitrophenyl, aminophenyl, etc.), arylalkyl having 7 to 19 carbon atoms, wherein the aryl portion has 6 to 14 carbon atoms and the alkyl portion, which is branched or unbranched, has 1 to 5 carbon atoms, arylalkyl radical is unsubstituted or substituted, in the aryl portion, one or more times by halogen, trifluoromethyl, CF30, nitro, amino, alkyl, alkoxy, amino, alkylamino, dialkylamino and/or substituted in the alkyl portion by halogen, cyano, or methyl benzyl, phenethyl, WO 02/074726 PCT/US02/01508 phenpropyl, methylbenzyl, methoxybenzyl, trfluoromethyl, benzyl, methylenedioxobenzyl, etc.), a heterocyclic group, which is saturated, partially saturated or unsaturated, having 5 to 10 ring atoms in which at least 1 ring atom is a N, O or S atom, which is unsubstituted or substituted one or more times by halogen, alkyl, hydroxy, alkoxy, alkoxyalkoxy, nitro, methylenedioxy, ethylenedioxy, trifluoromethyl, amino, aminomethyl, aminoalkyl, aminoalkoxy dialkylamino, hydroxyalkyl hydroxymethyl), hydroxamic acid, tetrazole-5-yl, hydroxyalkoxy, carboxy, alkoxycarbonyl tert-butyloxycarbonyl, ethoxycarbonyl), cyano, acyl, alkylthio, alkylsulfinyl, alkylsulfonyl, phenoxy, or combinations thereof pyridyl, thienyl, pyrazinyl, quinolinyl, isoquinolinyl, pyrimidinyl, imidazolyl, thiazolyl, etc.), or a heterocycle-alkyl group, wherein the heterocyclic portion is saturated, partially saturated or unsaturated, and has 5 to 10 ring atoms in which at least 1 ring atom is a N, O or S atom, ahd the alkyl portion which is branched or unbranched and has 1 to 5 carbon atoms, the heterocycle-alkyl group is unsubstituted or substituted one or more times in the heterocyclic portion by halogen, alkyl, alkoxy, cyano, trifluoromethyl, CF 3 0, nitro, oxo, amino, alkylamino, dialkylamino, or combinations thereof and/or substituted in the alkyl portion by halogen, cyano, or methyl or combinations thereof pyridylmethyl, pyridylpropyl, methylpridylmethyl, etc.); L is a single bond or a divalent aliphatic radical having 1 to 8 carbon atoms wherein one or more -CH 2 groups are each optionally replaced by -NR6-, -SO2NH-, -NHSO2-, -NR6CO-, -CONR6-, -NHCONH-, -OCONH, -NHCOO-, -SCONH-, -SCSNH-, or -NHCSNH-
CH
2 -CO-NH-, -NH-CO-, -CH 2
CH
2
CH
2
-NH-
P \WPDOCS\MDTSpc \78255153 doc-3 A1)7/2O)7 S-12- CO-, -CH 2
-CH
2 -S0 2
-NH-CH
2
CH
2
-O-CH
2
CH
2
-CH
2 -NH-CO-, -CO-
NH-CH
2 -S0 2
-CH
2
-NHSO
2
CH
2
CH
2
CH
2 -S0 2 etc.); and
R
6 is H, 00 O alkyl having 1 to 8, preferably 1 to 4 carbon atoms, which is branched or ¢c€ 0 5 unbranched and which is unsubstituted or substituted one or more times with halogen, Ci- 6 C 4 -alkyl, Ci- 4 -alkoxy, oxo, or combinations thereof methyl, ethyl, propyl, etc.); and pharmaceutically acceptable salts thereof, wherein if the compound exhibits chirality it can be in the form of a mixture of enantiomers such as a racemate or a mixture of diastereomers, or can be in the form of a io single enantiomer or a single diastereomer.
In an embodiment of the first aspect, there is provided a genus of compounds according to the formulas II and III: R/OI R 3 O -NH O NR R I
R
2 14 RH R R R wherein R 2
R
3 and R 4 are as defined above. The compounds of this subgenus is of formula I not only have PDE4 inhibitory activity, but also are useful as intermediates for preparing compounds of Formula I in which R 3 and R 4 are both other than H.
In addition, preferred compounds of formula I are those of the subformula IV R /OIV
R
2 4 1 R R wherein R 2 and R 4 are as defined in Formula I and one of A, B and D is N and P \WPDOCS\MDT1Spec\7X25) 13 d -3 )7/2(1117 0 -13the others are C. Preferably, B is N. Also, R 4 is preferably pyridyl or phenyl which in each case is substituted or unsubstituted.
In a second aspect the present invention provides compounds of the Formula I': 00
R'
X L O R 2' iN
R
wherein
R
1 is methoxy, F, Cl, CHF 2 or CF 3
R
2 is alkyl having 1 to 12 carbon atoms, alkyl having 1 to 12 carbon atoms which is substituted one or more times by to halogen, oxo, cyano, or combinations thereof, alkenyl having 2 to 12 carbon atoms, alkenyl having 2 to 12 carbon atoms which is substituted one or more times by halogen, oxo, cyano or combinations thereof, alkynyl having 2 to 12 carbon atoms, alkynyl having 2 to 12 carbon atoms which is substituted one or more times by halogen, oxo, cyano or combinations thereof, cycloalkyl having 3 to 10 carbon atoms, WO 02/074726 PCT/US02/01508 cycloalkyl having 3 to 10 carbon atoms substituted one or more times by halogen, oxo, alkyl, or combinations thereof, cycloalkylalkyl having 4 to 12 carbon atoms, cycloalkylalkyl having 4 to 12 carbon atoms which is substituted one or more times by halogen, oxo, alkyl or combinations thereof, a partially unsaturated carbocyclic group having 5 to 14 carbon atoms, a partially unsaturated carbocyclic group having 5 to 14 carbon atoms which is substituted one or more times by halogen, alkyl, alkyloxy, nitro, cyano, oxo, or combinations thereof, arylalkyl having 7 to 26 carbon atoms arylalkyl having 7 to 26 carbon atoms which is substituted one or more times by halogen, alkyl, alkoxy, nitro, cyano, oxo, trifluoromethyl, or combinations thereof, heteroarylalkyl having 5 to 10 ring atoms in which at least 1 ring atom is a heteroatom, or substituted heteroarylalkyl having 5 to 10 ring atoms in which at least 1 ring atom is a heteroatom and which is substituted one or more times in the heteroaryl portion by halogen, aryl, alkyl, alkoxy, cyano, trifluoromethyl, nitro, amino, alkylamino, dialkylamino or combinations thereof and/or substituted in the alkyl portion by halogen, oxo, cyano, or combinations thereof; P \WPDOCS\MD1Spe\782551I53 doc-31l7/207 X is O orS; oO R is aryl having 6 to 14 carbon atoms, 00 aryl having 6 to 14 carbon atoms which is substituted one or more times by halogen, alkyl, hydroxy, alkoxy, nitro, methylenedioxy, ethylenedioxy, amino, alkylamino, dialkylamino, hydroxyalkyl, hydroxyalkoxy, carboxy, cyano, acyl, alkoxycarbonyl, alkylthio, alkylsulfinyl, alkylsulfonyl, phenoxy, heteroaryl which is unsubstituted or substituted by halogen, alkyl or alkoxy, or combinations thereof, heteroaryl having 5 to 10 ring atoms in which at least 1 ring atom is a heteroatom, or substituted heteroaryl having 5 to 10 ring atoms in which at least I ring atom is a heteroatom which is substituted one or more times by halogen, aryl, alkyl, alkoxy, cyano, trifluoromethyl, nitro, oxo, amino, alkylamino, dialkylamino or combinations thereof;, L is -NR 4 -NR4'CH 2 or -CH 2 NR4'-; and
R
4 is alkyl having 1 to 12 carbon atoms, alkyl having 1 to 12 carbon atoms which is substituted one or more times by halogen, oxo, cyano, or combinations thereof, aryl having 6 to 14 carbon atoms and which is unsubstituted or substituted one or more times by halogen, alkyl, hydroxy, alkoxy, nitro, methylenedioxy, ethylenedioxy, amino, alkylamino, dialkylamino, hydroxyalkyl, hydroxyalkoxy, carboxy, cyano, acyl, alkoxycarbonyl, alkylthio, alkylsulfinyl, alkylsulfonyl, phenoxy or combinations thereof, P \WPDOCS\MDTSpccs\71255 153 doc-3117/21)7 S-16- 0 heteroaryl having 5 to 10 ring atoms in which at least 1 ring atom is a heteroatom, substituted heteroaryl having 5 to 10 ring atoms in which at least 1 ring atom is a Sheteroatom and which is substituted one or more times by halogen, aryl, alkyl, alkoxy, cyano, trifluoromethyl, nitro, oxo, amino, alkylamino, dialkylamino or combinations 00 5 thereof, arylalkyl having 7 to 16 carbon atoms, arylalkyl having 7 to 16 carbon atoms which is substituted one or more times by halogen, alkyl, alkoxy, nitro, cyano, oxo, trifluoromethyl, or combinations thereof, heteroarylalkyl having 5 to 10 ring atoms in which at least 1 ring atom is a heteroatom, or substituted heteroarylalkyl having 5 to 10 ring atoms in which at least 1 ring atom is a heteroatom and which is substituted one or more times in the heteroaryl portion by halogen, aryl, alkyl, alkoxy, cyano, trifluoromethyl, nitro, oxo, amino, alkylamino, dialkylamino or combinations thereof and/or substituted in the alkyl portion by halogen, oxo, cyano, or combinations thereof and pharmaceutically acceptable salts thereof, wherein if the compound exhibits chirality it can be in the form of a mixture of enantiomers such as a racemate or a mixture of diastereomers, or can be in the form of a single enantiomer or a single diastereomer.
In a third aspect, the present invention provides a compound of the Formula R1 N R 3
R
2
R
4 wherein:
R
1 is H, tert-butyldimethylsilyl, 3
H
3 14CH 3
"CH
3 or a phenolic protective group; P WPDOCS\MDT\Specs\7825515 doc-1/07/2007 -17-
SR
2 is alkyl having 1 to 12 carbon atoms, which is branched or unbranched and which is unsubstituted or substituted one or more times by halogen, hydroxy, cyano, Ca-4alkoxy, oxo or combinations thereof, and wherein optionally one or more -CH 2
CH
2
O
groups are replaced in each case by -CH=CH- or 00 cycloalkyl having 3 to 10 carbon atoms, which is unsubstituted or substituted one C or more times by halogen, hydroxy, oxo, cyano, alkyl having 1 to 4 carbon atoms, alkoxy C having 1 to 4 carbon atoms, or combinations thereof, Scycloalkylalkyl having 4 to 16 carbon atoms, which is unsubstituted or substituted in the cycloalkyl portion and/or the alkyl portion one or more times by halogen, oxo, cyano, hydroxy, C 1 4 -alkyl, C.-4-alkoxy or combinations thereof, aryl having 6 to 14 carbon atoms, which is unsubstituted or substituted one or more times by halogen, CF 3
OCF
3 alkyl, hydroxy, alkoxy, nitro, methylenedioxy, ethylenedioxy, cyano, or combinations thereof, arylalkyl in which the aryl portion has 6 to 14 carbon atoms and the alkyl portion, which is branched or unbranched, has 1 to 5 carbon atoms, which the arylalkyl radical is unsubstituted or is substituted in the aryl portion one or more times by halogen, CF 3
OCF
3 alkyl, hydroxy, alkoxy, nitro, cyano, methylenedioxy, ethylenedioxy, or combinations thereof, and wherein in the alkyl portion one or more -CH 2
CH
2 groups are each optionally replaced by -CH=CH- or and one or more -CH 2 groups are each optionally replaced by or -NH- and/or the alkyl portion is optionally substituted by halogen, oxo, hydroxy, cyano, or combinations thereof, a partially unsaturated carbocyclic group having 5 to 14 carbon atoms, which is unsubstituted or substituted one or more times by halogen, alkyl, alkoxy, hydroxy, nitro, cyano, oxo, or combinations thereof, a heterocyclic group, which is saturated, partially saturated or unsaturated, having to 10 ring atoms in which at least 1 ring atom is a N, O or S atom, which is unsubstituted or substituted one or more times by halogen, hydroxy, aryl, alkyl, alkoxy, cyano, trifluoromethyl, nitro, oxo, or combinations thereof, or P \WPDOCS\MDTSpCCX782551 3 doc-31A)7/2(t17 0 -17aa heterocycle-alkyl group, wherein the heterocyclic portion is saturated, partially saturated or unsaturated, and has 5 to 10 ring atoms in which at least 1 ring atom is a N, O or S atom, and the alkyl portion is branched or unbranched and has 1 to 5 carbon atoms, 0o the heterocycle-alkyl group is unsubstituted or substituted one or more times in the r- 5 heterocyclic portion by halogen, OCF 3 hydroxy, aryl, alkyl, alkoxy, cyano, ¢c€ trifluoromethyl, nitro, oxo, or combinations thereof, wherein in the alkyl portion one or CN more -CI-1 2
CH
2 groups are each optionally replaced by -CH=CH- or and one or
O
O more -CH 2 groups are each optionally replaced by or -NH- and/or the alkyl portion is optionally substituted by halogen, oxo, hydroxy, cyano, or combinations thereof;
R
3 is alkyl having 1 to 8 carbon atoms, which is branched or unbranched and which is unsubstituted or substituted one or more times with halogen, cyano, Ci.4-alkoxy, or combinations thereof, a partially unsaturated carbocycle-alkyl group wherein the carbocyclic portion has to 14 carbon atoms and the alkyl portion which is branched or unbranched has 1 to is carbon atoms, and which is unsubstituted or substituted in the carbocyclic portion one or more times by halogen, alkyl, alkoxy, nitro, cyano, oxo, or combinations thereof, and the alkyl portion is optionally substituted by halogen, Ci-4-alkoxy, cyano or combinations thereof, arylalkyl having 7 to 19 carbon atoms, wherein the aryl portion has 6 to 14 carbon atoms and the alkyl portion, which is branched or unbranched, has 1 to 5 carbon atoms, arylalkyl radical is unsubstituted or substituted, in the aryl portion, one or more times by halogen, trifluoromethyl, CF30, nitro, amino, alkyl, alkoxy, alkylamino, or dialkylamino and/or substituted in the alkyl portion by halogen, cyano or methyl, or heteroarylalkyl group, wherein the heteroaryl portion has 5 to 10 ring atoms in which at least 1 ring atom is a N, O or S atom, the alkyl portion, which is branched or unbranched, has 1 to 5 carbon atoms, the heteroarylalkyl group is unsubstituted or substituted one or more times in the heteroaryl portion by halogen, alkyl, alkoxy, cyano, trifluoromethyl, CF30, nitro, oxo, amino, alkylamino, dialkylamino, or combinations thereof and/or substituted in the alkyl portion by halogen, cyano, or methyl or P \WPWDOCSW)O Spe'74235553 dm-3 Ift3732( -17bcombinations thereof;
R
4 is aryl having 6 to 14 carbon atoms and which is unsubstituted or substituted one or more times by halogen, alkyl, alkenyl, alkynyl, hydroxy, alkoxy, alkoxyalkoxy, nitro, 00 methylenedioxy, ethylenedioxy, trifluoromethyl, OCF 3 amino, aminoalkyl, aminoalkoxy, dialkylamino, hydroxyalkyl, hydroxamic acid, tetrazole-5-yl, 2-(tetrahydropyranyl)hydroxyalkoxy, carboxy, alkoxycarbonyl, cyano, acyl, alkylthio, alkylsulfinyl, alkylsulfonyl, phenoxy, trialkylsilyloxy, R 5 or combinations thereof, or heteroaryl having 5 to 10 ring atoms in which at least 1 ring atom is a heteroatom, which is unsubstituted or substituted one or more times by halogen, alkyl, hydroxy, alkoxy, io alkoxyalkoxy, nitro, methylenedioxy, ethylenedioxy, trifluoromethyl, amino, aminomethyl, aminoalkyl, aminoalkoxy dialkylamino, hydroxyalkyl hydroxamic acid, hydroxyalkoxy, carboxy, alkoxycarbonyl, cyano, acyl, alkylthio, alkylsulfinyl, alkylsulfonyl, phenoxy, trialkylsilyloxy R 5 dialkylamino-L-, or combinations thereof; RS is H, Is alkyl having 1 to 8 carbon atoms, which is unsubstituted or substituted one or more times with halogen, C 14 -alkyl, C 1 -4-alkoxy, oxo, or combinations thereof, alkylamino or dialkylamino wherein each alkyl portion has independently 1 to 8 carbon atoms, a partially unsaturated carbocycle-alkyl group wherein the carbocyclic portion has 5 to 14 carbon atoms and the alkyl portion has 1 to 5 carbon atoms, which is unsubstituted or substituted, preferably in the carbocyclic portion, one or more times by halogen, alkyl, alkoxy, nitro, cyano, oxo, or combinations thereof, cycloalkyl having 3 to 10 carbon atoms, which is unsubstituted or substituted one or more times by halogen, hydroxy, oxo, cyano, alkoxy, alkyl having 1 to 4 carbon atoms, or combinations thereof, cycloalkylalkyl having 4 to 16 carbon atoms, which is unsubstituted or substituted in the cycloalkyl portion and/or the alkyl portion one or more times by halogen, oxo, P:\WPDOCS\MDT5pC\78255153 doc-3 1n7/2l)7 S- 17ccyano, hydroxy, alkyl, alkoxy or combinations thereof, Saryl having 6 to 14 carbon atoms and which is unsubstituted or substituted one or more times by halogen, alkyl, hydroxy, alkoxy, alkoxyalkoxy, nitro, methylenedioxy, 00 ethylenedioxy, trifluoromethyl, amino, aminomethyl, aminoalkyl, aminoalkoxy C 5 dialkylamino, hydroxyalkyl, hydroxamic acid, tetrazole-5-yl, hydroxyalkoxy, carboxy, Calkoxycarbonyl, cyano, acyl, alkylthio, alkylsulfinyl, alkylsulfonyl, or combinations Sthereof, or arylalkyl having 7 to 19 carbon atoms, wherein the aryl portion has 6 to 14 carbon atoms and the alkyl portion, which is branched or unbranched, has 1 to 5 carbon atoms, arylalkyl radical is unsubstituted or substituted, in the aryl portion, one or more times by halogen, trifluoromethyl, CF 3 0, nitro, amino, alkyl, alkoxy, amino, alkylamino, dialkylamino and/or substituted in the alkyl portion by halogen, cyano, or methyl, a heterocyclic group, which is saturated, partially saturated or unsaturated, having to 10 ring atoms in which at least 1 ring atom is a N, O or S atom, which is unsubstituted or substituted one or more times by halogen, alkyl, hydroxy, alkoxy, alkoxyalkoxy, nitro, methylenedioxy, ethylenedioxy, trifluoromethyl, amino, aminomethyl, aminoalkyl, aminoalkoxy, dialkylamino, hydroxyalkyl, hydroxamic acid, hydroxyalkoxy, carboxy, alkoxycarbonyl, cyano, acyl, alkylthio, alkylsulfinyl, alkylsulfonyl, phenoxy, or combinations thereof; or a heterocycle-alkyl group, wherein the heterocyclic portion is saturated, partially saturated or unsaturated, and has 5 to 10 ring atoms in which at least 1 ring atom is a N, O or S atom, and the alkyl portion which is branched or unbranched and has 1 to 5 carbon atoms, the heterocycle-alkyl group is unsubstituted or substituted one or more times in the heterocyclic portion by halogen, alkyl, alkoxy, cyano, trifluoromethyl, CF 3 0, nitro, oxo, amino, alkylamino, dialkylamino, or combinations thereof and/or substituted in the alkyl portion by halogen, cyano, or methyl or combinations thereof; L is a single bond or a divalent aliphatic radical having 1 to 8 carbon atoms wherein one or more -CH 2 groups are each optionally replaced by -NR 6 P\WPDOCS\MDlSpccs\7255 M3 6o..3]A)7/2(X)7 0 -17d-
-SO
2 NH-, -NHSO 2
-NR
6 CO-, -CONR 6 -NHCONH-, -OCONH, -NHCOO-, -SCONH-, -SCSNH-, or -NHCSNH-; and
R
6 is H, or alkyl having 1 to 8 carbon atoms, which is branched or unbranched and 00 which is unsubstituted or substituted one or more times with halogen, C-4-alkyl, C 1 4 C 5 alkoxy, oxo, or combinations thereof; and Ci pharmaceutically acceptable salts thereof, c wherein if the compound exhibits chirality it can be in the form of a mixture of enantiomers such as a racemate or a mixture of diastereomers, or can be in the form of a single enantiomer or a single diastereomer.
In a fourth aspect, the present invention provides a compound of the Formula
R
2
R
4 wherein: R' is alkyl having 1 to 4 carbon atoms, which is branched or unbranched and which is unsubstituted or substituted one or more times by halogen; is R 2 is H, tert-butyldimethylsilyloxy- or a phenolic protective group;
R
3 is alkyl having 1 to 8 carbon atoms, which is branched or unbranched and which is unsubstituted or substituted one or more times with halogen, cyano, Ci-4-alkoxy, or combinations thereof, a partially unsaturated carbocycle-alkyl group wherein the carbocyclic portion has 5 to 14 carbon atoms and the alkyl portion which is branched or unbranched has 1 to carbon atoms, and which is unsubstituted or substituted in the carbocyclic portion one or more times by halogen, alkyl, alkoxy, nitro, cyano, oxo, or combinations thereof, and the alkyl portion is optionally substituted by halogen, C 14 -alkoxy, cyano or combinations P \WPDOCS\MDTISp m\7125513 dmo.3]A)7a207 17ethereof, O arylalkyl having 7 to 19 carbon atoms, wherein the aryl portion has 6 to 14 carbon atoms and the alkyl portion, which is branched or unbranched, has 1 to 5 carbon atoms, 00 arylalkyl radical is unsubstituted or substituted, in the aryl portion, one or more times by halogen, trifluoromethyl, CF 3 0, nitro, amino, alkyl, alkoxy, alkylamino, dialkylamino and/or substituted in the alkyl portion by halogen, cyano, or methyl, or O heteroarylalkyl group, wherein the heteroaryl portion has 5 to 10 ring atoms in which at least I ring atom is a N, O or S atom, the alkyl portion, which is branched or unbranched, has 1 to 5 carbon atoms, the heteroarylalkyl group is unsubstituted or to substituted one or more times in the heteroaryl portion by halogen, alkyl, alkoxy, cyano, trifluoromethyl, CF 3 0, nitro, oxo, amino, alkylamino, dialkylamino, or combinations thereof and/or substituted in the alkyl portion by halogen, cyano, or methyl or combinations thereof;
R
4 is aryl having 6 to 14 carbon atoms and which is unsubstituted or substituted one or more times by halogen, alkyl, alkenyl, alkynyl, hydroxy, alkoxy, alkoxyalkoxy, nitro, methylenedioxy, ethylenedioxy, trifluoromethyl, OCF 3 amino, aminoalkyl, aminoalkoxy dialkylamino, hydroxyalkyl, hydroxamic acid, tetrazole-5-yl, 2-(tetrahydropyranyl)hydroxyalkoxy, carboxy, alkoxycarbonyl, cyano, acyl, alkylthio, alkylsulfinyl, alkylsulfonyl, phenoxy, trialkylsilyloxy, R 5 or combinations thereof, or heteroaryl having 5 to 10 ring atoms in which at least I ring atom is a heteroatom, which is unsubstituted or substituted one or more times by halogen, alkyl, hydroxy, alkoxy, alkoxyalkoxy, nitro, methylenedioxy, ethylenedioxy, trifluoromethyl, amino, aminomethyl, aminoalkyl, aminoalkoxy dialkylamino, hydroxyalkyl hydroxamic acid, hydroxyalkoxy, carboxy, alkoxycarbonyl, cyano, acyl, alkylthio, alkylsulfinyl, alkylsulfonyl, phenoxy, trialkylsilyloxy RS 5 dialkylamino-L-, or combinations thereof;
RS
5 is H, alkyl having 1 to 8 carbon atoms, which is unsubstituted or substituted one or more times with halogen, C 1 4 -alkyl, C 1 4 -alkoxy, oxo, or combinations thereof, P \WPDOCSMDTSpec\78255153 do-3 I )72()7 S- 17falkylamino or dialkylamino wherein each alkyl portion has independently 1 to 8 carbon atoms, a partially unsaturated carbocycle-alkyl group wherein the carbocyclic portion has 00 to 14 carbon atoms and the alkyl portion has 1 to 5 carbon atoms, which is unsubstituted or substituted, preferably in the carbocyclic portion, one or more times by halogen, alkyl, C alkoxy, nitro, cyano, oxo, or combinations thereof, O cycloalkyl having 3 to 10 carbon atoms, which is unsubstituted or substituted one or more times by halogen, hydroxy, oxo, cyano, alkoxy, alkyl having 1 to 4 carbon atoms, or combinations thereof, cycloalkylalkyl having 4 to 16 carbon atoms, which is unsubstituted or substituted in the cycloalkyl portion and/or the alkyl portion one or more times by halogen, oxo, cyano, hydroxy, alkyl, alkoxy or combinations thereof, aryl having 6 to 14 carbon atoms and which is unsubstituted or substituted one or more times by halogen, alkyl, hydroxy, alkoxy, alkoxyalkoxy, nitro, methylenedioxy, ethylenedioxy, trifluoromethyl, amino, aminomethyl, aminoalkyl, aminoalkoxy, dialkylamino, hydroxyalkyl, hydroxamic acid, tetrazole-5-yl, hydroxyalkoxy, carboxy, alkoxycarbonyl, cyano, acyl, alkylthio, alkylsulfinyl, alkylsulfonyl, or combinations thereof, or arylalkyl having 7 to 19 carbon atoms, wherein the aryl portion has 6 to 14 carbon atoms and the alkyl portion, which is branched or unbranched, has 1 to 5 carbon atoms, arylalkyl radical is unsubstituted or substituted, in the aryl portion, one or more times by halogen, trifluoromethyl, CF 3 0, nitro, amino, alkyl, alkoxy, amino, alkylamino, dialkylamino and/or substituted in the alkyl portion by halogen, cyano, or methyl, a heterocyclic group, which is saturated, partially saturated or unsaturated, having to 10 ring atoms in which at least 1 ring atom is a N, O or S atom, which is unsubstituted or substituted one or more times by halogen, alkyl, hydroxy, alkoxy, alkoxyalkoxy, nitro, methylenedioxy, ethylenedioxy, trifluoromethyl, amino, aminomethyl, aminoalkyl, aminoalkoxy, dialkylamino, hydroxyalkyl, hydroxamic acid, P \WPDOCS.MD~Spec\78255153 dmo-31/7/2l7I O 17ghydroxyalkoxy, carboxy, alkoxycarbonyl, cyano, acyl, alkylthio, alkylsulfinyl, alkylsulfonyl, phenoxy, or combinations thereof; or a heterocycle-alkyl group, wherein the heterocyclic portion is saturated, partially saturated or unsaturated, and has 5 to 10 ring atoms in which at least 1 ring atom is a N, O or S atom, and the alkyl portion which is branched or unbranched and has 1 to 5 carbon catoms, the heterocycle-alkyl group is unsubstituted or substituted one or more times in the 0 heterocyclic portion by halogen, alkyl, alkoxy, cyano, trifluoromethyl, CF 3 0, nitro, oxo, N amino, alkylamino, dialkylamino, or combinations thereof and/or substituted in the alkyl portion by halogen, cyano, or methyl or combinations thereof; L is a single bond or a divalent aliphatic radical having 1 to 8 carbon atoms wherein one or more -CH 2 groups are each optionally replaced by -NR 6
-SO
2 NH-, -NHSO 2 -NR6CO-, -CONR 6 -NHCONH-, -OCONH, -NHCOO-, -SCONH-, -SCSNH-, or -NHCSNH-; and
R
6 is H, oralkyl having 1 to 8 carbon atoms, which is branched or unbranched and which is unsubstituted or substituted one or more times with halogen, Ci-4-alkyl, CI.
4 alkoxy, oxo, or combinations thereof; and pharmaceutically acceptable salts thereof, wherein if the compound exhibits chirality it can be in the form of a mixture of enantiomers sucy as a racemate or a mixture of diastereomers, or can be in the form of a single enantiomer or a single diastereomer.
The compounds of the present invention are effective in inhibiting, or modulating the activity of PDE4 in animals, mammals, especially humans. These compounds exhibit neurological activity, especially where such activity affects cognition, including long term memory. These compounds will also be effective in treating diseases where decreased cAMP levels are involved. This includes but is not limited to inflammatory diseases. These compounds may also function as antidepressants, or be useful in treating cognitive and negative symptoms of schizophrenia.
P \WVPDOCSVA4DTSps\7K2S 153 do-3 I/7/2(X)7 -17h- Z In a fifth aspect, the present invention provides a method for enhancing cognition in a patient in whom such enhancement is desired comprising administering to said patient an effective amount of a compound according to the first aspect.
00 In a sixth aspect, the present invention provides a method of treating a patient suffering from cognition impairment or decline comprising administering to said patient an Seffective amount of a compound according to the first aspect.
OIn a seventh aspect, the present invention provides a method for treating a patient having a disease involving decreased cAMP levels comprising administering to said patient an effective amount of a compound according to the first aspect.
In an eighth aspect, the present invention provides a method of inhibiting PDE4 enzyme activity in a patient comprising administering to said patient an effective amount of a compound according to the first aspect.
In a ninth aspect, the present invention provides a method of treating a patient suffering from memory impairment due to a neurodegenerative disease comprising administering to said patient an effective amount of a compound according to the first aspect.
In a tenth aspect, the present invention provides a method of treating a patient suffering from memory impairment due to an acute neurodegenerative disorder comprising administering to said patient an effective amount of a compound according to the first aspect.
In an eleventh aspect, the present invention provides a method of treating a patient suffering from an allergic or inflammatory disease comprising administering to said patient an effective amount of a compound according to the first aspect.
Assays for determining PDE inhibiting activity as well as selectivity of PDE 4 inhibiting activity and selectivity of inhibiting PDE 4 isoenzymes are known within the art.
See, US 6,136,821, the disclosure of which is incorporated herein by reference.
Disclosed herein are compounds useful as intermediates for the production of the P \WPDOCS\MDTNSpecs\78255153 oc.3 )l)37/2 S- 17i- PDE4 inhibitors described herein PDE4 inhibitors of Formula I) and/or useful for the synthesis of radio-labeled analogs of the PDE4 inhibitors with in this application.
Thus, there are provided intermediate compounds which correspond to compounds 00 of Formula I, wherein R 2
R
3 and R 4 are as previously defined for Formula I, but R' is H, C 5 tert-butyldimethylsilyl, or a suitable phenolic protecting group. Suitable phenolic Cprotecting groups are described, for example, in Greene T.W. and Wuts, P.G.M., 0 Protective Groups in Organic Synthesis, 3rd Edition, John Wiley Sons, 1999, pp. 246- N 293. These intermediates are also useful for the synthesis of radio-labeled compounds such as where R' is 3
H
3 '4CH 3 or "'CH 3 for example by removing the protecting to group and reacting the resultant compound in which R' is H with suitable radio-labelled reagents. Such radio-labeled compounds are useful for determining compound tissue distribution in animals, in PET imaging studies, and for in vivo, ex vivo, and in vitro binding studies.
Also provided are intermediate compounds which correspond to compounds of is Formula I, wherein R 3 and R 4 are as previously defined for Formula I, but R 2 is H, tert-butyldimethylsilyloxy-, or a suitable phenolic protecting group. Suitable phenolic protecting groups are described, for example, in Greene, T.W. and Wuts, P.G.M., Protective Groups in Organic Synthesis, 3rd Edition, John Wiley Sons, 1999, pp. 246- WO 02/074726 PCT/US02/01508 293. Compounds in which R 2 is H are useful as intermediates, for example, as scaffolds for parallel or combinatorial chemistry applications. Further, these compounds are useful for the introduction of radio-labels such as 3 H or 11
C.
As previously described, compounds according to formula II, wherein R 2 and
R
4 are as previously described are useful intermediates for the production of compounds according to formula I where in R 3 is other than H.
Also, as previously described, compounds according to formula III, wherein R,
R
2 and R 3 are as previously described are useful intermediates for the production of compounds according to formula I where in R 4 is other than H.
Halogen herein refers to F, Cl, Br, and I. Preferred halogens are F and Cl.
Alkyl, as a group or substituent per se or as part of a group or substituent alkylamino, trialkylsilyloxy, aminoalkyl, hydroxyalkyl), means a straight-chain or branched-chain aliphatic hydrocarbon radical having 1 to 12 carbon atoms, preferably 1 to 8 carbon atoms, especially 1 to 4 carbon atoms. Suitable alkyl groups include methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl, hexyl, heptyl, octyl, nonyl, decyl, undecyl, and dodecyl. Other examples of suitable alkyl groups include 2- or 3methylbutyl, 1,2- or 2,2-dimethylpropyl, 1-ethylpropyl, 3- or 4-methylpentyl, 2,3- or 3,3-dimethylbutyl, 1- or 2-ethylbutyl, ethylmethylpropyl, trimethylpropyl, methylhexyl, dimethylpentyl, ethylpentyl, ethylmethylbutyl, dimethylbutyl, and the like.
Substituted alkyl groups are alkyl groups as described above which are substituted in one or more positions by halogens, oxo, hydroxyl, C 1 4 -alkoxy and/or cyano.. Halogens are preferred substituents, especially F and Cl.
Alkoxy means alkyl-O- groups and alkoxyalkoxy means alkyl-O-alkyl-O- groups in which the alkyl portions are in accordance with the previous discussion. Suitable WO 02/074726 PCT/US02/01508 alkoxy and alkoxyalkoxy groups include methoxy, ethoxy, propoxy, butoxy, pentoxy, hexoxy, heptoxy, octoxy methoxymethoxy ethoxymethoxy, propoxymethoxy, and methoxyethoxy. Preferred alkoxy groups are methoxy and ethoxy. Similarly, alkoxycarbonyl means alkyl -O-CO- in which the alkyl portion is in accordance with the previous discussion. Examples include methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, and tert-butoxycarbonyl.
Cycloalkyl means a monocyclic, bicyclic or tricyclic nonaromatic saturated hydrocarbon radical having 3 to 10 carbon atoms, preferably 3 to 8 carbon atoms, especially 3 to 6 carbon atoms. Suitable cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, norbomyl, 1-decalin, adamant-1-yl, and adamant-2-yl. Other suitable cycloalkyl groups include spiropentyl, bicyclo[2. 1.0]pentyl, bicyclo[3.1.0]hexyl, spiro[2.4]heptyl, bicyclo[5.1.0]octyl, spiro[2.6]nonyl, bicyclo[2.2.0]hexyl, spiro[3.3]heptyl, bicyclo[4.2.0]octyl, and spiro[3.5]nonyl. Preferred cycloalklyl groups are cyclopropyl, cyclopentyl and cyclohexyl. The cycloalkyl group can be substituted, for example, substituted by halogens and/or alkyl groups.
Cycloalkylalkyl refers to cycloalkyl-alkyl radicals in which the cycloalkyl and alkyl portions are in accordance with previous discussions. Suitable examples include cyclopropylmethyl and cyclopentylmethyl.
Aryl, as a group or substituent per se or as part of a group or substituent, refers to an aromatic carbocyclic radical containing 6 to 14 carbon atoms, preferably 6 to 12 carbon atoms, especially 6 to 10 carbon atoms. Suitable aryl groups include phenyl, naphthyl and biphenyl. Substituted aryl groups include the above-described aryl groups which are substituted one or more times by, for example, halogen, alkyl, hydroxy, alkoxy, nitro, methylenedioxy, ethylenedioxy, amino, alkylamino, dialkylamino, hydroxyalkyl, hydroxyalkoxy, carboxy, cyano, acyl, alkoxycarbonyl, alkylthio, alkylsulfinyl, alkylsulfonyl, and phenoxy.
WO 02/074726 PCT/US02/01508 Arylalkyl refers to an aryl-alkyl-radical in which the aryl and alkyl portions are in accordance with the previous descriptions. Suitable examples include benzyl, 1phenethyl, 2-phenethyl, phenpropyl, phenbutyl, phenpentyl, and napthylmethyl.
Heteroaryl refers to an aromatic heterocyclic group having one or two rings and a total number of 5 to 10 ring atoms wherein at least one of the ring atoms is a heteroatom.
Preferably, the heteroaryl group contains 1 to 3, especially 1 or 2, hetero-ring atoms which are selected from N, O and S. Suitable heteroaryl groups include furyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, tetrazolyl, dithialyl, oxathialyl, isoxazolyl, oxazolyl, thiazolyl, isothiazolyl, oxadiazolyl, oxatriazolyl, dioxazolyl, oxathiazolyl, thiadiazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, oxazinyl, isoxazinyl, oxathiazinyl, oxadiazinyl, benzofuranyl, isobenzofuranyl, thionaphthenyl, isothionaphthenyl, indolyl, isoindolyl, indazolyl, benzisoxazolyl, benzoxazolyl, benzthiazolyl, benzisothiazolyl, purinyl, benzopyranyl, quinolinyl, isoquinolinyl, cinnolinyl, quinazolinyl, naphthyridinyl, and benzoxazinyl, 2-thienyl, 3-thienyl, 2-, 3- or 4-pyridyl, 7- or 8-quinolinyl, and 7- or 8isoquinolinyl.
Substituted heteroaryl refers to the heteroaryl groups described above which are substitued in one or more places by, for example, halogen, aryl, alkyl, alkoxy, carboxy, methylene, cyano, trifluoromethyl, nitro, oxo, amino, alkylamino, and dialkylamino.
Heterocycles include heteroaryl groups as described above as well as nonaromatic cyclic groups containing at least one hetero-ring atom, preferably selected from N, S and 0, for example, tetrahydrofuranyl, piperidinyl, and pyrrolidinyl.
Heterocycle-alkyl refers to a heterocycle-alkyl-group wherein the heterocyclic and alkyl portions are in accordance with the previous discussions. Suitable examples are pyridylmethyl, thienylmethyl, pyrimidinylmethyl, pyrazinylmethyl, and isoquinolinylmethyl.
WO 02/074726 PCT/US02/01508 Partially unsaturated carbocyclic structures are non-aromatic monocyclic or bicyclic structures containing 5 to 14 carbon atoms, preferably 6 to 10 carbon atoms, wherein the ring structure(s) contains at least one C=C bond. Suitable examples are cyclopentenyl, cyclohexenyl, cyclohexadienyl, tetrahydronaphthenyl and indan-2-yl.
Alkenyl refers to straight-chain or branched-chain aliphatic radicals containing 2 to 12 carbon atoms in which one or more -CH 2
-CH
2 structures are each replaced by CH=CH-. Suitable alkenyl groups are ethenyl, 1-propenyl, 2-methylethenyl, 1-butene, 2butene, -pentenyl, and 2-pentenyl.
Alkynyl refers to straight-chain or branched-chain aliphatic radicals containing 2 to 12 carbon atoms in which one or more -CH 2
-CH
2 structures are each replaced by Suitable alkynyl groups are ethynyl, propynyl, 1-butynyl, and 2-butynyl.
Acyl refers to alkanoyl radicals having 1 to 13 carbon atoms in which the alkyl portion can be substituted by halogen, alkyl, aryl and/or alkoxy, or aroyl radicals having 7 to 15 carbon atoms in which the aryl portion can be substituted by, for example, halogen, alkyl and/or alkoxy. Suitable acyl groups include formyl, acetyl, propionyl, butanoyl and benzoyl.
Substituted radicals preferably have 1 to 3 substituents, especially 1 to 2 substituents.
In the compounds of Formula I, R' is an alkyl group having preferably 1 to 4 carbon atoms which is optionally substituted by halogen, preferably fluorine or chlorine.
In particular, R' is preferably methyl or difluoromethyl.
R
2 is preferably cycloalkyl, particularly cyclopentyl.
WO 02/074726 PCT/US02/01508
R
2 is also preferably aryl or arylalkyl, particularly substituted or unsubstituted phenyl or phenylalkyl, such as phenyl, methylphenyl, methoxyphenyl, chlorophenyl, phenethyl, phenpropyl, phenbutyl, phenylethenyl, phenoxyethyl, phenoxypropyl, phenoxybutyl, chlorophenylethyl, methoxyphenyl ethyl, chlorophenylethenyl, chlorophenoxyethyl, chlorophenypropyl, methoxyphenpropyl, methoxyphenbutyl, chlorophenbutyl, nitrophenbutyl, chlorophenylaminoethyl, and the like, R2 is also preferably a partially unsaturated carbocyclic groups, which is unsubstituted or substituted, particularly cyclohexenyl, cyclohexadienyl, indan-2-yl.
R
2 is also preferably an alkyl group having 1 to 8 carbon atoms, especially 1 to 4 carbon atoms, which is substituted or unsubstituted, methyl, difluoromethyl, trifluoromethyl, and methoxyethyl.
R is also preferably a heterocyclic or heterocycle--alkyl group, particularly radicals in which the heterocyclic group has 5 to 6 ring atoms and I to 2 hetero-ring atoms selected from N, O and S, tetrahydrofuranyl, pyrrolidinyl, pyrrolyl, pyridylmethyl, pyridylethyl, pyridylpropyl, piperazinylmethyl, piperazinylethyl, methylpiperazinylethyl and the like.
Preferred R 2 include cyclopentyl, tetrahydrofuranyl, CHF 2 methoxyethyl, cyclopropylmethyl, phenethyl, phenpropyl, phenylethenyl, phenoxyethyl, phenoxybutyl, phenylaminoethyl, indan-2-yl, pyridylethyl, and pyridylpropyl.
R
3 is preferably hydrogen, alkyl having 1 to 4 carbon atoms methyl, ethyl, n-propyl, or n-butyl), arylalkyl substituted or unsubstitituted benzyl, phenethyl, and phenpropyl), or a heteroarylalkyl group substituted or unsubstituted pyridylmethyl, furanylmethyl, thienylmethyl, pyrrolylmethyl, pyrimidinylmethyl, thiazolylmethyl, isoquinolinylmethyl and quinolinylmethyl). Preferred substituents for aryl and heteroaryl portions of R 3 are F, Cl, CH 3
C
2
H
5
OCH
3 and CN.
WO 02/074726 PCT/US02/01508
R
4 is preferably aryl, or heteroaryl, especially phenyl, naphthyl, biphenyl, furanyl, pyrazinyl, pyrimidinyl, pyridyl, quinolinyl, and isoquinolinyl, which in each case is unsubstituted or is substituted one or more times. Preferred substituents are OH, F, Cl,
CF
3 alkyl (such as methyl or ethyl), alkoxy (such as methoxy and ethoxy), CN, vinyl,
CH
2 OH, CONHOH, CONH 2 methylenedioxy, COOH, and combinations thereof.
In addition, when R 4 is aryl, especially, phenyl, preferred substituents include R 5
R
5
R
5 -NH-CO-, R 5 -S0 2
R
5 -S0 2 -NH-alkylene-O-, NH 2 alkyl-NH-CO-, R 5 -alkylene-NH-CO-, alkyl-CO-NH-alkyl- as well as methyl, ethyl, Cl, F, CN, OCH 3
CF
3 amino, nitro,*HOCH 2 and COOH.
When R 4 is aryl substituted by R 5
-SO
2 -NH- it is preferably a substituted phenyl group and R 5 is preferably methyl, ethyl, propyl or phenyl.
When R 4 is aryl substituted by R'-S0 2 -NH-alkylene-O- it is preferably a substituted phenyl. In such cases, R 5 is preferably methyl, ethyl, propyl or phenyl and alkylene is preferably -CH 2
-CH
2
CH
2 or -CH 2
CH
2
CH
2 When R 4 is aryl substituted by R 5 it is preferably substituted phenyl. In such cases, preferred R 5 groups include tetrazolyl, oxazinyl, piperazinyl, methylpiperazinyl, pyridyl, methylpyridyl, pyrrolinyl, methylpyrrolinyl, piperadinyl, or methylpiperadinyl, and L is preferably a single bond, -CH 2
-CH
2
CH
2
-CH
2
CH
2
CH
2
-CHCH
2
-CH
2
CH
2
CH
2
-CH
2
-NH-CH
2
CH
2 -CO-NH- or -NH-CO-.
In addition, preferred PDE4 inhibitors in accordance with the invention are compounds described by subformulas Ia-lh which correspond to formula I but exhibit the following preferred groups: Ia R' is methyl or CHF 2 WO 02/074726 PCT/US02/01508
R
2 is alkyl, alkenyl, alkynyl, cycloalkyl, arylalkyl, heterocycle-alkyl, cycloalkylalkyl, aryl, or heterocyclic, in each case substituted or unsubstituted;
R
3 is H, alkyl, arylalkyl or heteroarylalkyl, in each case substituted or unsubstituted; and
R
4 is aryl or heteroaryl; in each case substituted or unsubstituted.
Ib R 3 is heteroarylalkyl which is substituted or unsubstituted.
Ic R' is methyl or CHF2; and
R
2 is cyclopentyl, CHF 2 cyclopropylmethyl, pyridylethyl (particularly 2-pyridylethyl), or tetrahydrofuranyl (particularly (3R)-tetrahydrofuranyl).
Id R' is methyl or CHF 2
R
2 is cyclopentyl;
R
3 is heteroarylalkyl, in each case substituted or unsubstituted; and
R
4 is substituted or unsubstituted aryl or heteroaryl.
Ie R 1 is methyl;
R
2 is cyclopentyl; and
R
3 is heteroarylalkyl which is substituted or unsubstituted.
If R' is methyl;
R
2 is cyclopentyl;
R
3 is heteroarylalkyl which is substituted or unsubstituted; and
R
4 is phenyl which is substituted or unsubstituted.
Ig R 1 is methyl; WO 02/074726 PCT/US02/01508
R
2 is cyclopentyl;
R
3 is pyridylmethyl, phenethyl, benzyl, thienylmethyl, pyridylpropyl, piperidinylmethyl, or pyrazinylmethyl, which in each case is substituted or unsustituted, or methyl, ethyl, or propyl; and
R
4 is phenyl or phenyl substituted with 1 to 3 substituents.
Ih R' is methyl; 2 R is cyclopentyl;
R
3 is pyridylmethyl, phenethyl, benzyl, thienylmethyl, pyridylpropyl, piperidinylmethyl, pyrazinylmethyl, which in each case is substituted or unsustituted, or miethyl, ethyl, or propyl; and
R
4 is phenyl, naphthyl, biphenyl, pyridyl, pyrimidinyl, thiazolyl, pyrazinyl, quinolinyl, or isoquinolinyl, in each case substituted or unsubstituted.
In addition, preferred PDE4 inhibitors in accordance with the invention are compounds described by subformulas IIa-IId which correspond to formula II but exhibit the following preferred groups: IIa R' is methyl or CHF 2 R2 is cyclopentyl, CHF 2 cyclopropylmethyl, pyridylethyl (particularly 2-pyridylethyl), or tetrahydrofuranyl (particularly (3R)-tetrahydrofuranyl); and
R
4 is phenyl, naphthyl, pyridyl, quinolinyl, or isoquinolinyl, which in each case is substituted or unsubstituted.
WO 02/074726 PCT/US02/01508 JIb R' is methyl or CHF 2
R
2 is cyclopentyl, CHF 2 cyclopropylmethyl, pyridylethyl (particularly 2-pyridylethyl), or tetrahydrofuranyl (particularly (3R)-tetrahydrofuranyl); and
R
4 is phenyl which is unsubstituted or substituted by methyl, ethyl, methoxy, Cl, F, CF 3 vinyl, cyano, amino, carboxy, hydroxymethyl, or ethylsulfonamido, or is 3-pyridyl which is unsubstituted or substituted by carboxy or alkoxycarbonyl.
lIc R 1 is methyl;
R
2 is cyclopentyl; and
R
4 is phenyl, naphthyl, pyridyl, quinolinyl, or isoquinolinyl, which in each case is substituted or unsubstituted.
lid R 1 is methyl;
R
2 is cyclopentyl; and
R
4 is phenyl which is unsubstituted or substituted by methyl, ethyl, methoxy, Cl, F, CF 3 vinyl, cyano, amino, carboxy, hydroxymethyl, or ethylsulfonamido, or is 3-pyridyl which is unsubstituted or substituted by carboxy or alkoxycarbonyl.
WO 02/074726 WO 02/74726PCT/US02/01508 In addition, preferred PDE4 inhibitors in accordance with the invention are compounds described by subformulas Illa-hid which correspond to formula III but exhibit the following preferred groups: Illa R 1 is methyl or CHF 2 R2 is cyclopentyl, CHF 2 cyclopropylmethyl, pyridylethyl (particularly 2-pyridylethyl), or tetrahydrofuranyl (particularly (3R)-tetrahydrofuranyl); and R 3 is benzyl, phenethyl, cyclohexenylmethyl, furanylirethyl, thienylmethyl, pyridylmethyl, quinolinymethyl, isoquinolinylmethyl, thiazolylmethyl, or pyrrolylmethyl, which in each case is substituted or unsubstituted.
111b, R 1 is methyl or CHF 2
R
2 is cyclopentyl, CHF 2 cyclopropylmethyl, pyridylethyl (particularly 2py-ridylethyl), or tetrahydrofuranyl (particularly (3R)-tetrahydrofuranyl); and
R
3 is pyrazinylmethyl, pyrimidinylmethyl or pyridylmethyl, which in each is unsubstituted or substituted.
111c R' is methyl; R 2is cyclopentyl; and WO 02/074726 PCT/US02/01508
R
3 is benzyl, phenethyl, cyclohexenylmethyl, furanylmethyl, thienylmethyl, pyrazinylmethyl, pyrimidinylmethyl, pyridylmethyl, quinolinymethyl, isoquinolinylmethyl, isoimidazolyl, thiazolylmethyl, or pyrrolylmethyl, which in each case is substituted or unsubstituted.
IIId R 1 is methyl;
R
2 is cyclopentyl; and
R
3 is pyrazinylmethyl or pyridylmethyl, which in each is unsubstituted or substituted.
In addition, preferred PDE4 inhibitors in accordance with the invention are compounds described by subformulas IVa-IVp which correspond to formula IV but exhibit the following preferred groups: IVa R' is methyl or CHF 2 IVb R' is methyl or CHF 2 and BisN.
IVc R' is methyl or CHF 2 and
R
2 is cyclopentyl, CHF 2 cyclopropylmethyl, pyridylethyl (particularly 2pyridylethyl), or tetrahydrofuranyl (particularly (3R)-tetrahydrofuranyl).
WO 02/074726 WO 02/74726PCT/US02/01508 IVd R' is methyl or ClIP 2 B is N, and
R
2 is cyclopentyl, CHF 2 cyclopropylmethyl, pyridylethyl (particularly 2pyridylethyl), or tetrahydrofuranyl (particularly (3R)-tetrahydrofuranyl).
W~e R 1 is methyl or ClIP 2 and
R
4 is 3-pyridyl or phenyl, which in each case is substituted or unsubstituted.
IVf R' is methyl or CHF 2 B is N, and R 4 is 3-pyridyl or phenyl, which in each case is substituted or unsubstituted.
TVg R' is methyl or CHF 2 R 2is cyclopentyl, CHF 2 cyclopropylmethyl, pyridylethyl. (particularly .2pyridylethyl), or tetrahydrofuranyl (particularly (3R)-tetrahydrofuranyl), and R 4 is 3-pyridyl or phenyl, which in each case is substituted or unsubstituted.
IVh R' is methyl or CHF 2 B is N, WO 02/074726 WO 02/74726PCT/US02/01508
R
2 is cyclopentyl, CHF 2 cyclopropylmnethyl, pyridylethyl (particularly 2pyridylethyl), or tetrahydrofuranyl (particularly (3R)-tetrahydrofuranyl), and R 4 is 3-pyriclyl or phenyl, which in each case is substituted or unsubstituted.
IVi R 1 is methyl or CHF 2 and R4 is phenyl which is substituted in the 3- or 4- position.
IVj R 1 is methyl or CHF 2 B is N, and R4 is phenyl which is substituted in the 3- or 4- position.
IVk R' is methyl or CHF 2 R2 is cyclopentyl, CHF 2 cyclopropylmethyl, pyridylethyl (particularly 2pyridylethyl), or tetrahydrofuranyl (particularly (3R)-tetrahydrofuranyl), and R 4 is phenyl which is substituted in the 3- or 4- position.
IVI R1 is methyl or CHF 2 B is N, WO 02/074726 WO 02/74726PCT/US02/01508 R 2 is cyclopentyl, CHF 2 cyclopropylmethyl, pyridylethyl (particularly 2pyridylethyl), or tetrahydrofuranyl (particularly (3R)-tetralhydrofuranyl), and
R
4 is phenyl which is substituted in the 3- or 4- position.
IVm R 1 is methyl or CHF 2 and
R
4 is 3-pyridyl, 3-COOH-phenyl, 3-Ci-phenyl, 3-cyano-phenyl, 3ethylsulfonamido-phenyl, 3 -tetrazol-5-yl-phenyl, 3-hydroxymethylphenyl, 4-pynidyl, 4-CQOH-phenyl, 4-cyano-phenyl, 4-ethylsulfonamidophenyl, 4-tetrazol-5-yl-phenyl, or 4-hydroxymethyl-phenyl.
IWn R I is methyl or CHF 2 B is N, and Ri is 3-pyridyl, 3-COOH-phenyl, 3-Ci-phenyl, 3-cyano-phenyl, 3ethylsulfonamido-phenyl, 3-tetrazol-5-yl-phenyl, 3-hydroxymethylphenyl, 4-pyridyl, 4-COOH-phenyl, 4-cyano-phenyl, 4-ethylsulfonamidophenyl, 4-tetrazol-5-yl-phenyl, or 4-hydroxymethyl-phenyl.
IWo R 1 is methyl or CHF 2 R 2 is cyclopentyl, CHF 2 cyclopropylmethyl, pyridylethyl (particularly 2pyridylethyl), or tetrahydrofuranyl (particularly (3R)-tetrahydrofuranyl), and WO 02/074726 PCT/US02/01508
R
4 is 3-pyridyl, 3-COOH-phenyl, 3-Cl-phenyl, 3-cyano-phenyl, 3ethylsulfonamido-phenyl, 3-tetrazol-5-yl-phenyl, 3-hydroxymethylphenyl, 4-pyridyl, 4-COOH-phenyl, 4-cyano-phenyl, 4-ethylsulfonamidophenyl, 4-tetrazol-5-yl-phenyl, or 4-hydroxymethyl-phenyl.
Vp R 1 is methyl or CHF 2 B is N, R2 is cyclopentyl, CHF 2 cyclopropylmethyl, pyridylethyl (particularly 2pyridylethyl), or tetrahydrofuranyl (particularly (3R)-tetrahydrofuranyl), and
R
4 is 3-pyridyl, 3-COOH-phenyl, 3-Cl-phenyl, 3-cyano-phenyl, 3ethylsulfonamido-phenyl, 3-tetrazol-5-yl-phenyl, 3-hydroxymethylphenyl, 3-nitro-phenyl, 4-pyridyl, 4-COOH-phenyl, 4-cyano-phenyl, 4ethylsulfonamido-phenyl, 4-tetrazol-5-yl-phenyl, or 4-hydroxymethylphenyl.
Preferred aspects include pharmaceutical compositions comprising a compound of this invention and a pharmaceutically acceptable carrier and, optionally, another active agent as discussed below; a method of inhibiting a PDE4 enzyme, especially an isoenzyme, as determined by a conventional assay or one described herein, either in vitro or in vivo (in an animal, in an animal model, or in a mammal or in a human); a method of treating neurological syndrome, loss of memory, especially long-term memory, cognitive impairment or decline, memory impairment, etc. a method of treating a disease state modulated by PDE4 activity, in a mammal, a human, those mentioned herein.
WO 02/074726 WO 02/74726PCT/US02/01508 The compounds of the present invention may be prepared conventionally. Some of the processes which can be used are described below. All starting materials are known or can be conventionally prepared from known starting materials.
SCHEME 1 1a) R22r, K 2
CO
3
OMF
lb)R2OH, PPh 3 DIAD, THF 0 1~c) TBDMSCI, Imd., DMF 0 R ri 1 d) R 2 B(OH)2. Cu(OAc) 2
R
R'Et 3 N R'2) H2, 10% Pd/c, EtOH- HO '')NO 2 0 NO2 2 1 2 2 R2 Ol 3) R3CHO.' NaBH 4 Rl' 0. 4) Pd,dba,, NaOtBu, R1 0 R< pTsOH, WeOW P(tOu),, R44I 'N R3 0 'Na R3 O a NH 2 0 N'
N
1 2 H I2R R2Z R2 K4 3 ~45 Starting nitrophenols of the type 1 are either commercially available RI1
CH
3 or prepared by published procedures RI CHF 2 or both RI and R2 CHF 2 see Mueller, Klaus-Helmut. Eur. Pat. Appi. (1994), 8 pp. CODEN: EPXXDW EP 6 2636 lAl; Toumna, Toshihiko; Asai, Tomoyuki. Jpn. Kokai Tokkyo Koho (1999), 6 pp.
CODEN: JKXXAF JP 11071319 A2; Platonov, Andrew; Seavakov, Andrew; Maiyorova, Helen; Chistokletov, Victor. Int. Symp. Wood. Pulping Chem., 1995, 8th, 3, 295-29 9; Christensen, Siegfried Benjamin; Dabbs, Steven; Karpinski, Joseph M. PCT Int.
Appl. (1996), 12 pp. CODEN: PIXXD2 WO 9623754 Al 19960808). Aniline intermediates 3 are produced in two steps; first, an addition reaction provides intermediate 2, followed by reduction of the nitro group. Intermediate nitro compounds 2 WO 02/074726 PCT/US02/01508 can be prepared by numerous published procedures, such as by Mitsunobu reactions or standard alkylation reactions. Compounds where R2 is aryl or heteroaryl can be prepared by copper catalyzed reactions with aryl or heteroaryl iodides under Ullman conditions or by coupling aryl-, vinyl-, or heteroaryl- boronic acids with phenol 2 in the presence of a copper catalyst Cu(OAc) 2 and base such as TEA. Mitsunobu reaction between an appropriately substituted nitrophenol and a primary or secondary alcohol using an azodicarboxylate DEAD, DIAD), and a suitable phosphine Ph 3 P, Bu 3
P)
provides alkylated nitrophenols 2. Mitsunobu reactions are general performed in aprotic solvents such as dichloromethane or THF. Alternatively, alkylation can be achieved by the reaction between an appropriately substituted nitrophenol and an alkyl halide in the presence of a base K 2 C0 3 or NaH) in a polar aprotic solvent DMF or
CH
3
CN).
Nitrocatechols 2 are subsequently reduced to the corresponding anilines 3 by methods standard in the art such as by hydrogenation using a suitable catalyst Pd on carbon) in a polar protic solvent MeOH or EtOH) under an atmosphere of hydrogen. Alternatively, nitrocatechols 3 can be reduced by using a hydride source NaBH 4 and a transition metal catalyst NiCI 2 Pd on carbon) or by using metals Zn, Sn, Fe) in mineral acid solutions HC1) to produce the corresponding anilines. Generally polar protic solvents such as ethanol or methanol are used in these reactions.
N-Arylalkylanilines 4 are synthesized by standard methods in the art such as by reductive amination reaction, alkylation reaction, or by reduction of corresponding amides. For example, the reductive amination reaction of an aryl or arylalkyl aldehyde with appropriately substituted anilines in the presence of a borohydride reducing agent such as NaBH 4 or NaBH 3 CN with an acid catalyst such as acetic acid or pTsOH provides desired N-arylalkylanilines. These reactions generally take place in polar protic solvents such as methanol, ethanol, isopropanol, n-propanol and the like.
WO 02/074726 PCT/US02/01508 N-Arylalkylanilines 4 readily undergo N-arylation by methods standard to the art including Ullman coupling reaction, metal-catalyzed coupling, or aromatic nucleophilic substitution reaction. For example, the metal catalyzed reaction between an Nbenzylaniline and an aryl halide using a palladium catalyst, Pd 2 dba 3 a bulky electron rich phosphine ligand tributylphosphine), and suitable base NaOtBu) provides N-Arylalkyldiphenylamines. Nickel and copper catalysts have been employed as well. Solvents useful in this reaction include non-polar aprotic solvents such as toluene, benzene, xylenes, tetrahydrofuran, and ether. When synthesizing compounds of the type 5 wherein R4 is an alkoxycarbonylphenyl, it is advantageous that amine 4 is coupled with 1.1 equivalents of tert-butyl 3-iodobenzene and that 22 mol of(tBu) 3
P,
mol of Pd 2 (dba) 3 and 1.3 equivalents of tBuONa are used.
SCHEME 2 R 1 0 Rl 0 1 R3 5) NaOH, EtOH R R3 S N R3 6) H- INR3 R2 R2 R2 0 CO 2
H
0 7 6 Carboxylic ester intermediates 6 can be hydrolyzed under acidic or basic conditions to give the corresponding carboxylic acids 7. For example, an ethyl ester Et) can be hydrolyzed using a mixture of aqueous base NaOH, KOH) and a water miscible solvent EtOH, THF). While t-Butyl esters (R5 t-butyl) can be hydrolyzed using an aqueous acid HC1, formic acid, TFA) in a water miscible organic solvent, if necessary.
WO 02/074726 PCT/US02/01508 SCHEME 3 R1 Or~ NR3 7) THF O- .N R3 R2 R2 N.'N N,NH 9 8 Coupling of protected tetrazole bromo or iodobenzenes 5-(3-iodophenyl)-2- (2-tetrahydropyran)tetrazole) with N-substituted aniline derivatives 4 produce THPprotected tetrazoles 8. Hydrolysis ofTHP-protected tetrazoles 8 can be accomplished by using an aqueous acid, such as HCI in water and a miscible solvent such as THF or EtOH to provide tetrazoles 9. Further, THP tetrazoles 8 can also be oxidatively cleaved using reagents such as CAN and DDQ in halognenated hydrocarbon solvents such as dichloromethane, chloroform, dichloroethane and the like to yield tetrazoles 9.
Alternatively, tetrazole analogs 9 can be prepared from the corresponding nitriles by treatment with azide ion KN 3 NaN 3 etc.) and a proton source NH 4 C1) in a polar aprotic solvent such as DMF. They also may be prepared by treatment with an azide ion and a Lewis acid ZnBr 2 in water, using a water miscible co-solvent such as isopropanol if necessary. Another method of preparation is by treatment of a nitrile with tin or silicon azides Me 3 SiN 3 Bu 3 SnN 3 in an aprotic organic solvent such as benzene, toluene, dichloromethane, dichloroethane, ether, THF, and the like.
SCHEME 4 WO 02/074726 PCT/US02/01508 8A) R4-B(OH)2, Cu(OAc) 2 EtN, CH2CI 2 8B) R4-1, NaOtBu, Toluene, O Pd 2 (dba) 3 P(otol), 9A) KN(TMS), R3-1, R IN 8C) R4-Br, Pd(dppf)CI,, R1i 9B THF, 0 C R1 dppf, NaOtBu, THF 9) .3-Cl. Na, DNF R 2 NH1 1 "R3 R2 R2 R4 R2 R4 3 10 Diphenylamines 10 can be prepared by coupling appropriately substituted anilines 3, such as 3-cyclopentyloxy-4-methoxyaniline, with arylboronic acids in the presence of a base such as triethylamine and a copper catalyst such as copper acetate (as described by Chan et al, Tetrahedron Lett., 39, 2933-2936 (1998)). In general, halogenated solvents such as dichloromethane, chloroform, dichloroethane, and the like as well as nonpolar aprotic solvents such as benzene, toluene, or xylene are utilized. Such diphenylamines 10) can more preferably be synthesized by metal catalyzed amination reactions.
For example, reaction of an appropriately substituted aniline 3 with an arylhalide in the presence of a base K 3 P0 4 CsCO 3 or NaOtBu) and a palladium or nickel catalyst, for example Pd(dppf)Cl 2 a ligand dppf) and a base NaOtBu) (JACS. 1996, 118, 7217) or with Pd 2 dba 3 a bulky electron rich phosphine such as P(tBu) 3 and a base NaOtBu) Org. Chem. 1999, 64, 5575) provides the desired diphenylamines Solvents most commonly utilized in this type of reaction include non-polar aprotic solvents such as benzene, toluene, tetrahydrofuran, ether, and the like.
Diphenylamines 10 can then be alkylated with various alkyl halides or arylalkyl halides such as, but not limited to iodomethane, ethylbromide, benzylchloride, 3- (chloromethyl)pyridine, 4-(chloromethyl)-2,6-dichloropyridine, and 4-(bromomethyl)benzoic acid, or salts thereof, in the presence of a non-nucleophilic base such as sodium hydride, potassium hexamethyldisilazide or potassium diisopropylamide to provide Nsubstituted diphenylamines 5. Solvents useful in this reaction include aprotic solvents such as benzene, toluene, tetrahydrofuran, ether, DMF, and the like.
WO 02/074726 PCT/US02/01508 SCHEME R1OR R| 0 10) pyBOP, DIPEA, NHR5R6 0 N R3 ONN 3 CH 2
CI
2
R
R2
CO
2 H 7 R6 11 Carboxylic acids 7 can be further manipulated to form carboxamides 11 using methods standard in the art. For example, a carboxylic acid can be treated with a suitable primary or secondary amine, in the presence of a suitable coupling reagent such as BOP, pyBOP or DCC, and a base such as Et 3 N or DIEA to yield a carboxamide. These reactions generally take place in non-polar aprotic solvents such as dichloromethane, chloroform, or dichloroethane.
Carboxylic esters 6 or acids 7 can be reduced using methods standard in the art to give the corresponding carboxaldehyde or hydroxymethyl analogs. For example, an aryl ethyl ester structure 6, R5 ethyl) can be treated with an appropriate reducing agent LAH, DIBAL, etc.)'in an aprotic solvent such as ether or THF, to produce the corresponding carboxaldehydes or hydroxymethyl analogs. Such aldehydes and alcohols can be further derivatised by methods standard in the art.
Similarly carboxamides structure 11) and nitriles can be reduced using methods standard in the art to provide the corresponding substituted amines or aminomethyl analogs. For example, an aryl carboxamide 11 can be reduced with an appropriate reducing agent LAH) in an aprotic solvent benzene, toluene, ether, THF, etc.) to give the corresponding substituted aminomethyl analog. Whereas reduction of an aryl nitrile yields the corresponding primary aminomethyl analog.
WO 02/074726 PCT/US02/01508 SCHEME 6 R1 R3 11) 10% Pd/C, H2, 0 N EtOH R2
NO
z 12 .R3 12) R 5
SO
2 CI, or RCOCI Pyr., CH 2
CI
2
NH
2 R1' NR3 R2
NH
O
1 14 R1 O ,R3 R2
R
NH
R6-O 0 Nitrobenzene compounds 12 can be reduced to the corresponding anilines 13 by methods standard in the art such as hydrogenation using a suitable catalyst Pd on carbon) in a polar protic solvent EtOH, MeOH, etc.). Nitrobenzenes 12 can also be reduced using a hydride source NaBH 4 and a transition metal catalyst NiC1 2 Pd on carbon) in polar protic solvents such as EtOH, to produce the corresponding anilines 13. These anilines can then befurther substituted by methods standard in the art.
For example, anilines of the type 13 can be alkylated, acylated, or sulfonylated to give the corresponding N-alkyl amines, carboxamides structure 15) or sulfonamides structure 14) respectively. For example, a sulfonamide can be prepared from an aniline and an appropriate sulfonyl halide or sulfonic anhydride MeSO 2 C1, EtSO 2 Cl, BnSO 2 C1, PhSO 2 CI, etc.) in the presence of a base Et 3 N, pyridinc, DIEA, etc.).
Suitable solvents for this reaction include non-polar aprotic solvents such as dichloromethane, chloroform, ether, and the like.
WO 02/074726 PCT/US02/01508 SCHEME 7 R1 0 R a NR3 17)TBAF, THF, OC R1R3 0 N R3 I HO- Si R4 R 4 R4 16 17 18A) R2-Br, K 2 CO, DMF 18B) DIAD, PPh 3 Imd., R2-OH, THF O NR3 I I R2 R4 Trialkylsilylethers of the type 16 are prepared as described in Scheme 1. The tert-butyldimethylsilyl protected catechol intermediates 16 are readily deprotected by numerous literature methods (see Greene, T.W. and Wuts, Protective Groups in Organic Synthesis, 3 rd Edition, John Wiley Sons, 1999, pp. 273-276.) such as by using a fluoride ion source Bu 4 NF) in an aprotic solvent such as ether or THF; or under acidic conditions KF, 48% HBr, DMF). The resultant phenol 17, which is a very useful synthetic intermediate, can then be alkylated by methods standard in the art and in a similar manner as described for the alkylation ofnitrophenol 2 in Scheme 1. For example, by the Mitsunobu reaction, by reaction with an alkyl halide in the presence of a base, or by Ullman type aryl coupling or by reaction with vinyl-, aryl- or heteroarylboronic acids in the precence of a copper catalyst.
SCHEME 8 R1 O R1O O N,R3 21) NHRR 6
K
2
CO
3 O NR3 0 N CHCN 0 N R CH CNR2 Z 1 5. R2 I 19 R6 WO 02/074726 PCT/US02/01508 Haloalkoxy intermediates 18, prepared by alkylation of the corresponding phenol, can be alkylated by reactions with substituted amines, alcohols, or thiols in the presence of a base to provide analogs such as 19. For example, an alkyl halide can be aminated with an appropriate primary or secondary amine and a base such as K 2
CO
3 in a polar aprotic solvent such as THF, DMF, or CH 3
CN.
Many of these synthetic procedures are described more fully in the examples below.
One of ordinary skill in the-art will recognize that some of the compounds of Formulae and can exist in different geometrical isomeric forms. In addition, some of the compounds of the present invention possess one or more asymmetric carbon atoms and are thus capable of existing in the form of optical isomers, as well as in the form of racemic or nonracemic mixtures thereof, and in the form of diastereomers and diastereomeric mixtures inter alia. All of these compounds, including cis isomers, trans isomers, diastereomic mixtures, racemates, nonracemic mixtures of enantiomers, and substantially pure and pure enantiomers, are within the scope of the present invention.
Substantially pure enantiomers contain no more than 5% w/w of the corresponding opposite enantiomer, preferably no more than most preferably no more than 1%.
The optical isomers can be obtained by resolution of the racemic mixtures according to conventional processes, for example, by the formation ofdiastereoisomeric salts using an optically active acid or base or formation of covalent diastereomers.
Examples of appropriate acids are tartaric, diacetyltartaric, dibenzoyltartaric, ditoluoyltartaric and camphorsulfonic acid. Mixtures of diastereoisomers can be separated into their individual diastereomers on the basis of their physical and/or chemical differences by methods known to those skilled in the art, for example, by chromatography or fractional crystallization. The optically active bases or acids are then liberated from the separated diastereomeric salts. A different process for separation of optical isomers involves the use of chiral chromatography chiral HPLC columns), WO 02/074726 PCT/US02/01508 with or without conventional derivation, optimally chosen to maximize the separation of the enantiomers. Suitable chiral HPLC columns are manufactured by Diacel, e.g., Chiracel OD and Chiracel OJ among many others, all routinely selectable. Enzymatic separations, with or without derivitization, are also useful. The optically active compounds of Formulae I and I' can likewise be obtained by chiral syntheses utilizing optically active starting materials.
The present invention also relates to useful forms of the compounds as disclosed herein, such as pharmaceutically acceptable salts and prodrugs of all the compounds of the present invention. Pharmaceutically acceptable salts include those obtained by reacting the main compound, functioning as a base, with an inorganic or organic acid to form a salt, for example, salts of hydrochloric acid, sulfuric acid, phosphoric acid, methane sulfonic acid, camphor sulfonic acid, oxalic acid, maleic acid, succinic acid and citric acid. Pharmaceutically acceptable salts also include those in which the main compound functions as an acid and is reacted with an appropriate base to form, e.g., sodium, potassium, calcium, mangnesium, ammonium, and choline salts. Those skilled in the art will further recognize that acid addition salts of the claimed compounds may be prepared by reaction of the compounds with the appropriate inorganic or organic acid via any of a number of known methods. Alternatively, alkali and alkaline earth metal salts are prepared by reacting the compounds of the invention with the appropriate base via a variety of known methods.
The following are further examples of acid salts that can be obtained by reaction with inorganic or organic acids: acetates, adipates, alginates, citrates, aspartates, benzoates, benzenesulfonates, bisulfates, butyrates, camphorates, digluconates, cyclopentanepropionates, dodecylsulfates, ethanesulfonates, glucoheptanoates, glycerophosphates, hemisulfates, heptanoates, hexanoates, fumarates, hydrobromides, hydroiodides, 2-hydroxy-ethanesulfonates, lactates, maleates, methanesulfonates, nicotinates, 2-naphthalenesulfonates, oxalates, palmoates, pectinates, persulfates, 3phenylpropionates, picrates, pivalates, propionates, succinates, tartrates, thiocyanates, tosylates, mesylates and undecanoates.
WO 02/074726 PCT/US02/01508 Preferably, the salts formed are pharmaceutically acceptable for administration to mammals. However, pharmaceutically unacceptable salts of the compounds are suitable as intermediates, for example, for isolating the compound as a salt and then converting the salt back to the free base compound by treatment with an alkaline reagent. The free base can then, if desired, be converted to a pharmaceutically acceptable acid addition salt.
The compounds of the invention can be administered alone or as an active ingredient of a formulation. Thus, the present invention also includes pharmaceutical compositions of compounds of Formulae I or I' containing, for example, one or more pharmaceutically acceptable carriers.
Numerous standard references are available that describe procedures for preparing various formulations suitable for administering the compounds according to the invention. Examples of potential formulations and preparations are contained, for example, in the Handbook of Pharmaceutical Excipients, American Pharmaceutical Association (current edition); Pharmaceutical Dosage Forms: Tablets (Lieberman, Lachman and Schwartz, editors) current edition, published by Marcel Dekker, Inc., as well as Remington's Pharmaceutical Sciences (Arthur Osol, editor), 1553-1593 (current edition).
In view of their high degree of PDE4 inhibition, the compounds of the present invention can be administered to anyone requiring or desiring PDE4 inhibition, and/or enhancement of cognition. Administration may be accomplished according to patient needs, for example, orally, nasally, parenterally (subcutaneously, intraveneously, intramuscularly, intrastemally and by infusion), by inhalation, rectally, vaginally, topically, locally, transdermally, and by ocular administration.
Various solid oral dosage forms can be used for administering compounds of the invention including such solid forms as tablets, gelcaps, capsules, caplets, granules, lozenges and bulk powders. The compounds of the present invention can be administered WO 02/074726 PCT/US02/01508 alone or combined with various pharmaceutically acceptable carriers, diluents (such as sucrose, mannitol, lactose, starches) and excipients known in the art, including but not limited to suspending agents, solubilizers, buffering agents, binders, disintegrants, preservatives, colorants, flavorants, lubricants and the like. Time release capsules, tablets and gels are also advantageous in administering the compounds of the present invention.
Various liquid oral dosage forms can also be used for administering compounds of the invention, including aqueous and non-aqueous solutions, emulsions, suspensions, syrups, and elixirs. Such dosage forms can also contain suitable inert diluents known in the art such as water and suitable excipients known in the art such as preservatives, wetting agents, sweeteners, flavorants, as well as agents for emulsifying and/or suspending the compounds of the invention. The compounds of the present invention may be injected, for example, intravenously, in the form of an isotonic sterile solution.
Other preparations are also possible.
Suppositories for rectal administration of the compounds of the present invention can be prepared by mixing the compound with a suitable excipient such as cocoa butter, salicylates and polyethylene glycols. Formulations for vaginal administration can be in the form of a pessary, tampon, cream, gel, paste, foam, or spray formula containing, in addition to the active ingredient, such suitable carriers as are known in the art.
For topical administration the pharmaceutical composition can be in the form of creams, ointments, liniments, lotions, emulsions, suspensions, gels, solutions, pastes, powders, sprays, and drops suitable for administration to the skin, eye, ear or nose.
Topical administration may also involve transdermal administration via means such as transdermal patches.
Aerosol formulations suitable for administering via inhalation also can be made.
For example, for treatment of disorders of the respiratory tract, the compounds according to the invention can be administered by inhalation in the form of a powder WO 02/074726 PCT/US02/01508 micronized) or in the form of atomized solutions or suspensions. The aerosol formulation can be placed into a pressurized acceptable propellant.
The compounds can be administered as the sole active agent or in combination with other pharmaceutical agents such as other agents used in the treatment of cognitive impairment and/or in the treatment of psychosis, other PDE4 inhibitors, calcium channel blockers, chloinergic drugs, adenosine receptor modulators, amphakines NMDA- R modulators, mGluR modulators, and cholinesterase inhibitors donepezil, rivastigimine, and glanthanamine). In such combinations, each active ingredient can be administered either in accordance with their usual dosage range or a dose below its usual dosage range.
The present invention further includes methods of treatment that involve inhibition of PDE4 enzymes. Thus, the present invention includes methods of selective inhibition of PDE4 enzymes in animals, mammals, especially humans, wherein such inhibition has a therapeutic effect, such as where such inhibition may relieve conditions involving neurological syndromes, such as the loss of memory, especially long-term memory. Such methods comprise administering to an' animal in need thereof, especially a mammal, most especially a human, an inhibitory amount of a compound, alone or as part of a formulation, as disclosed herein.
The condition of memory impairment is manifested by impairment of the ability to learn new information and/or the inability to recall previously learned information.
Memory impairment is a primary symptom of dementia and can also be a symptom associated with such diseases as Alzheimer's disease, schizophrenia, Parkinson's disease, Huntington's disease, Pick's disease, Creutzfeld-Jakob disease, HIV, cardiovascular disease, and head trauma as well as age-related cognitive decline.
Dementias are diseases that include memory loss and additional intellectual impairment separate from memory. The present invention includes methods for treating patients suffering from memory impairment in all forms of dementia. Dementias are WO 02/074726 PCT/US02/01508 classified according to their cause and include: neurodegenerative dementias Alzheimer's, Parkinson's disease, Huntington's disease, Pick's disease), vascular infarcts, hemorrhage, cardiac disorders), mixed vascular and Alzheimer's, bacterial meningitis, Creutzfeld-Jacob Disease, multiple sclerosis, traumatic subdural hematoma or traumatic brain injury), infectious HIV), genetic (down syndrome), toxic heavy metals, alcohol, some medications), metabolic vitamin B12 or folate deficiency), CNS hypoxia, Cushing's disease, psychiatric depression and schizophrenia), and hydrocephalus.
The present invention includes methods for dealing with memory loss separate from dementia, including mild cognitive impairment (MCI) and age-related cognitive decline. The present invention includes methods of treatment for memory impairment as a result of disease. In another application, the invention includes methods for dealing with memory loss resulting from the use of general anesthetics, chemotherapy, radiation treatment, post-surgical trauma, and therapeutic intervention.
The compounds may be used to treat psychiatric conditions including schizophrenia, bipolar or manic depression, major depression, and drug addiction and morphine dependence. These compounds may enhance wakefulness. PDE4 inhibitors can be used to raise cAMP levels and prevent neurons from undergoing apoptosis. PDE4 inhibitors are also known to be anti-inflammatory. The combination of anti-apoptotic and anti-inflammatory properties make these compounds useful to treat neurodegeneration resulting from any disease or injury, including stroke, spinal cord injury, neurogenesis, Alzheimer's disease, multiple sclerosis, amylolaterosclerosis (ALS), and multiple systems atrophy (MSA).
Thus, in accordance with a preferred embodiment, the present invention includes methods of treating patients suffering from memory impairment due to, for example, Alzheimer's disease, schizophrenia, Parkinson's disease, Huntington's disease, Pick's disease, Creutzfeld-Jakob disease, depression, aging, head trauma, stroke, CNS hypoxia, cerebral senility, multiinfarct dementia and other neurological conditions including acute WO 02/074726 PCT/US02/01508 neuronal diseases, as well as HIV and cardiovascular diseases, comprising administering an effective amount of a compound according to Formula or or pharmaceutically acceptable salts thereof.
The compounds of the present invention can also be used in a method of treating patients suffering from disease states characterized by decreased NMDA function, such as schizophrenia. The compounds can also be used to treat psychosis characterized by elevated levels of PDE 4, for example, various forms of depression, such as manic depression, major depression, and depression associated with psychiatric and neurological disorders.
As mentioned, the compounds of the invention also exhibit anti-inflammatory activity. As a result, the inventive compounds are useful in the treatment of a variety of allergic and inflammatory diseases, particularly disease states characterized by decreased cyclic AMP levels and/or elevated phosphodiesterase 4 levels. Thus, in accordance with a further embodiment of the invention, there is provided a method of treating allergic and inflammatory disease states, comprising administering an effective amount of a compound according to Formulae or or a pharmaceutically acceptable salt thereof.
Such disease states include: asthma, chronic bronchitis, chronic obstructive pulmonary disease (COPD), atopic dermatitis, urticaria, allergic rhinitis, allergic conjunctivitis, vernal conjunctivitis, esoniophilic granuloma, psoriasis, inflammatory arthritis, rheumatoid arthritis, septic shock, ulcerative colitis, Crohn's disease, reperfusion injury of the myocardium and brain, chronic glomerulonephritis, endotoxic shock, adult respiratory distress syndrome, cystic fibrosis, arterial restenosis, artherosclerosis, keratosis, rheumatoid spondylitis, osteoarthritis, pyresis, diabetes mellitus, pneumoconiosis, chronic obstructive airways disease, chronic obstructive pulmonary disease, toxic and allergic contact eczema, atopic eczema, seborrheic eczema, lichen simplex, sunburn, pruritis in the anogenital area, alopecia areata, hypertrophic scars, discoid lupus erythematosus, systemic lupus erythematosus, follicular and wide-area pyodermias, endogenous and exogenous acne, acne rosacea, Beghet's disease, WO 02/074726 PCT/US02/01508 anaphylactoid purpura nephritis, inflammatory bowel disease, leukemia, multiple sclerosis, gastrointestinal diseases, autoimmune diseases and the like.
PDE4 inhibitors for, treating asthma, chronic bronchitis, psoriasis, allergic rhinitis, and other inflammatory diseases, and for inhibiting tumor necrosis factor are known within the art. See, WO 98/58901, JP11-18957, JP 10-072415, WO 93/25517, WO 94/14742, US 5,814,651, and US 5,935,9778. These references also describe assays for determining PDE4 inhibition activity, and methods for synthesizing such compounds.
The entire disclosures of these documents are hereby incorporated by reference.
PDE4 inhibitors may be used to prevent or ameliorate osteoporosis, as an antibiotic, for treatment of cardiovascular disease by mobilizing cholesterol from atherosclerotic lesions, to treat rheumatoid arthritis for long-term inhibition of mesenchymal-cell proliferation after transplantation, for treatment of urinary obstruction secondary to benign prostatic hyperplasia, for suppression of chemotaxis and reduction of invasion of colon cancer cells, for treatment of B cell chronic lymphocytic leukemia (B- CLL), for inhibition of uterine contractions, to attenuate pulmonary vascular ischemiareperfusion injury (IRI) for coreal hydration, for inhibition of IL-2R expression and thereby abolishing HIV-1 DNA nuclear import into memory T cells, for augmentation of glucose-induced insulin secretion, in both the prevention and treatment of colitis, and to inhibit mast cell degranulation.
The compounds of the present invention can be administered as the sole active agent or in combination with other pharmaceutical agents such as other agents used in the treatment of cognitive impairment and/or in the treatment of psychosis, other PDE4 inhibitors, calcium channel blockers, chloinergic drugs, adenosine receptor modulators, amphakines NMDA-R modulators, mGluR modulators, and cholinesterase inhibitors donepezil, rivastigimine, and glanthanamine). In such combinations, each active ingredient can be administered either in accordance with their usual dosage range or a dose below their usual dosage range.
WO 02/074726 PCT/US02/01508 The dosages of the compounds of the present invention depend upon a variety of factors including the particular syndrome to be treated, the severity of the symptoms, the route of administration, the frequency of the dosage interval, the particular compound utilized, the efficacy, toxicology profile, phannrmacokinetic profile of the compound, and the presence of any deleterious side-effects, among other considerations.
The compounds of the invention are typically administered at dosage levels and in a mammal customary for PDE4 inhibitors such as those known compounds mentioned above. For example, the compounds can be administered, in single or multiple doses, by oral administration at a dosage level of, for example, 0.01-100 mg/kg/day, preferably 0.1mg/kg/day, especially 0.5-10 mg/kg/day. Unit dosage forms can contain, for example, 0.1-50 mg of active compound. For intravenous administration, the compounds can be administered, in single or multiple dosages, at a dosage level of, for example, 0.001-50 mg/kg/day, preferably 0.001-10 mg/kg/day, especially 0.01-1 mg/kg/day. Unit dosage forms can contain, for example, 0.1-10 mg of active compound.
In carrying out the procedures of the present invention it is of course to be understood that reference to particular buffers, media,;reagents, cells, culture conditions and the like are not intended to be limiting, but are to be read so as to include all related materials that one of ordinary skill in the art would recognize as being of interest or value in the particular context in which that discussion is presented. For example, it is often possible to substitute one buffer system or culture medium for another and still achieve similar, if not identical, results. Those of skill in the art will have sufficient knowledge of such systems and methodologies so as to be able, without undue experimentation, to make such substitutions as will optimally serve their purposes in using the methods and procedures disclosed herein.
The present invention will now be further described by way of the following nonlimiting examples. In applying the disclosure of these examples, it should be kept clearly in mind that other and different embodiments of the methods disclosed according to the present, invention will no doubt suggest themselves to those of skill in the relevant art.
WO 02/074726 PCT/US02/01508 In the foregoing and in the following examples, all temperatures are set forth uncorrected in degrees Celsius; and, unless otherwise indicated, all parts and percentages are by weight.
The entire disclosures of all applications, patents and publications, cited above and below, are hereby incorporated by reference.
EXAMPLE 1A 1-Cyclopentyloxy-2-methoxy-5-nitrobenzene To a suspension of 2-methoxy-5-nitrophenol (525g, 3.104 mol) and potassium carbonate (643.5g, 4.66 mol) in dimethylformamide (1 under N 2 protection, was added cyclopentyl bromide (499.2 mL, 4.66 mol). The suspension was heated to 100°C for 6h. Potassium carbonate (85.8g, 0.62 mol) and cyclopentyl bromide (50 mL, 0.46 mol) were added. The suspension was heated to 100 0 C for 4h. TLC indicated the reaction was complete (9:1 DCM:MeOH). The reaction mixture was cooled to room temperature and diluted with water (3L) and ether The layers were separated and the aqueous layer was re-extracted with ether The combined organic layers were washed with IN NaOH water and brine The organic layer was dried over sodium sulfate, filtered, and evaporated. The resulting solid was azeotroped with toluene (2 x 300 mL) to obtain 736:7g (99.6% yield) as a yellow solid.
The following compounds were prepared in a similar manner as described above: a) 1-Cyclopropylmethoxy-2-methoxy-5-nitrobenzene b) 1-Cyclopentoxy-2-difluoromethoxy-5-nitrobenzene WO 02/074726 WO 02/74726PCT/US02/01508 c) 1 -Cyclopropylmethoxy-2--diflioromethoxy-5 -nitrobenzene EXAMPLE lB 2-Meth oxy-5-nitro-1I-((3R)-tetrahydrofu ryloxy)b enzene To a mixture of 2-Methoxy-5-nitrophenol (1.69 g, 10 mmol), triphenyiphosphine (5.24 g, 20 mmol) and 3-(R)-hydroxytetrahydrofuran (1.80 g, 20 mimol) in anhydrous tetrahydrofuran (40 mL) was added drop-wise, with stirring, diisopropylazodicarboxylate mL, 20 mmol) and the mixture was allowed to stir at room temperature for 16 h.
The mixture was diluted with ether (15 0 mL) and washed with 2N NaOH (3 x 5 0 mL) and brine (50 mL), (MgSO 4 and concentrated in vacuo. The crude residue was purified by flash column chromatography over silica gel (Biotage Flash 40M) eluting with ethyl acetate in hexanes to give 1.05 g of product The following compounds were prepared in a similar manner as described above: a) 2 -Methoxy- 5-nitro- 1 -tetrahydro furyloxy)benzene b) 2-Methoxy- 5-nitro- 1 S)-tetrahydro furyloxy)benzene c) 2-Difluoromethoxy-5 -nitro- 1 -(3-tetrahydiofuryloiy)benzene d) 2-Difluoromethoxy-5 -nitro- I -((3R)-tetrahydrofuryloxy)benzene e) 2-Difluoromethoxy-5 -nitro- 1 -((3S)-tetrahvdrofuryloxy)benzene f) 2-Methoxy-5 -nitro-1I -phenpropyloxy)benzene g) 1 -(2-Indanyloxy)-4-methoxy-5-nitrobenzene EXAMPLE iC 1 -(tert-B To a mixture of 2-methoxy-5-nitrophenol (1.53 g, 9.0 mmol) and imidazole (1.08 g, 15.9 mmol) in anhydrous DMF (40 mL) was added, with stirring, tertbutyldimethylsilyl chloride (2.05 g, 13.6 mmol) and the mixture was allowed to stir at room temperature for 16 h. The solvent was removed in vacuo and the residue was dissolved in 40 mL of 5 0% ethyl acetate in hexanes and, filtered through 10 g of silica gel.
The silica gel was washed with an additionatV200 mL of 50% ethyl acetate in hexanes and WO 02/074726 WO 02/74726PCT/US02/01508 the filtrates were combined and concentrated in vacue to give 2.01 g of product as a tan crystalline solid, 'H NMR (CDCl 3 8 7.89 (dd, 1H, J 9.0 Hz, 2.8 Hz), 7.69 lH, J= 2.8 Hz), 6.88 1H, J 3.90 3H), 1.00 9H), 0.18 6H).
EXAMPLE 2 3-Cyclopentyloxy-4-methoxyaniline To a suspension of 10% Pd on activated carbon (25g) in ethanol under N 2 protection, was added 1-cyclopentyloxy-2-methoxy-5-nitrobenzene (250g, 1.054 mol).
The reaction mixture was degassed under vacuum three times. The reaction mixture was stirred vigorously while hydrogen gas was allowed to flow over the reaction mixture.
After 4h the reaction was complete by TLC (5:1 hex:EA). The reaction mixture was filtered through a pad of celite and the celite was rinsed with additional ethanol. The solvent was removed in-vacuo to obtain 208.38g (95% yield) of 3-cyclopentyloxy-4methoxyaniline as a red liquid, I'H NMR (CDCl 3 5 6.85 J =8.4Hz, IH), 6.29 1H), 6.19 (dd, J 8.4, 11H), 4.69 J =4.4 Hz, 111), 3.75 3H), 3.44 (bs, 2H), 1.90-1.81 (in, 61H), 1.61-1.55 (in, 2H1).
The following compounds were prepared in a similar manner as described above:.
a) 3 -Cyclopentyloxy-4-difluoromethoxyaniline b) 3-Cyclopropylmethoxy-2-methoxyaniline c) 3 -Cyclopropylmethoxy-4-difluoromethoxyaniline d) 4-Methoxy-3-((3R)-tetrahydrofuryloxy)anilinc e) 4-Methoxy- 3-(tetrahydro furyloxy)ani line f) 4-Methoxy-3 +(35S)-tetrahydrofurytoxy)ani line g) 4-Difluoromethoxy-3 -tetrahydrofuryloxy) aniline h) 4-Difluoromethoxy-3-((3R)-tetrahydrofuryloxy)aniline i)4-Difluoromethoxy-3-((38S)-tetrahydro flryloxy)ani line j) 3-(tert-Butyldimethylsilyl)oxy-4-methoxyaniline WO 02/074726 WO 02/74726PCT/US02/01508 k) 4-Methoxy-3 -phenpropyloxy) aniline 1) 3-(2-lndanyloxy)-4-methoxyaniline EXAMPLE 3 3-Cyclopentyl-4-inethoxy-N-(3-pyridylmethyl)aniline To a mixture of 3-py'ridinecarboxaldehyde (106.55g, 0.995 mot) in methanol (5L) was added 3-cyclopentyloxy-4-methoxyaniline (208.38g, 1.005 mot) and p-toluenesulfonic acid monohydrate (200 mg). The reaction mixture was stirred for 4h. The flask was then cooled to 0 0 C and sodium borohydride (37.64g, 2.3 mol) was added portionwise over 4h.
0 The reaction mixture was allowed to warm to room temperature over 1 6h with stirring.
TLC indicated the reaction was complete (1:3 hex:EA). The solvent was evaporated until approximately 0.5L of slurry remained. The slurry was diluted with water (IL) anad extracted With ethyl acetate (2 x 2L). The combined organic layers were washed with brine (500 mL), dried over sodium sulfate, and concentrated to yield 300g (100% yield) of the desired product as a brown viscous liquid- 'HNMR (CDC1 3 )568.61-S.48(in,211), 7.69-7,67 (in, IH), 7.24-7.21 (in, lH), 6.72 J =8.4 Hz, 111), 6.23 LH), 6.13 (dd, J 2.6, 8.6, 1H), 4.65 (bs, 111), 4.27 2H),,4.0 (bs, 1H1), 3.73 3H1), 1.88-1.70 (mn, 6H), 1.65-1.45 (in, 2H).
!0 The following compounds were prepared in a similar manner as described above: a) 3-Cyclopentyloxy-4-inethoxy-N-(3-thienylmethyl)aniline b) 3-Cyclopentyloxy-4-inethoxy-N-(4-pyridylinethyl)aniline c) 3-Cyclopentyloxy-N-(2,6-dichloro-4-pyridylmethyl)- 4-niethoxyaniline d) 3 -Cyclopentyloxy-4-methoxy-N-(2-quinolinylmethyl)anitine e) 3 -Cyclopentyloxy-4-inethoxy-N'-(3-quinolinylmethyl)aniline f) 3-Cyclopentyloxy-4-inethoxy-N-(4-quinolinylmethyl)aniline g) 3 -Cyclopentyloxy-4-methoxy-N-(2-pyrazinylmethyl)aniline h) 4-Methoxy-N-(3 -pyridylmethyl)-3 -tetrahydro-furyloxy)ani line 0 i) 4.Methoxy-N-(3 -pyridylmethyl)-3-((3R)-tetrahydrofuryloxy)aniline j) 4-Methoxy-N-(3j-pynidylmethyl)-3-((35)-tetrahydrofuryloxy)aniine WO 02/074726 WO 02/74726PCT/US02/01508 k) 3-Cyclopropylmethoxy-4-difluoromethoxy-N-(3-pyridylmethyl)aniline 1) 3-Cyclopentyloxy-4-difluoromethoxy-N'-(3-pyridylmethyl)aniline m) 4-Difl uoromethoxy-N-(3 -pyridylmethyl)-3 -tetrahydro furyloxy) aniline n) 4-Difluoromethoxy-N-(3 -pyridylmnethyl)-3 -((3R)-tetrahydrofuryloxy)aniline o) 3 ,4-Bis(difluoromethoxy-N-(3 -p yridylmethy1) aniline p) 3 -tert-Butyldimethylsilyloxy-4-methoxy-N-(3 -pyridylmethyl) aniline q) 3 -Cyclopentyloxy-4-methoxy-N-(2-pyridylmethyl)aniline r) 3 -Cyclopentyloxy-4-methoxy-N- r[I -(2-phenethyl)] aniline s) N-Benzyl-3-cyclopentyloxy-4-methoxyaniline t) N-[(Cyclohex- 1 -en- I yl)methyl] -3-cyclopentyloxy-4-methoxyani line u) 3-Cyclopentyloxy-4-methoxy-N-(3 v) N-[(Cyclohex-3 -en-i -yl)methyl] -3-cyclopentyloxy-4-methoxyaniline w) 3 -Cyclopentyloxy-4-mcthoxy-N-(2,4,6-trimethylbenzyl)aniline x) 3-Cyclopentyloxy-4-methoxy-N-(2-methylbenzyl)aniline y) 3 -Cyclopentyloxy-4-methoxy-N-(2 -tifluoromethylbenzyl)aniline z) 3 -Cylclopentylox y-4-methoxy-N-((3 ,4-methylenedioxy)benzyl)ani line aa) 3-Cyclopentyloxy-N-(2-hydroxy-3-methoxylbenzyl)-4-methoxyaniline bb) 3 -Cyclopentyloxy-N-(3 -furylmethyl)-4-methoxyaniline cc) 3-Cyci opentyloxy-4-methoxy-N-(3 -methylbenzyl)aniline dd) 3 -Cyclopentyloxy-4-methoxy-N-(2 -methoxybenzyl) aniline ee) 3 -Cyclopentyloxy-4-methoxy-N-(3 -chlorabenzyl)aniline ff) 3 -Cyclopentyloxy-4-methoxy-N-(3 -methoxybenzyl)aniline gg) 3-Cyclopentyloxy-4-methoxy-N-(2 -chlorobenzyl)aniline hh) 3-Cyclopentyloxy-4-methoxy-N-(3 -methylbenzyl)aniline ii) 4-Methoxy-3-(3 -phenpropyloxy)-N-(4-pyridylmethyl)aniline jj) N-(2 ,6-Dichloro-4-pyrictylmethyl)-3-(2-indanyloxy)-4-methoxyaniline kk) 4-Methoxy-3-(3-phenpropyloxy)-N-(2-pyridylmethyl)aniline 11) N-(2,6-Dichloro-4-p yridylmethyl)-4-methoxy-3-(3-phenpropyloxy) aniline nun) 4-Methoxy-3 -phenpropylox yridylmethyl) aniline nn) 3 -Cyclopentyloxy-4-methoxy-N-(2-thienylmethyl)aniline oo) 3 -(2-Indanyloxy)-4-methoxy-N-(3-thienylmethyl)aniline WO 02/074726 WO 02/74726PCT/US02/01508 pp) 4-Methoxy-3 -phenprop yloxy)-N-( 3 -thi enyl methyl)ani line qq) 3 -(2-Jndanyloxy)-4-methoxy-N-(2 -pyri dylmethyl)ani line a) 3-(2-Tndanyloxy)-4-methoxy-N-(3-pyridyhmethyl)aniline ss) 3-(2-lndanyloxy)-4-methoxy-N-(4-pyridylmethyl)aniline tt) 3 -Cyclopentyloxy-4-methoxy-N-(3 -piperidinemethyl)aniline uu) 3-Cyclopentyloxy-4-methoxy-N-(3 -terlbutyloxycarbonyl)piperidinemethyl)aniline vv) 3-Cyclope-ntyloxy-4-methoxy-N-(6-methyl-2-pyridylmethyl)aniline ww) N-(2-Chloro-3-pyridylmethyt)-3-cyclopentyloxy-4-methoxyaniline xx) N-(2 -Chloro- 5 -pyridylmethyl)-3 -cyclopentyloxy-4-methoxyani line yy) 3 -Cyclopentyloxy-4-methoxy-N-(2-thiazolylmethyl)aniline EXAMPLE 4 3-Cyclopentyloxy-4-methoxy-N-(3-pyridylmethyl)diphenylamine To a 100 mL oven dried, argon flushed flask was added in the following order 0.59 g (6.10 mmol) of NaOtBu, 360 mg of Pd 2 dba 3 20 mL of toluene, 0.14 mL of P(tBU) 3 and a mL solution of 1.3 g (4.36 mmol) of N-(3-pyridylmethyl)-3-cyclopentyloxy-4methoxyaniline in toluene. With stirring, 3.1 Z (151 mmol) of iodoberizene was added dropwise and the mixture was stirred for 18 hours. The reaction mixture was diluted with EtOAc and washed twice with H 2 0 and extracted with 3 x 15 mL of 3N HCL. The combined acid extracts were washed with 15 rnL of EtOAc and then carefully neutralized with 6N NaOH to pH greater than 12. The basic solution was extracted with 2 x 15 mL of EtOAc and the combined organic fractions were subsequently washed with 15 mL of
H
2 0 and brine, dried (MgS0 4 and concentrated. The residue was purified by chromatography over silica gel (Biotage Flash 40M) eluting with 25% EtOAc in hexanes.
The material was further purified by crystallization from hexanes to give 550 mng of a white solid.. 1 H NMR (CDCl 3 8 8.61 I 8.49 I1H, J =4.2 Hz), 7.67 IlH, 7.9 Hz), 7.30-7.10 (in, 3H), 6.90-6.80 (in, 4H), 6.80-6.60 (in, 2H), 4.94 2H), 4.64 1H, J =4.1 Hz),3.84 3H), 1.86-1.70 (in, 6H), 1.65-1.45 (in, 2H).
The following compounds were prepared in a similar manner as described above: WO 02/074726 WO 02/74726PCT/US02/01508 a) 3-Cyclopentyloxy-4-methoxy-2 '-methyl-N-(3 -pyridylmethyl)diphenylamine b) 3-Cyclopentyloxy-4-methoxy-3 '-melhyl-N-(3 -pyridylmethyl)diphenylamine c) 3-Cyclopentyloxy-4-methoxy-4 '-methyl-N-(3 -pyridylmethyl)diphenylamine d) 3-Cyclopentyloxy-4 '-ethyl-4-methoxy-N-(3 -pyridylmethyl)diphenylamine e) 3 '-Chloro-3 -cyclopentyloxy-4-methoxy-N-(3-pyridylmethyl)diphenylamine f) 4'-Chloro-3-cyclopentyloxy-4-methoxy-N-(3-pyridylmethyl)diphenylamine g) 3-Cyclopentyloxy-2 ',4-dimethoxy-N-(3-pyridylmethyl)diphenylamine h) 3-Cyclopentyloxy-3 ',4-dimethoxy-N-(3 -pyridylmethyl)diphenylamine 3-.Cyclopentyloxy-4,4 '-di methoxy-N-(3 -pyridylmethyl)diphenylamine j) 3-Cyclopentyloxy-4-methoxy-N-(3 -pyridylmethyl)-3 '-trifluoromethyldiphenylamine k) 3-Cyc lopentyloxy-4-methoxy-N-(3 -pyridylmethyl)-4 '-trifluoromethyldiphenylamine 1) 3-Cyclopentyloxy-3 -loo4mtoy--3prdlehy~ihnlmn m) 3-Cyclopentyloxy-4 '-fluoro-4-methoxy-iV-(3-pyridylmethyl)diphenylamine n) 3-Cyclopentyloxy-4-methoxy-3 '-phenyl-N-(3 -pyridylmethyl)diphenylamine o) 3-Cyclopentyloxy-4-methoxy-4' -phenyl-N-(3-pyridylmethyl)diphenylamine p) 3 '-Cyano-3-cyclopentyloxy-4-methoxy-N-(3 -pyridylmethyl)diphenylamine q) 4 '-Cyano-3-cyclopentyloxy-4-methoxy-N-(3 -pyridylmethyl)diphenylamine r) Ethyl N-(3-cyclopentyloxy-4-methoxyphenyl)-N-(3 -pyridylmethyl)-3-aminobenzoate s) Ethyl N-(3-cyclopentyloxy-4-methoxyphenyl)-N-(3 -pyridylmethyl)-4-arninobenzoate t) 3:-Cyclopentyloxy-4-methoxy-3 '-nitro-N-(3 -pyridylmethyl)diphenylamine u) 3-Cyclope-ntyloxy-4-methoxy-4' -nitro-N-(3 -pyridylmethyl)diphenylamine v) N-(3-Cyclopentyloxy-4-methoxyphenyl)-N-(3-pyridylmethyl)-l1-naphthylamine w) 3-Cyclopentyloxy-2 '-dimethyl-4-methoxy-N-(3 -pyridylmethyl)diphenylamine x) 3-Cyclopentyloxy-2 '-dimethyl-4-methoxy-N-(3 -pyridylmethyl~cdiphenylamine y) 3-Cyclopentyloxy-2 '-dimethyl-4-methoxy-N-(3 -pyr-idylmethyl)diphenylamine z) 3-Cyclopentyloxy-3 -dimethyl-4-methoxy-N-(3-pyridylmethyl)diphenylamine aa) 3-Cyclopentyloxy-2 '-dichloro-4-methoxy-N-(3-pyridylmethyl)diphenylamine bb) 3-Cyclopentyloxy-3 -dichloro-47methoxy-N-(3-pyridylmethyl)diphenylamine cc) 3-Cyclopentyloxy-3 '-dichloro-4-methoxy-Nr-(3-pyridylmethyl)diphenylarnine dd) 3 '-Chloro-3 -cyclopentyloxy-4' -fluoro-4-methoxy-N -(3-pyridylmethyl)diphenylamine WO 02/074726 WO 02/74726PCT/US02/01508 ee) 4 '-Chloro-3-cyclopentyloxy-3 '-fluoro-4-methoxy-N-(3-pyridylmethyl)dphenylaminle ff) 4 '-Chloro-3-cyclopentyloxy-4-methoxy-N-(3 -pyridylmethyl)-3 trifluoromethyldiphenylamine gg) 3 -Cyclopentyloxy-4-methoxy-N-(3 -thienylmethyl)diphenylamine hh) N-(3 -Cyclopentyloxy-4-methoxyphenyl)-N-(3-thienylmethyl)-lI-naphthylamine ii) 3 -Cyclopentyloxy-2 '-dichloro-4-methoxy-N'-(3-thienylmethyl)diphenylaminre Jj) 3-Cyclopentyloxy-4-methoxy-4'-methyl-N-(4-pyridylmethyl)diphenylanine kk) 3-Cyclopentyloxy-N-(2,6-dichloro-4-pyridylmethyl)-4-methoxy-3 methyldiphenylarnine 11) 2' -Chloro-3-cyclopentyloxy-N-(2,6-dichloro-4-pyridylmethyl)-4methoxydiphenylamine mm) 3-Cyclopentyloxy-N-(2,6-dichloro-4-pyridylmethyl)-4-mnethoxydiphenylamine nn) 3 -Cyclopentyloxy-4-methoxy-N-(6-methyl-2-pyridylmethyl)diphenylamine oo) 3-Cyclopentyloxy-4-methoxy-N-(3 -quinolinylmethyl)diphenylamine pp) 3-Cyclopentyloxy-4-methoxy-N-(4-quinolinylmethyl)diphenylamine qq) 3 -Cyclopentyloxy-4-methoxy-N-(2 -pyrazinylmethyl)diphenylamine rr) 4-Methoxy-3 '-methyl-N-(3 -pyridylmethyl)-3 -(3-tetrahydrofuryloxy)diphenylamine ss) 4-Methoxy-4'-methyl-N-(3-pyridylmethyl)-3-(3-tetrahydrofuryloxy)diphenylamine tt) 4,4' -Dimethoxy-N-(3 -pyridylmethyl)-3 -(3-tetrahydrofuryloxy)diphenylamine uu) 3 '-Chloro-4-methoxy-N-(3-pyridylmethyl)-3-(3-tetrahydrofuryloxy)dphenylamine vv) 4-Methoxy-4' -(4-methylpiperazin- 1-ylcarbonyl)-N-(3 -pyridylmethyl)-3 tetrahydrofuryloxy)diphenylamine ww) 3 '-Cyano-4-inethoxy-N-(3-pyridylmethyl)-3-((3R)tetrahydrofuryloxy)diphenylamine xx) 3' -Cyano-4-methoxy-N-(3-pyridylmethyl)-3 -((3,R)-tetrahydrofuryloxy)diphenylamine yy) 3 -Cyclopropylmethoxy-4-difluoromethoxy-N-(3 -pyridylmethyl)diphenylamine zz) 3 -Cyclopentyloxy-4-difluoromethoxy-N-(3-pyridylmethyl)diphenylamine aaa) 4-Difluoromethoxy-N-(3-pyridylmethyl)-3-(3 -tetrahydrofuryloxy)diphenylamine bbb) 3,4-Bis(clifluoromethoxy)-N-(3-pyridylmethyl)diphenylamine ccc) 4-Difluoromethoxy-N-(3-pyriclylmethyl)-3-((3R)tetrahydrofuryloxy)diphenylamine WO 02/074726 WO 02/74726PCT/US02/01508 ddd) 3 '-Cyano-4-difluoromethoxy-N-(3-pyridylmethyl)-3-((3R)tetrahydrofuryloxy)diphenylamine eee) 3 '-Chloro-4-difluoromethoxy-N-(3-pyridylmethyl)-3-((3R)tetrahydrofuryloxy)diphenylamine fff) Ethyl N-(3-cyclopropylmethoxy-4-difluoromethoxyphenyl)-N-(3-pyridylmethyl)-3aminobenzoate ggg) 3 -Cyclopentyloxy-4-methoxy-3 '-(4-methylpiperazin- 1 -ylcarbonyl)-N-(3 pyridylmethyl)diphenylamine hhh) 3-Cyclopentyloxy-4-methoxy-4'-(4-methylpiperazin-1I-ylcarbonyl)-N-(3 pyridylmethyl)diphenylamine iii) 3 '-tert-Butyldirnethy Isilyloxy-3 -cyclopentyloxy-4-methoxy-N-(3 pyridylmethyl)diphenylamine ADj 4 '-tert-Butyldimethylsilyloxy-3 -cyclopentyloxy-4-methoxy-N-(3 pyridylmethyl)diphenylamine kkk) tert-Butyl N-(3 -Cyclopentyloxy-4-methoxyphenyl)-N-(3 -pyridylmethyl)-3aminobenzoate 111) Ethyl N-(3-cyclopentyloxy-4-difluoromethoxyphenyl)-N-(3-pyridylmethyl)-3aminobenzoate mmm) Ethyl N-(4-difluoromethoxy-3-(3 -tetrahydrofuryloxy)phenyl)-N-(3pyridylmethyl)-3 -amninobenzoate nnn) Ethyl N-(3 ,4-Bis(difluoromethoxy)phenyl)-N-(3-pyridylmethyl)-3-aminobenzoate 000) Ethyl N-(4-methoxy-3-((3R)-tetrahydrofuryloxy)phenyl)-N-(3 -pyridylmethyl)- -3aminobenzoate ppp) Ethyl N-(3 -cyclopropylmethoxy-4-methoxyphenyl)-N-(3 -pyridylmethyl)-3aminobenzoate qqq) 3-Cyclopentyloxy-4-rnethoxy-4'-(2-(tetrahydropyran-2-yl)-2H-tetrazol-5-yl)-N- (3-pyridylmethyl)diphenylamine rrr) 3 -Cyclopentyloxy-4-methoxy-3 '-(2-(tetrahydropyran-2-yl)-21J-tetrazol-5-yl)-N-(3 pyridylmethyl)diphenylamine sss) 4-Methoxy-4' -(2-(tetrahydropyran-2- ,yl)-2H-tetrazol-5-yl)-N-(3 -pyridylrnethyl)-3- ((3R)-tetrahydrofuryloxy)diphenylamine WO 02/074726 WO 02/74726PCT/US02/01508 ttt) 3 -Cyclopropylmethoxy-4-methoxy-4' -(2-(tetrahydropyran-2-yl)-2H-tetrazol-5-yl)-N- (3-pyridylmnethyl)diphenylamine uuu) 4-Difluoromethoxy-4 '-(2-(tetrahydropyran-2-yl)-2H-tetrazol-5 pyridylmethyl)-3-((3R)-tetrahydrofuryloxy)diphenylamine vvv) 3-Cyclopropylrnethoxy-4-difltuoromethoxy-4' -(2-(tetrahydropyran-2-yl)-2Htetrazol-5-yl)-N-(3-pyridylmethyl)diphenylamine www) 3 -Cyclopentyloxy-4-difluoromethoxy-4 -(2-(tetrahydropyran-2-yl)-2H-tetrazol-5yl)-N-(3 -p yridylmethyl)diphenyl amine xxx) 3 -Cyclopropylmethoxy-4-di fluoromethoxy-3 '-(2-(tetrahydropyran-2-yl)-2H- .tetrazol-5-yl)-N-(3-pyridylmethyl)diphenylamine yyy) Bis-(3,4-difluoromethoxy)-3 '-(2-(tetrahiydropyran-2-yl)-2H-tetrazol-5-yl)-N-(3 pyridylmethyl)diphenylamine zzz) 3 -tert-Butyldimethylsilyloxy-4-methoxy-N-(3-pyridylmethy1)diphenylamine aaaa) 3 -tert-B utyldimethylsilyloxy-3 hloro-4-methoxy-N-(3 pyridylmethyl)diphenylamine bbbb) Ethyl N-(3 -tert-butyldimethylsilyloxy-4-methixypheny)-N-(3-pyidylmethy)-3aminobenzoate cccc) 3-Cyclopentyloxy-2 '-chloro-4-methoxy-N-(3-pyr-idylmethyl)diphenylarnine dddd) 3 -(2-indanyloxy)-4-methoxy-N-(3-pyridylmethyl)diphenylamine EXAMPLE N-(3-Cyclopentyloxy-4-methoxyphenyl)-N-l(3-pyridylmethyl)-3-aminobenzoic acid A solution of 6.5 g of ethyl iV-(3-cyclopentyloxy-4-methoxyphenyl)-N-(3pyridylmethyl)-3-aminobenzoate in 50 mL of EtOH was treated with 10 mL of 6N NaOH. The mixture was allowed to stand for 6 hours, concentrated, and diluted with mL of H 2 0. The aqueous mixture was extracted with 2 x 50 mL of ether, acidified with AcOH to pH 3, and extracted with 2 x 50 mL of EtOAc. The combined EtOAc fractions were washed with 25 mL of H 2 0 and 25 miL of brine, dried (MgSO 4 and concentrated.
The residue was purified by chromatography over Si0 2 (35 g RediSepO column) using a linear gradient of EtOAc and hexanes as eluant (50% EtOAc to 70% EtOAc over minutes) to provide 4.8 g of a yellow solid product after drying in vacuo, for 12 h at 601C.
WO 02/074726 WO 02/74726PCT/US02/01508 'H1 NMR (CDC1 3 6 11.15 (bs, 1H), 8.70-8.55 (in, 2H), 7.77-6.7 1 (in, 9H), 4.99 2H), 4.65 J 3.8 Hz, 1H), 3.84 3H), 1.86-1.70 (in, 6H), 1.65-1.45 (mn, 211).
The following compounds were prepared in a similar manner as described above: a) N-(3-Cyclopentyloxy-4-methoxyphenyl)-N-(3-pyridylmethyl)-4-aminobenzoic acid b) N-(3-Cyclopentyloxy-4-difluoromethoxyphenyl)-N-(3 -pyridylmethyl)-3aminobenzoic acid c) N- [4-Difluoromethoxy-3 -(3-tetrahydrofuiryloxy)phenyl]-N-(3-pyridylmethyl)-3 .aminobenzoic acid d) N-3 ,4-Bis(difluoromethoxy)phenyl)-N-(3-pyridylmethyl)-3 -aminobenzoic acid e) N- [4-Methoxy-3 -((3R)-tetrahydrofuryloxy)phenyl] -N-(3-pyridylmethyl)-3 aminobenzoic acid f) N-(3-Cyclopropylinethoxy-4-methoxyphenyl)-N-(3 -pyridylmethyl)-4-aininobenzoic acid g) N-(3-Cyclopropylinethoxy-4-difluoromethoxyphenyl)-N-(3 -pyridylinethyl)-3 aminobenzoic acid h) N-(3-Cyclopentyloxy-4-methoxyphenyl)-3-aminobenzoic acid i) N-[3-(4-Chlorophenyl)prop- 1-yloxy-4-inethoxyphenyl]-N-(3 -pyridylmethyl)-3aininobenzoic acid J) N-(3-Cyclopropylinethoxy-4-inethoxyphenyl)-N-(3-pyridylmethyl)-3-aminobenzoic acid k) N-[3-(2-Jndanyloxy)-4-methoxyphenyl]-N-(3 -pyridylinethyl)-3 -aminobenzoic acid 1) N- [4-Methoxy-3-(3-tetrahydrofuryloxy)phenyl]-N-(3-pyridylmethyl)-3-aininobenzoic acid in) N-[4-Methoxy-3-((3R)-tetrahydrofuryloxy)phenyl]-N-(3-pyridylmethyl)-3aininobenzoic acid n) N-[3-(2-Methoxyethoxy)-4-inethoxyphenyl]-N-(3 -pyridylmethyl)-3 -aminobenzoic acid o) N-[4-Methoxy-3-(2-(2-pyridyl)ethyl)oxyphenyl]-N-(3-pyridylmethyl)-3aininobenzoic acid WO 02/074726 WO 02/74726PCT/US02/01508 EXAMPLE 6 N-(3-Cyclopentyloxy-4-methoxyphenyl)-N-(3-pyridylmethyl)-2-aninobenzoic acid Tert-Butyl N-(3-cyclopentyloxy-4-methoxyphenyl)-N-(3-pyridylmethyl)-2aminobenzoate (60 mg, 0.13 mmol) was taken up in 2 mL 98% formic acid and heated at 0 C for 4 The formic acid was removed in vacuo and the residue was loaded onto a column of silica gel (RediSep, 4.2 The product was eluted with a linear gradient from EtOAc in hexanes to 60% EtOAc in hexanes over 15 min to yield 16 mg of product as a brown solid. 1'H NMIR (CDCl 3 5 8.47 1 H, J3 8.43 I1H), 8.10 I1H, J 7.67 1H, J 7.8 Hz), 7.56 (in, IH), 7.40-7.20 (in, 3H), 6.75 lH, J 6.57 (d 1H, J 6.47 1H), 4.72 2H), 4.54 IH, J 3.77 3H1), 1.80-1.60 (in, 6H), 1.60-1.40 (in, 2H).
The following compounds were prepared in a similar manner as described above: a) N-(3-Cyclopentyloxy-4-methoxyphenyl)-N-(3-pyridylmethyl)-3-aminobenzoic acid b) N-(3-Cyclopentyloxy-4-methoxyphcnyl)-N-(3-pyridylmcthyl)-6-aminonicotinic acid EXAMPLE 7 3-Cyclop ropylmethyloxy-4-difluoromethoxy-N-(3-pyridylmethyl)-4'- (211-tetrazol-5- yI)diphenylamine 3 -Cyclopropylinethoxy-4-di'fluoromethoxy-N-(3 -pyridylmethyl)-4 '-112-(2- (1.5 g, 0.26 minol) was dissolved in THE (5 mL) and 3 mL of 1N HCl was added. After 6 h at room temperature, the mixture was neutralized to pH 5 with saturated aqueous sodium bicarbonate and extracted with EtOAc (3 x 50 mL). The EtOAc extracts were combined, washed with brine (50 mL), dried (MgSO 4 and concentrated in vacuc. The crude residue was loaded onto a RediSep column (10 g, silica gel) and the product was eluted using a linear gradient from 0% MeOH in EtOAc to 5% MeOH in EtOAc; over 20 min to give 0.96 g of product as a white powder. 'H NMR (CD 3 OD) 6 8.55 1H1), 8.43 1H, J 4.9 Hz), 7.65 111, 8.0 Hz), 7.21 (dd, 1H, J 4.9 Hz, 8.0 Hz), 7.18 1H, J 8.9 Hz), 7.10-6.90 (in, 3H), 6.87 (dd, WO 02/074726 WO 02/74726PCT/US02/01508 1H, J 8.6 Hz, 2.5 6.75 1H, J 75.5 Hz), 5.14 2H), 3.82 2H, J 6.9 Hz), 1.23 (in, 1H), 0.60 (in, 211), 0.33 (in, 2H).
The following compounds were prepared in a similar manner as described above: a) 3 -Cyclopentyloxy-4-methoxy-N-(3 -pyridylinethyl)-4 yl)diphenylamine b) 3 -Cyclopentyloxy-4-methoxy-N-(3 -pyridylmethyl)-3 yl)diphenylamine c) 4-Methoxy-N-(3-pyridylmethyl)-3-((3R)-tetrahydrofuryloxy)-4' yl)diphenylamine d) 3 -Cyclopropylmethyloxy-4-methoxy-N-(3-pyridylmethyl)-4 yl)diphenylamnine e) 4-Difluoromethoxy-NT-(3-pyridylmethyl)-3 -((3R)-tetrahydrofuryloxy)-4' -(2H-tetrazol- -yI)di phenyl amine f) 3-Gyclopentyloxy-4-difluromethoxy-N-(3-pyridylinethyl)-4' yl)diphenylarnine g) 3 -Cyclopropylmethyloxy-4-difluoromethoxy-N-(3'-pyridylmethyl)-3 yl)diphenylamine h) Bis-3 ,4-difluoromethoxy-N-(3-pyridylmethyl)-4 '-(2H-tetrazol-5 -yl)diphenylamine EXAMPLE 8 (Method A) 3-Cyclopentyloxy-4-methoxydiphenylamine Method A. (Ref. Chan, Monaco, Wang, Winters, M.P., Tetrahedron Lett., 1998, 39, 2933-2936.). A slurry of 207 mg of 4-methoxy-3cyclopentyloxyaniline, 280 mg of phenylboronic acid, 182 mng of Cu(OAc) 2 280 [IL of Et 3 N and 4.0 mnL of CH 2 C1 2 was stirred for 20 h at room temp. The black mixture was filtered through silica eluting with CH 2 Cl 2 concentrated, and purified by chromatoghraphy over SiO 2 using EtOAc/Hexanes (15/85) as eluant to provide 75 ing of the desired product. 'H NMR (CDCl 3 5 7.26-7.20 (in, 2H), 6.94-6.63 (in, 6H), 5.50 (s, IH), 4.71 (in, 111), 3.82 3H), 1.89-1.54 (in, 8H).
WO 02/074726 WO 02/74726PCT/US02/01508 The following compounds were prepared in a similar manner as described above:a) 3-Cyclopentyloxy-3 ',4-dimethoxydiphenylamine b) 3 '-Chloro-3 -cyclopentyloxy-4-methoxydiphenylamine c) 3-Cyclopentyloxy-4-methoxy-3 'methyldiphenylamine d) 3-Cyclopentyloxy-4'-fluoro-4-methoxydiphenylamine e) 3 -Cyclopentyloxy-4-methoxy-4' -vinyldiphenylammne f) 3 '-Cyano-3-cyclopentyloxy-4-methoxydiphenylamine g) 4 '-Chloro-3 -cyclopentyloxy-4-methoxydiphenylamine h) 3-Cyclopentyloxy-4,4 '-dirnethoxydiphenylamine i) 3-Cyclopentyloxy-4-methoxy-2 '-methyldiphenylamine D) 3-Cyclopentyloxy-4-methoxy-4'-methyldiphenylamine k) 2' -Chloro-3 -cyclopentyloxy-4-methoxydiphenylamine 1) 3 -Cyclopentyloxy-2 ',4-dimethoxydiphenylamine m) 3-Cyclopentyloxy-4-methoxy-3 '-trifluoromethyldiphenylamine n) 3 -Cyclopentyloxy-4-methoxy-4 '-trifluoromethyldiphenylamine o) 3 -Cyclopentyloxy-2 '-dimethyl-4-methoxydiphenylamine EXAMPLE 8 (Method B) 3-Cyclopentyloxy-4-methoxydiphenylamine Method B (Angerw Chem. Int. Ed., 1995, 34(17), 1348-1351.) A mixture of 207 mg of 3-cyclopentyloxy-4-mnethoxyaniline, 204 mg of iodobenzene, 115 mg of NaOtBu, 9 mg of Pd 2 (dba) 3 12mTrg Of P(o-tOl) 3 and 7 mL of toluene was combined and warmed with stirring to 100 'C for 4h, The mixture was cooled to room temp, diluted with 25 mL of EtOAc and washed with 10 mL of H 2 0, 10 mL of brine, dried (MgSO 4 and concentrated. The residue was purified by chromatography over SiO 2 using EtOAc/hexanes (5/95) as eluant to provide 84 mg of the desired product.
The following compounds were prepared in a similar manner as described above: WO 02/074726 WO 02/74726PCT/US02/01508 a) 3-Cyclopentyloxy-4-methoxy-2' ,4'-dimethyldiphenylamine b) 3-Cyclopentyloxy-2 '-dimethyl-4-methoxydiphenylamine c) 3 -Cyclopentyloxy-2 '-dimethyl-4-methoxydiphenylamine d) 3-Cyclopentyloxy-3 ',4'-dimethyl-4-methoxydiphenylamine e) 3 -Cyclopentyloxy-3 -methylenedioxydiphenylamine f) 4'-tert-Butyl-3-cyclopentyloxy-4-methoxydiphenylamine S) 3 -Cyclopentyloxy-3 -dichloro-4-methoxydiphenylamine h) 3-Cyclopentyloxy-2 '-dichloro-.4-methoxydiphenylamine EXAM~'PLE 8 (Method C) 3-Cyclopentyloxy-2 Method C. To a mixture of Pd(dppf)C[ 2 (0.025 mmol, 5mol%), dppf (0.075 mmol, 3dppf/Pd) and NaOtBu (0.70 mmol, 1.4 equivalents) and 1.0 mL THF was added 1- (0.55 mmol, 1.1 equivalents) followed by 1.0 mL of a solution of 3-cyclopentyloxy-4-methoxyaniline in THF. The mixture was heated to 'C for 3 hours and diluted with ether and washed with H 2 0 and brine, dried (MgSO 4 and concentrated. The crude residue was purified by chromatography over silica gel (Biotage Flash 12) etuting with 15% EtOAc in hexanes' The following compounds were prepared in a similar manner as described above: a) N-(3 -Cyclopentyloxy-4-methoxyphenyl)-3-pyridylamine b) 3-Cyclopentyloxy-2 ,4-trimethoxydiphenylamine c) N-(3 -Cyclopentyloxy-4-methoxyphenyl)-2-pyridylamine d) N-(3 -Cyclopentyloxy-4-methoxyphenyl)-8-quinolinylamine e) NT-(3-Cyclopentyloxy-4-methoxyphenyl)-2-naphthylamine f) N-(3-Cyclopentyloxy-4-methoxyphenyl)-1 -naphthylamine g) 3-Cyclopentyloxy-4'-ethyl-4-methoxydiphenylamine h) 3-Cyclopentyloxy-2 '-fluoro-4-inethoxy-5 '-methyldiphenylamine i) 3-Cyclopentyloxy-3 '-fluoro-4-methoxy-4'-methyldiphenylamine j) N-(3-Cyclopentyloxy-4-methoxyphenyl)-2-pyrimidinylamine WO 02/074726 WO 02/74726PCT/US02/01508 k) 3-Cyclopentyloxy-3 ',5.'-dichloro-4-methoxydiphenylamine 1) 3-CyclopentyloXY72 '-ethyl-4-methoxydiphenylamine mn) 4 '-Chloro-3 -cyclopentyloxy-3 '-tluoro-4-methoxydiphenylamine n) N-3Ccoetlx--ehxpey)4iounlnlmn o) N-(3-Cyctopentyloxy-4-methoxyphenyl)-2-pyrazinylamine p) N-(3-Cyctopentyloxy-4-methoxyphenyl)-5 -pyrimidinylamine q) N-(3-Cyclopentyloxy-4-methoxyphenyl)- I-isoquinolinylamine r) N-(3-CycloPentyloxy-4-methoxyphenyl)-3-quinolinylamine s) N-(3-Cyclopentyloxy-4-methoxyphenyl)-4-pyridylamine t) N-(3-Cyclopentyloxy-4-difluoromethoxyphenyl)-3-pyridylamine u) N-(3-Cyctopropylmethyloxy-4-methoxyphenyl)-3-pyridylamine v) N-(3-Cyclopropylmethyloxy-4-difluoromethoxyphenyl)-3-pyridylamine w) N-(4-Methoxy-3-(3R)-tetrahydrofuryloxyphenyl)-3 -pyridylamine x) N-(4-Difluoromethoxy-3-(3R)-tetrahydrofuryloxyphenyl)-3-pyridylamine y) Ethyl N-(3-cyclopentyloxy-4-methoxyphenyl)-3-aminobenzoate z) 3-Cyclopentyloxy-4'-(NN-dimethylamino)-4-methoxydiphenylamine aa) N-(3-Cyclopentyloxy-4-methoxyphenyl)-3-(6-methoxypyridyl)amine bb) Methyl N-(3 -cyclopentyloxy-4-methoxyphenyl)-2 -aminonicotinate cc) tert-Butyl N-(3 -cyelopentyloxy-4-methoxyphenyl)-6-aminonicotinate dd) 2' -Amino-3 -cyclopentyloxy-4-methoxydiphenylamine ee) 3 -Cyclopentyloxy-4-rnethoxy-3 -phthalimido)diphenylamine ff) 3 -Cyclopentyloxy-4-methoxy-3 '-[2-(2-tetrahydropyranyl)-2H-tetrazol-5yl]diphenylamine EXAMPLE 9 (Method A) 3-Cyclopentyloxy-4-methoxy- N-methyldiphenylamine To a solution of 3-cyclopentyloxy-4-methoxydiphenylamine (70 mg, 0.25 mmol) in 3 mL of THEF at 0 'C was added 0.55 mL of 0.5 M KN(TMS) 2 in toluene. The solution was stirred at 0 'C for 0.5 h and 2.0 equivalents of iodomethane was added and the WO 02/074726 WO 02/74726PCT/US02/01508 reaction mixture was warmed to room temperature. Upon reaction completion as indicated by TLC, 10 mL of EtOAc was added and the mixture was washed with 3 mL of
H
2 0, 3 mL of brine, dried (Mg9SO 4 and concentrated. The crude residue was purified by column chromatography (Biotage flash 12) using 5% EtOAc in hexanes as eluant.
The following compounds were prepared in a similar manner as described above: a) 3-Cyclopentyloxy-NV-ethyl-4-methoxydiphenylamine b) 3-Cyclopentyloxy-4-methoxy-N-( I -propyl)diphenylamine c) 3 -Cyclopentyloxy-4-methoxy-N- I1 -(3-phenpropyl)]diphenylaminc d) N-Benzyl-3-cyclopentyloxy-4-methoxydiphenylamine e) 3-Cyclopentyloxy-4-methoxy-N-(4-pyridylmethyl)diphenylamine f) 3-Cyclopentyloxy-4-methoxy-N-(2-pyridylmethyl)diphenylamine g) 3-Cyclopentyloxy-4-methoxy-N-(3 -pyridylmethyl)diphenylamine h) 3-Cyclopentyloxy-4-methoxy-N- [3-(3-pyridyl)- 1 -propylldiphenyl amine i) N-(3-Cyclopentyloxy-4-methoxyphenyl)-N-ethyl-4-isoquinolinylamine j) N-(3-Cyclopentyloxy-4-methoxyphenyl)-N-benzyl-4-isoquinolinylamine k) N-(3 -Cyclopentytoxy-4-methoxyphenyl)-N-inetliyl-4-isoquinoliniylarnine 1) N-(3 -Cyclopentyloxy-4-methoxyphenyl)-N-propyl-4-isoquinolinylamine m) N-(3-Cyclopentyloxy-4-methoxyphenyl)-N-(4-isoquinolinyl)-N-(4pyridylmethyl)amine n) N-(3-Cyclopentyloxy-4-methoxyphenyl)-N-(4-isoquinolinyl)-N-(3 pyridylmethyl)amine o) N-(3 -Cyclopentyloxy-4-methoxyphenyl)-N-(3 pyrimidinyl)amine p) N-(3-Cyclopentyloxy-4-methoxyphenyl)-NV-(2-pyrazinyl)-N-(3-pyridylmethyl)amine q) N-(3-Cyclopentyloxy-4-methoxyphenyl)-N-(2-pyridyl)-N-(3 -pyridylmethyl)amine r) N-(3 -Cyclopentyloxy-4-methoxyphenyl)-N-(3-pyridyl)-N-(3 -pyridylmethyl)amine s) -Cyclopentyloxy-4-methoxyphenyl)-N-(4-pyridyl)-N-(3 -pyridylmethyl)amine t) tert-Butyl Nr-(3-cyclopentyloxy-4-methoxyphenyl)-N-(3 -pyridylmethyl)-6aminonicotiflate WO 02/074726 WO 02/74726PCT/US02/01508 u) N-(3 -Cyclopropylmethoxy-4-methoxyphenyl)-N-(3 -pyridyl)-N-(3pyridylmethyl)amine v) N-(4-Methoxy-3-(3R)-tetrahydrofuryloxyphenyl)-N-(3-pyridyl)-N-(3pyr-idylmethyl)amine w) N-(3-Cyclopentyloxy-4-difluoromethoxyphenyl)-N-(3 -pyridyl)-N-(3 pyridylmethyl)amine x) NV-(3-Cyclopropylmethoxy-4-difluoromethoxyphenyl)-N-(3 -pyridyl)-N-(3 pyridylmethyl)amine y) NT-(4-Difluoromethoxy-3 -(3R)-tetrahydrofuryloxyphenyl)-N-(3-pyridyl)-N-(3 pyridylmethyl)amine z) N-(4-Chloro-3 -pyridylrnethyl)-N-(3-cyclopentyloxy-4-methoxyphenyl)-N-(2pyridyl)amine aa) N-(3-cyclopentyloxy-4-methoxyphenyl)-N-(4-methyl-3-pyridylmethyl)-N-(2pyridyl)amine bb) 3-Cyclopentyloxy-4-methoxy-N-(2-thiazolylmethyl)diphenylamine cc) NT-(2-Chloro-3-pyridylmethyl)-3-cyclopentyloxy-4-methoxydiphenylamine dd) N-(6-Ghloro-3-pyridylmethyl)-3-cyclopentyloxy-4-methoxydiphenylamine EXAMPLE 9 (Method B) N-4-Chloro-3-pyridylmethyl)-N-(3-cyclopentyl-4methoxyphenyl)-N-(2-pyridyl)amine To a solution of (3-cyclopentyloxy-4-methoxyphenyl)-2-pyridylamine (30 mg, 0.10 mmol) and 4-chioropicolyl chloride hydrochloride (50 mg, 0.25 mmol) was dissolved in DMF (1 mL) and sodium hydride (50 mg of a 60% mineral oil dispersion, 1.3 mmol) was added in small portions. After stirring for lb at room temperature, the mixture was poured into 25 mL ice water. The mixture was extracted with EtOAc (2 x mL) and the EtOAc extracts were combined, washed with brine (15 mL), dried (MgSO 4 and concentrated in vacuc. The crude residue was loaded onto a RediSep colurim (4.2 g, silica gel) and the product was eluted with 15% EtOAc in hexanes to give mng of produc t as a yellow crystalline solid. 1H NMR (CDCl 3 6 8.61 1H), 8.34 (d, IH, J 5.3 Hz), 8.17 lH, 5.0 Hz), 7.33 (in, 7.25 (in, lH), 6.83 114, J WO 02/074726 WO 02/74726PCT/US02/01508 6.75 1H, J 6.71 1H), 6.62 (in, 1H), 6.42 III, J 5.31 2H), 4.63 lH, J 4.12 Hz), 3.83 3H), 1. 86-1 .70 (in, 6H), 1.65-1.45 (in, 2H).
The following compounds were prepared in a similar manner as described above: a) 3 ,4-Bis(difluoromethoxy)-N'-(4-chloro-3-pyndylmethyl)-3 '-(2-(tetrahydropyran-2- -yl)diphenylamine b) 3,4-Bis(difluoromethoxy)-N-(4-inethyl-3 -pyridylmethyl)-3 '-(2-(tetrahydropyran-2- EXAMPLE 3-Cyclopentyloxy-4-methoxyanilino-N-(3-pyridylmethyl)-N-3-(4-pyridyl)benzamide To a solution of N-(3 -cyclopentyloxy-4-methoxyphenyl)-N-(3-pyridylmethyl)-3 aininobenzoic acid (20 ing, 0.05 inmol) and pyBOP (40 ing. 0.08 inmol) in CH 2 C1 2 (2 mL) at room temperature was added diisopropylethylamine (20 L, 0.11 imnol). After stirring for 15 min, 4-aminopyridine (15 mng, 0. 15 iniol) was added and the mixture was allowed to stir 16 h. The mixture was diluted with EtOAc (25 mL) and washed with water (2 x 15 inL) and bri ne (15 mL), dried (MgSO 4 and concentrated in vacuo. The crude residue was loaded onto a RediSep column (4.2 g, silica gel) and the product was eluted with a linear gradient from 40% EtOAc in hexanes to 60% EtOAc in hexanes over min to give 22 mng of product. 'H NMR (CDCl 3 8 8.70-8.40 (in, 3H), 8.24 1H), 7.72 1H, 9.0 Hz), 7.68-7-55 (in, 2H), 7.30-7.20 (in, 11H), 6.88 2H, J 6.80- 6.65 (in, 3H), 4.98 2H), 4.66 III, J 4.1 Hz), 3.86 3H), 1.86-1.70 (in, 6H), 1.65-1.45 (in, 2H).
The following compounds were prepared in a similar manner as described above: a) 3 -(3-Cyclopentyloxy-4-methoxyanilino)-N-(3-pyridylnethyl)-N-3-13-(NNdimethylainino)prop- 1 -yl]benzamide b) 3 -Cyclopentyloxy-4-methoxy-3 '-(4-inethylpiperazin-1I-ylcarbonyl)-N-(3 pyridylinethyl)diphenylamine WO 02/074726 WO 02/74726PCT/US02/01508 c) 3 -Cyci opentYloxy-4.difluoromethoxy-4 '-(4-methylpiperazin- 1-ylcarbonyl)-N-(3pyridylmethyl)diphenylamine d) 3 -Cyclopentyloxy-4-methoxy-4' -(4-methylpiperazin- 1-ylcarbonyl)-N-(3 pyridylmethyl)-3 -tetrahydrofuranyloxyl)-diphenylamine EXAMPLE 11 The following compounds were prepared in a similar fashion as described in Example 2: a) 4'-Amino-3-cyclopentyloxy-4-methoxy-N-(3-pyridylmethyl)diphenylamine b) 3 '-Amino-3-cyclopentyloxy-4-methoxy-N-(3-pyridylmethyl)diphenylamine c) 3 '-A-mino-3-cyclopropylmethoxy-4-methoxy-N-(3 -pyridylmethyl)diphenylamine d) 3 '-Amino-4-methoxy-N-(3 -pyridylmethyl)-3 tetrahydrofuryloxy] diphenyl amine EXAMPLE 12 3-Cyclopentyloxy-4'-methanesulfonylAmino-4-methoxy-N- (3-pyridylmethyl)-diphenylamine To a solution of 4' -amino-3 -cyclopentyloxy-4-methoxy-N-(3-pyridylmethyl)diphenylamine (47 mg, 0. 12 mmol) in CH 2
CI
2 (2 mL) at room temperature was added pyridine (20 microliters, 0.24 mmol) followed by methanesulfonyl chloride microliters, 0. 18 mmol) and the mixture was allowed to stand at room temperature for 16 h. The mixture was diluted with ether (50 mL) and washed with water (25 mL) and brine mL), dried (MgSO 4 and concentrated. The crude residue was purified by flash column chromatography (4.2 g RediSep column, silica gel) eluting with a linear gradient from 4S% EtOAc in hexanes to 60% EtOAc in hexanes over 20 min to yield 41 mg of product. 'H NIVIR (CDCI 3 8 8.51 111), 8.41 1H, J =4.8 Hz), 7.56 1H, 7.9 Hz), 7.16 (in, lH), 6.98 2H, J =9.0 Hz), 6.80-6.60 (in, 6H), 4.82 2H), 4.56 1H, J Hz), 3.75 3H), 2.86 3H), 1.86-1.70 (in, 6H), 1.65-1.45 (in, 2H).
WO 02/074726 WO 02/74726PCT/US02/01508 The following compounds were prepared in a similar manner as described above: a) 3-Cyclopentyloxy-3 '-ethanesulfonylamnino-4-methoxy-N-(3pyridylmethyl)diphenylamine b) 3 -Cyclop entyloxy-4-methoxy-3 -prop anesulfonylamino)-N-(3 pyridylmethyl)diphenylamine c) 3 -Butanesulfonylamino)-3-cyclopentyloxy-4-methoxy-IV-(3 pyridylmethyl)diphenylamine d) 3 '-Benzylsulfonylamino-3 -cyclopentyloxy-4-methoxy-N-(3pyridylmethyl)diphenylamine e) 3 '-Acetan'iido-3-cyclopentyloxy-4-methoxy-N-(3-pyridylmethyl)diphenylamine f) 3-Cyclopentyloxy-4 '-ethanesuilfonylamino-4-rnethoxy-N-(3pyridylmethyl)diphenylamine g) 3-Cyclopentyloxy-4-methoxy-4' -propanesul fonylamino)-N-(3pyridylmethyl)diphenylamine h) 3-Cyclopropylmethoxy-3 '-ethanesulfonylamino-4-methoxy-N-(3pyridylmethyl)diphenylamine i) 4-Difluoromethoxy-3 '-ethanesulfonylamino-N-(3 -pyridylmethyl)-3 tetrahydrofuryloxy] diphenyl amine EXAMPLE 13 3-Cyclopentyloxy-4--methoxy-3 '-hydroxymethyl-N-(3-pyrid-ylmethyl)diphenylamine To a solution of Ethyl N-(3-cyclopentyloxy-4-methoxyphenyl)-N-(3pyridylmethyl)-3 -aminobenzoate (50 mg, 0. 11 mmol) in THF (5 mL) at 0 0 C was added drop-wise, with stirring, 2,5M diisobutylaluminum hydride in toluene (0.4 mL, 1.00 nunol). The mixture was stirred at 0 OC for 1 h and the excess diisobutylaluminum hydride was quenched by adding 5 drops of EtOAc to the mixture. The mixture Was concentrated and the residue was partitioned between CH 2 Cl 2 (50 mL) and water mL). The layers were separated and the aqueous layer was extracted with CH 2
CI
2 (2 x mL). The organic extracts were combined and washed with brine (50 mL), dried (MgSO 4 and concentrated. The crude residue was purified by flash column WO 02/074726 WO 02/74726PCT/US02/01508 chromatography (4.2 g RediSep column, silica gel) eluting with 300 ml- 50% EtOAc in hexanes then 100% EtOAc to give 15 mg of product. 1H1 NMR (CDCI 3 8.51 111), 8.40 (br, 11H), 7.58 111, 7.9 Hz), 7.25-7.05 (in, 3H), 6.80-6.60 (in, 5H), 4.85 2H), 4.56 111, J =4.1 Hz), 4.50 2H1), 3.76 3H), 1.86-1.70 (in, 7H), 1.65-1.45 (in, 2H).
The following compounds were prepared in a similar manner as described above: a) 3 -Cyclopentyloxy-4-methoxy-4' -hydroxymethyl-N-(3 -pyridylmethyl)diphenylamine EXAMPLE 14 3-Cyclopentyloxy-4-methoxy-N-(3-pyridylmethyl)-4 yl)diphenylamine To a solution of N-(3 -cyclopentyloxy-4-methoxyphenyl)-N-(3 -pyridylinethyl)-3aminobenzonitrile (100 mng, 0.25 inmol) in DMF (3 rnL) was added NaN 3 (163 mng, iniol) and NIH 4 C1 (135 mng, 2.5 rnmol) and the mixture was stirred at 120 0 C for 6 h. The mixture was cooled to room temperature, diluted with water (50 mL) and extracted with EtOAc (2 x 25 mL). The EtOAc extracts were combined, washed with water (25 inL) and brine (25 mL), dried (MgSO 4 and concentrated iln vacuo. The residue was loaded onto a RediSep column (4.2 g, silica gel) and eluted with a linear gradient from 50% to EtOAc in hexanes to yield 12 ing of product. I NMIR (CDCl 3 6 12.50 (br, 11H), 8.64 IH), 8.54 (br, 111), 7.86 211, J 8.8 Hz), 7.75 111, 7.8 Hz), 7.36 (in, 1H-), 6.80-6.60 (in, 5H), 4.99 2H), 4.66 1H1, J 4.1 Hz), 3.84 3H), 1.86-1.70 (in, 7H1), 1.65-1.45 (in, 2H1).
EXAMPLE 3-Cyclopentyloxy-4-methoxy-4'-(4-methyl-1 -piperazinylmethyl)- N-(3-pyridylmethyl)diph enyla mine To a solution of 3-cyclopentyloxy-4-inethoxy-4'-(4-inethylpiperazin- 1ylcarbonyl)dipheylamine (100 ing, 0.20 inmol) in THE (5 mL) was carefully added, with stirring, lithium aluminum hydride (50 mng, 1.3 mnmol). The mixture was stirred for WO 02/074726 PCT/US02/01508 min and a few drops of EtOAc was carefully added to quench the excess hydride. Water mL) and CH 2 C1 2 (50 mL) were added and the mixtures were filtered through Celite.
The CH 2 C1 2 layer was separated, washed with brine (25 mL), dried (MgS0 4 and concentrated in vacuo. The crude residue was purified on an ISCO RediSep column (4.2 g, silica) eluting with a gradient from 5% MeOH in EtOAc to 15% MeOH in EtOAc to yield 60 mg of product as a light yellow oil. 1 H NMR (CDC13) 5 8.59 1H), 8.47 (d, 1H, J 4.8 Hz), 7.65 1H, 7.9 Hz), 7.21 (dd, 1H, J 4.8 Hz, 7.9 Hz), 7.11 2H, J= 8.6 Hz), 6.82-6.73 3H), 6.70-6.65 2H), 4.91 2H), 4.62 1H, J 4.12 Hz), 3.82 3H), 3.41 2H), 2.75-2.20 8H), 2.27 3H), 1.86-1.70 6H), 1.65-1.45 2H).
The following compounds were prepared in a similar manner as described above: a) 3-Cyclopentyloxy-4-methoxy-3'-(4-mcthyl- 1 -piperazinylmethyl)N-(3pyridylmethyl)diphenylamine EXAMPLE 16 3'-Aminomethyl-3-cyclopentyloxy-4-methoxy-N-(3-pyridylmethyl)diphenylamine To a solution of N-(3-cyclopentyloxy-4-methoxyphenyl)-N-(3-pyridylmethyl)-3aminobenzonitrile (50 mg, 0.12 mmol) in THF (5 mL) was carefully added, with stirring, lithium aluminum hydride (20 mg, 0.52 mmol). The mixture was stirred for 4 h and a few drops of water were carefully added to quench the excess hydride. Water (50 mL) and CH 2 C1 2 (50 mL) were added and the mixtures were filtered through Celite. The
CH
2 C12 layer was separated, washed with brine (25 mL), dried (MgSO 4 and concentrated in vacuo. The crude residue was purified on an ISCO RediSep column (4.2 g, silica) eluting with 10% MeOH in EtOAc to yield 20 mg of product. 1 H NMR (CDCI 3 6 8.60 1H), 8.47 (br, 1H), 7.65 1H, 7.8 Hz), 7.26-7.10 2H), 6.90-6.65 6H), 4.94 2H), 4.63 1H, J Hz), 3.83 3H), 3.75 2H), 2.29 (br, 2H), 1.86-1.70 6H), 1.65-1.45 2H).
WO 02/074726 WO 02/74726PCT/US02/01508 EXAMPLE 17 3-Hydr-Oxy-4-methoxy-N-(3-pyridylmethyl)dipheuylamine To a solution of 3-(tert-butyldimethylsiloxy)-N-(3-pyridylmethyl)-4methoxydiphenylamine (1.20 g, 2.85 mmol) in THF (40 mL) at 0 0 C, was added 1 OM tetrabutylammonium fluoride in THE (10 mL, 10 mmol). The mixture was stirred at 0 0
C
for 30 min. Water (50 mL) was added and the mixture was extracted with ether (3 x mL). The ether extracts were combined and washed with water (3 x 25 mL) and brine mnL), dried (MgSO 4 and concentrated in vacuc. The residue was triturated with hexanes and collected by vacuum filtration to give 0.85 g of product. 'H NMR 6 8 I1H), 8.46 (br, I 7.67 1 H, 7.8 Hz), 7.26-7. 10 (in, 3H), 6.90-6.65 6.64 (dd, 1H, J =8.6 Hz, 2.6 Hz), 6.53 (br, 1H), 4.92 2H), 3.86 3H).
The following compounds were prepared in a similar manner as described above: a) 3 '-Chloro-3-hydroxy-4-methoxy-N-(3-pyridylmethyl)diphenylamine b) Ethyl N-(3-hydroxy-4-methoxyphenyl)-N-(3 -pyridylmcthyl)-3-aminobenzoate EXAMPLE 18 (Method B) The following compounds were prepared in a similar manner as described in Example I B a) 3- [3-(4-Chlorophenyl)prop- 1-yloxy] -4-methoxy-N-(3-pyridylmethyl)diphenylamine b) 3 -[2-(4-Chl orophenyl)ethoxy]-4-methoxy-N-(3-pynidylmethyl)dphenylaminc c) 4-Methoxy-3 -(4-phenoxybut-1I-yl)oxy-N-(3-pyridylmnethyl)diphcnylamine d) 4-Methoxy-N-(3 -pyridylmethyl)-3-(3 -tetrahydrofuryloxy)diphenylamine e) 4-Methoxy-3-[3-(4-methoxyphenyl)prop- 1-ylloxy-N-(3pyridylmethyl)diphenylamine f)4-Methoxy-3 -[3-(4-pyridyl)prop- I -yl]oxy-N-(3 -pyridylmethyl)diphenylamine g) 4-Methoxy-3 -[2-(4-methoxyphenyl)ethoxy]-N-(3-pyridylmethyl)diphenylamine h) 4-Methoxy-3 -(4-phenylbut- 1-yl~oxy-N-(3-pyridylmethyl)diphenyl amine i) 4-Methoxy-3-[4-(4-methoxyphenvl)but- l-yl] oxy-N-(3 -pyridylmethyl)diphenylamine j) 4-Methoxy-3 -[4-(4-nitrophenyl)but- I -yl]oxy-N-(3 -pyridylmethyl)diphenylamine WO 02/074726 WO 02/74726PCT/US02/01508 k) 4-Methoxy-3-[2-(2-pyridyl)ethoxy] -N-(3-pyridylmethyl)diphenylamine 1) 4 -Methoxy-3-[2-(4-pyridyl)ethoxy]-.N-(3-pyridylmethyl)diphenylamine m) 4-Methoxy-3-[3-(2-pyridyl)prop-1I-yl]oxy-N-(3 -pyridylmethyl)diphenylaminc n) 4-Methoxy-3-(2-methoxyethoxy)-N-(3 -pyridylmethyl)diphenylamine o) 3 -Cyclopropylmethoxy-4-methoxy-N-(3-pyridylmethyl)diphenylamine p) 4-Methoxy-3-(l -methylpyrrolidin-3-yl)oxy-N-(3-pyridylmethyl)diphenylamine q) 4-Methoxy-3-(1 -methylpiperidin-4-yl)oxy-N-(3-pyridylmcthyl)diphenylamine r) 4 -Methoxy-N-(3-pyridylmethyl)-3-[(35)-tetrahydrofuryloxy]diphenylamine s) 4-Methoxy-N-(3-pyridylmethyl)-3-[(3R)-tetrahydrofuryloxy]diphenylamine t) 3' -Chloro-4-methoxy-3 -[2-(2-pyridyl)ethoxy]-N-(3-pyridylmethyl)diphenylamine u) 3' -Chloro--4-methoxy-3 -[2-(4-pyridyl)ethoxylj-N-(3-pyridylmethyl)diphenylarnine v) 3' -Chloro-4-methoxy-3-(2-methoxyethoxy)-N-(3 -pyridylmethyl)diphenylamnine w) 3' -Chloro-4-methoxy-N-(3-pyridylmethyl)-3-[(3R)tetrahydrofuryloxy]diphenylamine x) 3-Cyclohexyloxy-4-mcthoxy-N-(3-pyridylmethyl)diphenylamine y) 3 -Cycloheptyloxy-4-methoxy-N-(3 -pyridylmethyl)diphenylamnine z) 3 2 -Cyclopropylethoxy)-4-methoxy-N-(3-pyridylmethyl)diphenylamine aa) 3 -Cyclopentylmethoxy-4-methoxy-N-(3-pyridylmethyl)diphenylamine bb) Ethyl N-13-(4-chlorophenyl)prop- 1-yloxy-4-methoxyphenyl]-N-(3 -pyridylmethyl)-3aminobenzoate cc) Ethyl N-(3 -cyclopropylmethoxy-4-methoxyphenyl)-N-(3-pyridylmethyl)-3 aiminobenzoate dd) Ethyl N-(3-cyclopropylmethoxy-4-difluoromethoxyphenyl)-N-(3-pyridylmethyl)-3 aminobenzoate ee) Ethyl N-[3 -(2-indanyloxy)-4-methoxyphenyl]-N-(3 -pyridylmethyl)-3-.aminobenzoate ff) Ethyl N-[4-methoxy-3-(3-tetrahydrofuryloxy)phenyl]-N-(3 -pyridylmethyl)-3aminobenzoate gg) Ethyl N-[4-methoxy-3-((3R)-tetrahydrofuryloxy)phenyl]-N-(3 -pyridylmethyl)-3aminobenzoate hh) Ethyl N-[3-(2-methoxyethoxy)-4-methoxyphenyl]-N-(3 -pyridylmethyl)-3aminobenzoate WO 02/074726 WO 02/74726PCT/US02/01508 ii) Ethyl N-[4-methoxy-3-(2-(2-pyridyl)ethyl)oxyphenyl]-N-(3 -pyridylmethyl)-3 aminobenzoate EXAMPLE 18 (Method C) The following compounds were prepared in a similar manner as described in Example 8A by coupling a phenol with a boronic acid rather than coupling an aniline with a boronic acid: a) 4 -Methoxy-3-(4-methoxyphenoxy)-N-(3-pyridylmethyl)diphenylamine b) 4-Methoxy-3-phenoxy-N-(3-pyridylmethyl)diphenylamine c) 4-Methoxy-3-(4-methylphenoxy)-N-(3-pyridylmethyl)diphenylamine d) 3-(4-Chlorophenoxy)-4-methoxy-NV-(3-pyridylmethyl)diphenylamine e) 3-[2-(4-Chlorophenyl)ethenyloxy] -4-methoxy-N-(3 -pyridylmethyl)diphenylamine EXAMPLE 19 The following compounds were prepared in a similar manner as described in Example 17: a) 3-Cyclopentyloxy-3 '-hydroxy-4-methoxy-N-(3-pyridylmethyl)diphenylamine b) 3-Cyclopentyloxy-4 '-hydroxy-4-methoxy-N-(3-pyridymethyl)diphenyla-ine c) 3 -Cyclopropylmethoxy-4 '-hydroxy-4-methioxy-N-(3-pyridylmethyl)diphenylamine EXAMPLE 20 (Method A) The following compounds were prepared in a similar manner as described in Example
IA:
a) 3 '-(2-Bromoethoxy)-3-cyclopentyloxy-4-methoxy-Ar-(3pyridylmethyl)diphenylamine EXAMPLE 20 (Method B) The following compounds were prepared in a similar manner as described in Example 113: WO 02/074726 WO 02/74726PCT/US02/01508 a) 3-Cyclopentyloxy-4 '-(2-methoxyethoxy)-4-methoxy-N-(3pyridylmethyl)diphenylamine b) 3-Cyclopentyloxy-4 '-(3-methyl-i -butoxy)-4-methoxy-N-(3 pyridylmethyl)diphenylamine c) 3 -Cyclopentyloxy-4-methoxy-N-(3-pyridylinethyl)-4' -[(3S)-tetrahydrofuranyloxy] diphenylamine d) 3-Cyclopentyloxy-4-methoxy-N-(3-pyridylmethyl)-4' -[(3R)-tetrahydrofuranyloxy] diphenylamine e) 3 -Cyclopentyloxy-4 '-cyclopropylmethoxy-4-methoxy-N-(3 pyridylmethyl)diphenylamnine f)4'-Cyclohexylethoxy-3-cyclopentyloxy-4-methoxy-N-(3pyridylmethyl)diphenylamine g) 4' -Cyclopentylethoxy-3-cyclopentyloxy-4-methoxy-N-(3pyridylmethyl)diphenylamine h) 3-Cyclopentyloxy-4-methoxy-4'-(1 -methylpipericlin-4-yloxy)-N-(3 pyridylmethyl)diphenylamine i) 3 -Cyclopentyloxy-4-methoxy-4'-(1 -methylpyrrolidin-3 -yloxy)-N-(3 pyridylmethyl)diphenylamine j 3 -Cyclop entyloxy-4-methoxy-4'-[2-( I -methylpyrrolidin-2-yl)ethoxy] pyridylmethyl)diphenylamine k) 3 -Cyclopentyloxy-4-methoxy-4'-[2-( 1 -pyrrolidinylethoxy)-N-(3 pyridylmethyl)diphenylamine 1) 3-Cyclopentyloxy-4-methoxy-4'-[2-(6-methylpyridyl)methoxy)-N-(3pyridylmethyl)diphenylamine m) 3 -Cyclopentyloxy-4-methoxy-4'-[3 -(I1 -methylpipenidinyl)methoxy] pyridylmethyl)diphenylamine n) 3 -Cyclopentyloxy-4-methoxy-4'-[2-( 1 -methylpiperidinyl)methoxy] pyridylmethyl)diphenylamine o) 3-Cyclopentyloxy-4-methoxy-4' -[2-(5-oxopyrrolidinyl)methoxy]-N-(3pyridylmethyl)diphenylamine WO 02/074726 WO 02/74726PCT/US02/01508 p) 4 -Bromopropyl)oxy]-3-cyclopentyloxy-4-methoxy-N-(3pyridylmethyl)diphenylamine q) 3 -Cyclopentyloxy-4-methoxy-4'-[2-(N-phthalimido)ethoxyl pyridylmethyl)diphenylamine EXAMPLE 21 3-Cyclopentyloxy-4-methoxy-3 '-[2-(1-piperidinyl)ethoxyl-N-(3pyridylmethyl)diphenylamine To a solution of 3 '-(2-bromoethoxy)-3 -cyclopentyloxy-4-methoxy-N-(3pyridylmethyl)diphenylamine (17 mg, 0.03 mmol) in acetonitrile (1 m.L) was added potassium carbonate (25 mg, 0. 18 mmol) and piperidine (5 ptL, 0.05 mmol) and the mixture was stirred at 60 0 C for 4 h. The mixture was partitioned between water (50 mL) and EtOAc (50 mL). The layers were separated and the organic layer was washed with water (25 mL) and brine (25 mL), dried (MgSO 4 and concentrated in vacuo. The residue was loaded on an ISCO RediSep column (4.2g, silica) and the column was eluted with a linear gradient from 5% MeOH in EtOAc to 15% MeOH in EtOAc to give 11 mg of product. 'H NMR (CDCl 3 8 8.5 9 I1H), 8.48 I1H, J 7.64 I1H, 8.2 Hz), 7.26-7.20 (in, 1H), 7.06 IH, J 8.6 Hz), 6.81 1H, J 9.2 Hz), 6.75-6.68 (in, 2H), 6.45-6.35 (in, 3H), 4.91 2H), 4.64 1H, J 4.1 Hz), 4.00 2H, J 6.2 Hz), 3.84 (s, 3H), 2.71 2H, J 6.2 Hz), 2.47 (in, 4H), 1.90-1.70 (in, 6H), 1.86-1.70 (in, 6H1), 1.65- 1.45 (in, 2H).
The following compounds were prepared in a similar manner as described above: a) 3-Cyclopentyloxy-3 I-imidazolyl)ethoxy]-4-methoxy-N-(3pyridylmethyl)diphenylamine b) 3-Cyclopentyloxy-4-methoxy-3 1-methylpiperazin-4-yl)ethoxy]-N-(3 pyridylmethyl)diphenylamine c) 3-Cyclopentyloxy-4-methoxy-4 [3-(2-methylpiperazin-4-yl)propoxy-N-(3pyridylmethyl)diphenylamine WO 02/074726 WO 02/74726PCT/US02/01508 d) 3 -Cyclopentyloxy-4-methoxy-4'-13 -methylpiperazin-4-yl)propoxy]-N-(3pyridylmethyl)diphenylamine e) 3 -Cyclopentyloxy-4-methoxy-4'-[3 -(2-morpholin-4-ylethylamino)propoxy]-N-(3pyridylmethyl)diphenylamine f) 4-Methoxy-3-(2-phenoxyethoxy)-N-(3-pyridylmethyl)diphenylamine g) 3-[2-(4-Chlorophenoxy)ethoxy)-4-methoxy-N-(3 -pyridylmethyl)diphenylamine h) 4-Methoxy-3-(2-pyrrolidin-1I-yl)cthoxy-N-(3 -pyridylmethyl)diphenylamine i) 4-Methoxy-3-(2-(4-methylpiperazin- 1-yl)ethoxy)-N-(3 -pyridylmethyl)diphenylamnine j) 3-[2-(4-Chlorophenylamino)ethoxy] -4-methoxy-N-(3 -pyridylmethyl)diphenylamine EXAMPLE 22 4'-Aminoethoxy-3-cyclopeiityloxy-4-methoxy-N-(3-pyridylmethyl)diphenylamine To a solution of N-(3 -pyridylmethyl)-3 '-[2-(2-phthalimido)ethoxyl-3 cyclopentyloxy-4-methoxydiphenylamine (0.39 g, 0.69 mmol) in MeOH (5 mL) was added hydrazine hydrate (1.0 mL, 20 mmol). After 6 h at room temperature, EtOAc. was added (50 mL) and the precipitate was filtered off. The filtrate was washed with water mL) and brine (25 mnL), dried (MgSO 4 and concentrated in vacuo. The residue was loaded on an ISCO RediSep column (10 g, silica). The column was washed with MeOH in EtOAc (200 mL) and the product was eluted with 50% MeOR in EtOAc to yield 0.21 g. 1 11 NMR (CDCI 3 8 8.55 1H), 8.42 IIH, J 3.8 Hz), 7.62 lH, 7.7 Hz), 7.20-7.10 (in, IH), 6.91 2H, J 9.0 Hz), 6.78 2H, J 9.0 Hz), 6.70 1H4, J 8.6 Hz), 6.50-6.35 (in, 2H), 4.82 2H), 4.54 1H, J 4.1 Hz), 3.90 2H, J 6.1 Hz), 3.74 3H), 3.01 (in, 2H), 1.86-1.70 (in, 8H), 1.65-1.45 (in, 2H).
EXAMPLE 23 The following compounds were prepared in a similar manner as described in Example 12: a) 3 -Cyclopentyloxy-4 '-(2-methanesulfonylamino)ethoxy-4-mthoxy-N-(3pyridylmethyl)diphenylamine WO 02/074726 PCT/US02/01508 b) 3-Cyclopentyloxy-4'-(2-ethanesulfonylamino)ethoxy-4-methoxy-N-(3pyridylmethyl)diphenylamine c) 3-Cyclopentyloxy-4-methoxy-4'-[2-(2-propanesulfonylamino)ethoxy]-N-(3pyridylmethyl)diphenylamine d) 3-Cyclopentyloxy-4-methoxy-4'-[2-( 1-propanesulfonylamino)ethoxy]-N-(3pyridylmethyl)diphenylamine e) -Butanesulfonylamino)ethoxy]-3-cyclopentyloxy-4-mcthoxy-N-(3pyridylmethyl)diphenylamine EXAMPLE 24 In Vitro Measurement of Type 4 Phosphodiesterase Inhibition Activity Human PDE4 was obtained from baculovirus-infected Sf9 cells that expressed the recombinant enzyme. The cDNA encoding hPDE-4D6 was subcloned into a baculovirus vector. Insect cells (Sf9) were infected with the baculovirus and cells were cultured until protein was expressed. The baculovirus-infected cells were lysed and the lysate was used as source ofhPDE-4D6 enzyme. The enzyme was partially purified using a DEAE ion exchange chromatography. This procedure can be repeated using cDNA encoding other PDE-4 enzymes.
Assay: Type 4 phosphodiesterases convert cyclic adenosine monophosphate (cAMP) to monophosphate Nucleotidase converts 5'-AMP to adenosine.
Therefore the combined activity of PDE4 and nucleotidase converts cAMP to adenosine.
Adenosine is readily separated from cAMP by neutral alumina columns.
Phosphodiesterase inhibitors block the conversion of cAMP to adenosine in this assay; consequently, PDE4 inhibitors cause a decrease in adenosine.
Cell lysates (40 ul) expressing hPDE-4D6 were combined with 50 ul of assay mix and 10 ul of inhibitors and incubated for 12 min at room temperature. Final concentrations of assay components were: 0. 4 ug enzyme, 10mM Tris-HCl (pH WO 02/074726 PCT/US02/01508 MgCI 2 3 uM cAMP, 0.002 U 5'-nucleotidase, and 3 x 10 4 cpm of [3H]cAMP.
The reaction was stopped by adding 100 pl of boiling 5mN HC1. An aliquot of 75 p. of reaction mixture was transferred from each well to alumina columns (Multiplate; Millipore). Labeled adenosine was eluted into an OptiPlate by spinning at 2000 rpm for 2 min; 150 p1 per well of scintillation fluid was added to the OptiPlate. The plate was sealed, shaken for about 30 min, and cpm of 3 H]adenosine was determined using a Wallac Triflux®.
All test compounds are dissolved in 100% DMSO and diluted into the assay such that the final concentration of DMSO is DMSO does not affect enzyme activity at this concentration.
A decrease in adenosine concentration is indicative of inhibition of PDE activity..
pICso values were determined by screening 6 to 12 concentrations of compound ranging from 0.1 nM to 10,000 nM and then plotting drug concentration versus H-adenosine concentration. Nonlinear regression software (Assay Explorer®) was used to estimate pIC s o values.
EXAMPLE 25 (Method A) Passive Avoidance in Rats, an in vivo Test for Learning and Memory The test was performed as previously described (Zhang, Crissman, A.M., Dorairaj, Chandler, and O'Donnell, Neuropsychopharmacology, 2000, 23, 198-204.). The apparatus (Model E10-16SC, Coulbourn Instruments, Allentown, PA) consisted of a two-compartment chamber with an illuminated compartment connected to a darkened compartment by a guillotine door. The floor of the darkened compartment consisted of stainless steel rods through which an electric foot-shock could be delivered from a constant current source. All experimental groups were first habituated to the apparatus the day before the start of the experiment. During the training, the rat (Male Spraque-Dawley (Harlan) weighing 250 to 350 g) was placed in the illuminated compartment facing away from the closed guillotine door for 1 minute before the door was raised. The latency for entering the darkened compartment was recorded. After the WO 02/074726 PCT/US02/01508 rat entered the darkened compartment, the door was closed and a 0.5 mA electric shock was administered for 3 seconds. Twenty-four hours later, the rat was administered 0.1 mg/kg MK-801 or saline, 30 minutes prior to the injection of saline or test compound (dosed from 0.1 to 2.5 mg/kg, which was 30 minutes before the retention test started. The rat was again placed in the illuminated compartment with the guillotine door open. The latency for entering the darkened compartment was recorded for up to 180 seconds, at which time the trial was terminated.
All data were analyzed by analyses of variance (ANOVA); individual comparisons were made using Kewman-Keuls tests. Naive rats required less than seconds, on average, to cross from the illuminated compartment to the darkened compartment. However, 24 hours after the electric shock exposure, most rats pretreated with vehicle did not re-enter the darkened compartment; the average latency was increased up to 175 seconds (p 0.001). Pretreatment with MK-801 (0.1 mg/kg) markedly reduced this latency when compared to the vehicle (p<0.001). This amnesic effect ofMK-801 is reversed in a statistically significant manner by actual test compounds in a dose-dependent fashion 3-cyclopentyloxy-4-methoxy-N-(3pyridylmethyl) diphenylamine, Effective dose range 0.5 to 2.5 mg/kg, and N-(3cyclopentyloxy-4-methoxyphenyl)-N-(3-pyridylmethyl)-3-aminobenzoic acid, effective dose range 0.1 to 2.5 mg/kg, ip).
EXAMPLE 25 (Method B) Radial arm maze task in Rats, an in vivo Test for Learning and Memory The test was performed as previously described (Zhang, Crissman, A.M., Dorairaj, Chandler, and O'Donnell, Neuropsychopharmacology, 2000, 23, 198-204.). Five days after initial housing, rats (male Spraque-Dawley (Harlan) weighing 250 to 350 g) were placed in the eight-arm radial maze (each arm was WO 02/074726 PCT/US02/01508 60x10x12 cm high; the maze was elevated 70 cm above the floor) for acclimation for two days. Rats were then placed individually in the center of the maze for 5 minutes with food pellets placed close to the food wells, and then, the next day, in the wells at the end of the arms; 2 sessions a day were conducted. Next, four randomly selected arms were then baited with one pellet of food each. The rat was restricted to the center platform (26 cm in diameter) for 15 seconds and then allowed to move freely throughout the maze until it collected all pellets of food or 10 minutes passed, whichever came first. Four parameters were recorded: 1) working memory errors, entries into baited arms that had already been visited during the same trial; 2) reference memory errors, entries into unbaited arms; 3) total arm entries; and 4) the test duration (seconds), the time spent in the collection of all the pellets in the maze. If the working memory error was zero and the average reference memory error was less than one in five successive trials, the rats began the drug tests. MK-801 or saline was injected 15 minutes prior to vehicle or test agent, which was given 45 minutes before the test. Experiments were performed in a lighted room, which contained several extra-maze visual cues.
All data were analyzed by analyses of variance (ANOVA); individual comparisons were made using Kewman-Keuls tests. Compared to control, MK-801 (0.1 mg/kg, increased the frequencies of both working and reference memory errors This amnesic effect of MK-801 on working memory is reversed in a statistically significant manner by the administration of actual test compounds in a dosedependent fashion 3-cyclopentyloxy-4-methoxy-N-(3pyridylmethyl)diphenylamine, Effective dose 2.5 mg/kg, p<0.01) The preceding examples can be repeated with similar success by substituting the generically or specifically described reactants and/or operating conditions of this invention for those used in the preceding examples.
While the invention has been illustrated with respect to the production and of particular compounds, it is apparent that variations and modifications of the invention can be made without departing from the spirit or scope of the invention.
Throughout this specification and the claims which follow, unless the context requires otherwise, the word "comprise", and variations such as "comprises" or "comprising", will be understood to imply the inclusion of a stated integer or step or group of integers or steps but not the exclusion of any other integer or step or group of integers or steps.
The reference to any prior art in this specification is not, and should not be taken as, an acknowledgment or any form of suggestion that that prior art forms part of the common general knowledge in Australia.

Claims (55)

1. A compound of Formula I 0 00 RR 3 SR 2 R4 wherein: C 5 R' is alkyl having 1 to 4 carbon atoms, which is branched or unbranched and which is unsubstituted or substituted one or more times by halogen; R 2 is alkyl having 1 to 12 carbon atoms, which is branched or unbranched and which is unsubstituted or substituted one or more times by halogen, hydroxy, cyano, C 1 4 alkoxy, oxo or combinations thereof, and wherein optionally one or more -CH 2 CH 2 o1 groups are replaced in each case by -CH=CH or cycloalkyl having 3 to 10 carbon atoms, which is unsubstituted or substituted one or more times by halogen, hydroxy, oxo, cyano, alkyl having 1 to 4 carbon atoms, alkoxy having 1 to 4 carbon atoms, or combinations thereof, cycloalkylalkyl having 4 to 16 carbon atoms, which is unsubstituted or substituted in the cycloalkyl portion and/or the alkyl portion one or more times by halogen, oxo, cyano, hydroxy, Ci-4-alkyl, C1- 4 -alkoxy or combinations thereof, aryl having 6 to 14 carbon atoms, which is unsubstituted or substituted one or more times by halogen, CF 3 OCF 3 alkyl, hydroxy, alkoxy, nitro, methylenedioxy, ethylenedioxy, cyano, or combinations thereof, arylalkyl in which the aryl portion has 6 to 14 carbon atoms and the alkyl portion, which is branched or unbranched, has 1 to 5 carbon atoms, which the arylalkyl radical is unsubstituted or is substituted in the aryl portion one or more times by halogen, CF 3 OCF 3 alkyl, hydroxy, alkoxy, nitro, cyano, methylenedioxy, ethylenedioxy, or combinations thereof, and wherein in the alkyl portion one or more -CH 2 C-1 2 groups are each optionally replaced by -CH=CH- or and one or more -CH 2 groups are each P \WPDOCSMDTSpc\7B25I53dc-3 IV1W1O7 0 -84- optionally replaced by or -NH- and/or the alkyl portion is optionally substituted by halogen, oxo, hydroxy, cyano, or combinations thereof, a partially unsaturated carbocyclic group having 5 to 14 carbon atoms, which is 00 unsubstituted or substituted one or more times by halogen, alkyl, alkoxy, hydroxy, nitro, cyano, oxo, or combinations thereof, a heterocyclic group, which is saturated, partially saturated or unsaturated, having Sto 10 ring atoms in which at least 1 ring atom is a N, O or S atom, which is unsubstituted or substituted one or more times by halogen, hydroxy, aryl, alkyl, alkoxy, cyano, trifluoromethyl, nitro, oxo, or combinations thereof, or a heterocyclicalkyl group, wherein the heterocyclic portion is saturated, partially saturated or unsaturated, and has 5 to 10 ring atoms in which at least 1 ring atom is a N, O or S atom, and the alkyl portion is branched or unbranched and has 1 to 5 carbon atoms, the heterocycle-alkyl group is unsubstituted or substituted one or more times in the heterocyclic portion by halogen, OCF 3 hydroxy, aryl, alkyl, alkoxy, cyano, trifluoromethyl, nitro, oxo, or combinations thereof, wherein in the alkyl portion one or more -CH 2 CH 2 groups are each optionally replaced by -CH=CH- or -CEC-, and one or more -CH 2 groups are each optionally replaced by or -NH- and/or the alkyl portion is optionally substituted by halogen, oxo, hydroxy, cyano, or combinations thereof, R 3 is alkyl having 1 to 8 carbon atoms, which is branched or unbranched and which is unsubstituted or substituted one or more times with halogen, cyano, Ci-4-alkoxy, or combinations thereof, a partially unsaturated carbocycle-alkyl group wherein the carbocyclic portion has to 14 carbon atoms and the alkyl portion which is branched or unbranched has 1 to carbon atoms, and which is unsubstituted or substituted in the carbocyclic portion one or more times by halogen, alkyl, alkoxy, nitro, cyano, oxo, or combinations thereof, and the alkyl portion is optionally substituted by halogen, Ci_ 4 -alkoxy, cyano or combinations thereof, arylalkyl having 7 to 19 carbon atoms, wherein the aryl portion has 6 to 14 carbon P \WPDOCS\MDTSp-c\7M255513 do-3 I1A7/207 atoms and the alkyl portion, which is branched or unbranched, has I to 5 carbon atoms, arylalkyl radical is unsubstituted or substituted, in the aryl portion, one or more times by halogen, trifluoromethyl, CF30, nitro, amino, alkyl, alkoxy, alkylamino, or dialkylamino 00and/or substituted in the alkyl portion by halogen, cyano, or methyl, or heteroarylalkyl group, wherein the heteroaryl portion has 5 to 10 ring atoms in which at least 1 ring atom is a N, O or S atom, the alkyl portion, which is branched or unbranched, has 1 to 5 carbon atoms, the heteroarylalkyl group is unsubstituted or C1 substituted one or more times in the heteroaryl portion by halogen, alkyl, alkoxy, cyano, trifluoromethyl, CF 3 0, nitro, oxo, amino, alkylamino, dialkylamino, or combinations to thereof and/or substituted in the alkyl portion by halogen, cyano, or methyl or combinations thereof; R 4 is aryl having 6 to 14 carbon atoms and which is unsubstituted or substituted one or more times by halogen, alkyl, alkenyl, alkynyl, hydroxy, alkoxy, alkoxyalkoxy, nitro, methylenedioxy, ethylenedioxy, trifluoromethyl, OCF 3 amino, aminoalkyl, aminoalkoxy, Is dialkylamino, hydroxyalkyl, hydroxamic acid, tetrazole-5-yl, 2-(tetrahydropyranyl)- hydroxyalkoxy, carboxy, alkoxycarbonyl, cyano, acyl, alkylthio, alkylsulfinyl, alkylsulfonyl, phenoxy, trialkylsilyloxy, R 5 or combinations thereof, or heteroaryl having 5 to 10 ring atoms in which at least I ring atom is a heteroatom, which is unsubstituted or substituted one or more times by halogen, alkyl, hydroxy, alkoxy, alkoxyalkoxy, nitro, methylenedioxy, ethylenedioxy, trifluoromethyl, amino, aminomethyl, aminoalkyl, aminoalkoxy dialkylamino, hydroxyalkyl hydroxamic acid, hydroxyalkoxy, carboxy, alkoxycarbonyl, cyano, acyl, alkylthio, alkylsulfinyl, alkylsulfonyl, phenoxy, trialkylsilyloxy, or combinations thereof; R' is H, alkyl having 1 to 8 carbon atoms, which is unsubstituted or substituted one or more times with halogen, C 14 -alkyl, C 4 -alkoxy, oxo, or combinations thereof, alkylamino or dialkylamino wherein each alkyl portion has independently 1 to 8 carbon atoms, P\WPDOCS\MDTSpecs\7H255153 do(-31/)72()>7 0 -86- a partially unsaturated carbocycle-alkyl group wherein the carbocycle portion has to 14 carbon atoms and the alkyl portion has 1 to 5 carbon atoms, which is unsubstituted or substituted, preferably in the carbocyclic portion, one or more times by halogen, alkyl, 00 alkoxy, nitro, cyano, oxo, or combinations thereof, cycloalkyl having 3 to 10 carbon atoms, which is unsubstituted or substituted one Cor more times by halogen, hydroxy, oxo, cyano, alkoxy, alkyl having 1 to 4 carbon atoms, Sor combinations thereof, cycloalkylalkyl having 4 to 16 carbon atoms, which is unsubstituted or substituted in the cycloalkyl portion and/or the alkyl portion one or more times by halogen, oxo, cyano, hydroxy, alkyl, alkoxy or combinations thereof, aryl having 6 to 14 carbon atoms and which is unsubstituted or substituted one or more times by halogen, alkyl, hydroxy, alkoxy, alkoxyalkoxy, nitro, methylenedioxy, ethylenedioxy, trifluoromethyl, amino, aminomethyl, aminoalkyl, aminoalkoxy, dialkylamino, hydroxyalkyl, hydroxamic acid, tetrazole-5-yl, hydroxyalkoxy, carboxy, alkoxycarbonyl, cyano, acyl, alkylthio, alkylsulfinyl, alkylsulfonyl, or combinations thereof, arylalkyl having 7 to 19 carbon atoms, wherein the aryl portion has 6 to 14 carbon atoms and the alkyl portion, which is branched or unbranched, has 1 to 5 carbon atoms, arylalkyl radical is unsubstituted or substituted, in the aryl portion, one or more times by halogen, trifluoromethyl, CF30, nitro, amino, alkyl, alkoxy, amino, alkylamino, dialkylamino and/or substituted in the alkyl portion by halogen, cyano, or methyl, a heterocyclic group, which is saturated, partially saturated or unsaturated, having to 10 ring atoms in which at least 1 ring atom is a N, O or S atom, which is unsubstituted or substituted one or more times by halogen, alkyl, hydroxy, alkoxy, alkoxyalkoxy, nitro, methylenedioxy, ethylenedioxy, trifluoromethyl, amino, aminomethyl, aminoalkyl, aminoalkoxy, dialkylamino, hydroxyalkyl, hydroxamic acid, hydroxyalkoxy, carboxy, alkoxycarbonyl, cyano, acyl, alkylthio, alkylsulfinyl, alkylsulfonyl, phenoxy, or combinations; or P kWPDOCSMDfpo Th255153 dOC.31A)7/2(X)7 0 -87- (N, a heterocyclicalkyl group, wherein the heterocyclic portion is saturated, partially saturated or unsaturated, and has 5 to 10 ring atoms in which at least 1 ring atom is a N, O or S atom, and the alkyl portion which is branched or unbranched and has 1 to 5 carbon 00 atoms, the heterocyclic-alkyl group is unsubstituted or substituted one or more times in the heterocyclic portion by halogen, alkyl, alkoxy, cyano, trifluoromethyl, CF 3 0, nitro, oxo, amino, alkylamino, dialkylamino, or combinations thereof and/or substituted in the alkyl NC portion by halogen, cyano, or methyl or combinations thereof; C L is a single bond or a divalent aliphatic radical having 1 to 8 carbon atoms wherein one or more -CH 2 groups are each optionally replaced by -NR 6 io -S02NH-, -NHSO 2 -NR 6 CO-, -CONR 6 -NHCONH-, -OCONH, -NHCOO-, -SCONH-, -SCSNH-, or -NHCSNH-; and R 6 is H or alkyl having 1 to 8 carbon atoms, which is branched or unbranched and which is unsubstituted or substituted one or more times with halogen, C-4-alkyl, CI- 4 alkoxy, oxo, or combinations thereof; and pharmaceutically acceptable salts thereof, wherein if the compound exhibits chirality it can be in the form of a mixture of enantiomers such as a racemate or a mixture of diastereomers, or can be in the form of a single enantiomer or a single diastereomer.
2. A compound according to claim 1, wherein R' is methyl or CHF 2 R is alkyl, alkenyl, alkynyl, cycloalkyl, arylalkyl, heterocycle-alkyl, cycloalkylalkyl, aryl, or heterocyclic, in each case substituted or unsubstituted; and R 3 is alkyl, arylalkyl or heteroarylalkyl, in each case substituted or unsubstituted.
3. A compound according to claim 1, wherein R 3 is heteroarylalkyl which is substituted or unsubstituted.
4. A compound according to claim 1, wherein R' is methyl or CHF 2 and R 2 is cyclopentyl, CHF 2 cyclopropylmethyl, pyridylethyl, or (3R)-tetrahydrofuranyl. A compound according to claim 1, wherein R' is methyl or CHF 2 R 2 is P WPDOCSMDTSp-\7925I 53 d-3 I A 17MMi 0 -88- cyclopentyl; and R 3 is heteroarylalkyl which is substituted or unsubstituted.
6. A compound according to claim 1, wherein R' is methyl; R 2 is cyclopentyl; R 3 is arylalkyl or heteroarylalkyl, in each case substituted or unsubstituted; and R 4 is 00 substituted or unsubstituted aryl.
7. A compound according to claim 1, wherein R' is methyl; R 2 is cyclopentyl; N and R 3 is heteroarylalkyl which is substituted or unsubstituted.
8. A compound according to claim 1, wherein R' is methyl; R 2 is cyclopentyl; R 3 is heteroarylalkyl which is substituted or unsubstituted; and R 4 is phenyl which is substituted or unsubstituted.
9. A compound according to claim 1, wherein R' is methyl; R 2 is cyclopentyl; R 3 is pyridylmethyl, pyrimidinylmethyl, phenethyl, benzyl, thienylmethyl, pyridylpropyl, or pyrazinylmethyl, which in each case is substituted or unsubstituted, or methyl, ethyl, or propyl; and R 4 is phenyl or phenyl substituted with 1 to 3 substituents. A compound according to claim 1, wherein R' is methyl; R 2 is cyclopentyl; R 3 is pyridylmethyl, pyrimidinylmethyl, phenethyl, benzyl, thienylmethyl, pyridylpropyl, pyrazinylmethyl, which in each case is substituted or unsubstituted, or methyl, ethyl, or propyl; and R 4 is phenyl, naphthyl, biphenyl, pyridyl, pyrimidinyl, thiazolyl, pyrazinyl, quinolinyl, or isoquinolinyl, in each case substituted or unsubstituted.
11. A compound according to claim 1, wherein R' is methyl or CHF 2 R 2 is cyclopentyl, CHF 2 cyclopropylmethyl, pyridylethyl, or tetrahydrofuranyl; and R 4 is phenyl, naphthyl, pyridyl, quinolinyl, or isoquinolinyl, which in each case is substituted or unsubstituted.
12. A compound according to claim 1, wherein R' is methyl or CHF 2 R 2 is cyclopentyl, CHF 2 cyclopropylmethyl, pyridylethyl, or tetrahydrofuranyl; and R 4 is phenyl which is unsubstituted or substituted by methyl, ethyl, methoxy, Cl, F, CF 3 vinyl, cyano, amino, carboxy, hydroxymethyl, ethylsulfonamido, or combinations thereof, or is 3- pyridyl which is unsubstituted or substituted by carboxy, alkoxycarbonyl, or combinations P \W\VDOCS\MATSpcu%7M235153 dc3 /07/2(X) -89- thereof.
13. A compound according to claim 1, wherein R' is methyl; R 2 is cyclopentyl; and R 4 is phenyl, naphthyl, pyridyl, quinolinyl, or isoquinolinyl, which in each case is 00 substituted or unsubstituted. O2 O s 14. A compound according to claim 1, wherein R' is methyl; R is cyclopentyl; N and R 4 is phenyl which is unsubstituted or substituted by methyl, ethyl, methoxy, Cl, F, O CF 3 vinyl, cyano, amino, carboxy, hydroxymethyl, ethylsulfonamido, or combinations thereof, or is 3-pyridyl which is unsubstituted or substituted by carboxy, alkoxycarbonyl, or combinations thereof. to 15. A compound according to claim 1, wherein R, is methyl or CHF 2 R 2 is cyclopentyl, CHF 2 cyclopropylmethyl, pyridylethyl, or tetrahydrofuranyl; and R 3 is benzyl, phenethyl, cyclohexenylmethyl, furanylmethyl, thienylmethyl, pyridylmethyl, quinolinylmethyl, isoquinolinylmethyl, thiazolylmethyl, or pyrrolylmethyl, which in each case is substituted or unsubstituted.
16. A compound according to claim 1, wherein R' is methyl or CHF 2 R 2 is cyclopentyl, CHF 2 cyclopropylmethyl, pyridylethyl, or tetrahydrofuranyl; and R 3 is pyrazinylmethyl, pyrimidinylmethyl, or pyridylmethyl, which in each case is unsubstituted or substituted.
17. A compound according to claim 1, wherein R' is methyl; R 2 is cyclopentyl; and R 3 is benzyl, phenethyl, cyclohexenylmethyl, furanylmethyl, thienylmethyl, pyrazinylmethyl, pyrimidinylmethyl, pyridylmethyl, quinolinylmethyl, isoquinolinylmethyl, thiazolylmethyl, or pyrrolylmethyl, which in each case is substituted or unsubstituted.
18. A compound according to claim 1, wherein R' is methyl; R 2 is cyclopentyl; and R 3 is pyrazinylmethyl or pyridylmethyl, which in each is unsubstituted or substituted.
19. A compound according to claim 1, wherein said compound is of formula IV P \WPDOC5\MDTSpec\7X2 5153 doc 31/7/2(l}7 0 (NN R 1 N A- B wherein R' and R 2 are as defined in claim 1, at least one of A, B, and D is N and the others are CH, and R 4 is pyridyl or phenyl which in each case is substituted or unsubstituted, and pharmaceutically acceptable salts thereof.
20. A compound according to claim 19, wherein R 1 is methyl or CHF 2
21. A compound according to claim 20, wherein B is N.
22. A compound according to claim 19, wherein R 1 is methyl or CHF 2 and R 2 is cyclopentyl, CHF 2 cyclopropylmethyl, pyridylethyl or tetrahydrofuranyl.
23. A compound according to claim 22, wherein B is N. 0 24. A compound according to claim 19, wherein R' is methyl or CHF 2 and R 4 is 3-pyridyl or phenyl, which in each case is substituted or unsubstituted. A compound according to claim 24, wherein B is N.
26. A compound according to claim 19, wherein R is methyl or CHF 2 R 2 is cyclopentyl, CHF 2 cyclopropylmethyl, pyridylethyl or tetrahydrofuranyl, and R 4 is 3- pyridyl or phenyl, which in each case is substituted or unsubstituted.
27. A compound according to claim 26, wherein B is N.
28. A compound according to claim 19, wherein R 1 is methyl or CHF 2 and R 4 is phenyl which is substituted in the 3- or 4- position.
29. A compound according to claim 28, wherein B is N.
30. A compound according to claim 19, wherein R' is methyl or CHF 2 R 2 is cylcopentyl, CHF 2 cyclopropylmethyl, pyridylethyl, or tetrahydrofuranyl, and R 4 is phenyl which is substituted in the 3- or 4- position. R 2 R D I which is substituted in the 3- or 4- position. P 3VDOCS3).DPSp-X7825 53 dm -3 W5712(M -91- ;Z31. A compound according to claim 30, wherein B is N.
32. A compound according to claim 19, wherein R' is methyl or CHF 2 and R 4 is 3-pyridyl, 3-COOH-phenyl, 3-Cl-phenyl, 3 -cyano-phenyl, 3 -ethyl -s ul fonam ido-phenyl, 00 3 -hydroxym ethyl -phenyl, 3-nitro-phenyl, 4-pyridyl, 4-COOH- phenyl, 4-cyano-phenyl, 4-ethyl-sulfonamido-phenyl, 4-tetrazol-5-yl-phenyt, or 4- hydroxymethyl-phenyl.
33. A compound according to claim 32, wherein B is N.
34. A compound according to claim 19, wherein R1 is methyl or CHF 2 R 2 is cyclopentyl, CHF 2 cyclopropylmethyl, pyridylethyl, or tetrahydrofuranyl, and R 4 is 3- o pyridyl, 3-COOI-I-phenyl, 3-CI-phenyl, 3-cyano-phenyl, 3-ethyl-sulfonamido-phenyl, 3- 3 -hydroxym ethyl -phenyl1, 3-nitro-phenyl, 4-pyridyl, 4-COOH-phenyl, 4-cyano-phenyl, 4-ethyl-sulfonamido-phenyl, 4-tetrazol-5-yl-phenyl, or 4-hydroxym ethyl phenyl. A compound according to claim 34, wherein B is N.
36. A compound according to claim 1, wherein said compound is selected from: P \WPDOCSWMOT3Speu,3T2S3I 53 dm,-31A) 7/2(X)7 -92- a);Zcoetlx-'ety--ehx--3priymty~ihnlmn b) 3-Cyclopentyloxy-3 '-et,4-methoxy-N-(3 -pyridylethyl)diphenylaine c) 3-Cyclopentyloxy-34-methoxy-N-(3-pyridymethyl) -rfuohydiphenylamine c0 3-Cyclopentyloxy3-fr-4-methoxy-N-(3-pyridylmethyl)rfurmydiphenyla raine 00 e) 3-Cyclopentyloxy-4 '-fluoro-4-niethoxy-N-(3-pyridylmethyl)diphenylamine e) 3-Cyclopentyloxy-4'fr4-methoxyey-N-(3 -pyidylmethyl)diphenylamine g)4'-Cyncyclopentyloxy-4-rnethoxy-hnyli-(3-pyidylmethyl)dphenyamine g) 43-Cyncyclopentyloxy-4-methoxy ir-N-(3-pyridylmethyl)diphenylamine i) 4 '-Chloro-3-cyclopentyloxy-4-methoxy-N-(3 -pyridylmethyl)-3 trifluoromethyldiphenylamine j) 4-Methoxy-3 '-methyl-N-(3-pyridylmethyl)-3-(3-tetrahydrofuryloxy)diphenylamine k) 3-Cyclopentyloxy-4-difluoromethoxy-N-(3-pyridylmethyl)diphenylamine 1) N-(3 -Cyclopentyloxy-4-methoxyphenyl)-N-(3-pyridylmethyl)-6-aminonicotinic acid m) N-(3-Cyclopentyloxy-4-methoxyphenyl)-N-(2-pyrazinyl)-N-(3-pyridymethy)amine n) 3' -Benzylsulfonylamino-3-cyclopentyloxy-4-methoxy-N-(3- pyridylmethyl)diphenylamine o) 3-[3-(4-Chlorophenyl)prop- 1-yloxy] -4-methoxy-N-(3 -pyridylmethyl)diphenyl amine p) 4-Methoxy-3 -(4-methoxyphenyl)prop-1I-yI]oxy-N-(3 pyridylmethyl)diphenylarnine P \V'PDOCSW DT\Spms74255153 dox-3 1/0712(X)7 -93 q) 4-Methoxy-3-[3-(2-pyridyl)prop-1I-yl]oxy-N-(3-pyridylrnethyl)diphenylaxnine r) 3 -Cyclopentyloxy-4 '-(2-methoxyethoxy)-4-methoxy-M-(3 pyridyLmethyl)diphenylarmine 00 s) 3-Cyclopentyloxy-4-methoxy-N-(3-pyridylniethyl)-4'-[(3R)-tetrahydrofiiranyloxy)- diphenylamine t) 3-Cyclopentyloxy-4-methoxy-4' -methylpiperidin-4-yloxy)-N-(3- pyridylmethyl)diphenylaniine u) 3-Cyclopentyloxy-4-methoxy-4' -niethylpyrrolidin-3 -yloxy)-N-(3 pyridylmethyl)diphenylamine v) 3-Cyclopentyloxy-4-.methoxy-4' I -pyrrolidinylethoxy)-N-(3- pyridylmethyl)diphenylamine w) 3-Cyclopentyloxy-4-methoxy-4' -[2-(6-methylpyridyl)methoxy)-N-(3- pyridylmethyl)diphenylamine x) 3 -Cyclopentyloxy4-methoxy-4'-[2-( 1 -methylpiperidinyl)methoxy]- N-(3 pyridylmethyl)diphenylamine y) 3-Cyclopentyloxy-4-methoxy-3 I -piperidinyl)ethoxy]-N-(3- pyridylmethyl)diphenylamine z) 3-Cyclopentyloxy-3 I -imidazolyl)ethoxy] -4-methoxy-N-(3- pyridylniethyl)diphenylamine aa) 3-Cyclopentyloxy-4-methoxy-4'-[3-(2-methylpiperazin-4-yl)propoxy]-N-(3- pyridylmethyl)diphenylamine bb) 3-Cyclopentyloxy-4-methoxy-4' -[3-(2-morpholin-4-ylethylamino)propoxy]-N-(3- pyridylmethyl)diphenylamine cc) 3-[2-(4-Chlorophenoxy)ethoxy)-4-methoxy-N-(3-pyridylmethyl)diphenylamine dd) 3-[2-(4-Chlorophenylamino)ethoxy]-4-methoxy-N-(3-pyridyhnethyl)diphenylamine ee) 3-Cyclopentyloxy-4'-(2-methanesulfonylamino)ethoxy-4-nethoxy-N-(3- pyridylmethyl)diphenylarnine fi) 4 1-Butanesulfonylamino)ethoxy]-3-cyclopentyloxy-4-methoxy-N-(3- pyridylmethyl)diphenylamine gg) 3-Cyclopentyloxy-4 -methoxy-N-(3-pyridylmethyl)diphenylaniine hh) 3-Cyclopentyloxy-4-methoxy-3 '-methyl-N-(3-pyridylniethyl)diphenylaniine P \\WPDOCSW~DT\Spe-\7K2S5I53 do.-3 I Al7,2(P7 -94- ;Z.3Ccoetlx--etoy4-ehlN(-yidlnty~ihnlmn jj) 3-Cyclopentyloxy-4-methoxy-4 '-nito-N-(3-pyridylmethyl)diphenylamine k)3-Cyclopentyloxy-34-dihor4-mito-N-(3-pyridylmetbyl)diphenylamine k) 3'-Cho3-yclopentyloxy- 4 '-dcluoro-4-methoxy-N-(3-pyridylmethyl)diphenylamine mm) 3.Cyclopentyloxy-N-(2,6-dichloro-4-pyridylmethyl)-4-methoxydiphenylamine rin) 4-Methoxy-4' -methyl-N-(3 -pyridylmethyl)-3-(3-tetrahydrofuryloxy)diphenylamine oo) 4,4'-Dimethoxy-N-(3-pyridylmethyl)-3-(3-tetrahydrofuyloxy)diphenylamine pp) 3-Indanyloxy-4-methoxy-N-(3-pyridylmethyl)diphenylamine qq) N-[4-Methoxy-3-(2-(2-pyridy)ethy)oxyphenyI-N-(3-pyridylmethy).3- aminobenzoic acid rr) N-(3-Cyclopentyloxy-4-methoxyphenyl)-N-(4-isoquinolinyl)-N-(3 pyridylmethyl)amine ss) N-(3-Cyclopentyloxy-4-methoxyphenyl)-N-(3-pyridylmethyl)-N-(5- pyrimidinyl)amine tt) N-(3-Cyclopentyloxy-4-methoxyphenyl)-N-(2-pyridyl)-N-(3-pyridylmethyl)amine uu) N-(4-Methoxy-3-(3R)-tetrahydrofuryloxyphenyl)-N-(3-pyridyl)-N-(3- pyridylmethyI)armine vv) 3-Cyclopentyloxy-4-methox yanilino-N-(3-pyridylmethyl)-N-3 -(4.pyridyl)benzamide ww) 3-Cyclopentyloxy-4-methoxy-3 '-(4-methylpiperazin- 1-ylcarbonyl)-N-(3 pyridylrnethyl)diphenylamine xx) 3-Cyclopentyloxy-4-difluoromethoxy-4 '-(4-methylpiperazin-1I-ylcarbonyl)-N-(3- pyridylmethyl)diphenylamine yy) 4-Methoxy-4 '-(4-methylpiperazin-1I-ylcarbonyl)-N-(3-pyridylmethyl)-(3.-(3- tetrahydrofuiryloxy)diphenylamine zz) -Butanesulfonyl amino)-3-cyclopentyloxy-.4-methoxy-N-(3 pyridylmethyl)diphenylamine aaa) 3 '-Acetamido-3-cyclopentyloxy-4-methoxy-N-(3-pyridylniethyl)diphenylamine bbb) 4-Methoxy-N-(3-pyridylmethyl)-3-(3-tetrahydrofuryloxy)diphenylamine ccc) 4-Methoxy-3 -[2-(4-pyridyl)ethoxy]-N-(3-pyridylmethyl)diphenylamnine ddd) 4-Methoxy-3-(2-methoxyethoxy)-N-(3-pyridylmethyl)diphenylanine eee) 3-Cyclopropylmethoxy-4-methoxy-N-(3-pyridylmethyl)diphenylaxnine P XWPOCSVD~k~cc0855S5 dm-l I/S)7/2(X)7 ifi) 4-Methoxy-N-(3-pyridylmethy)-3-[(3ST.-tetrahydroffiryloxy]diphenylamine ggg) 3 '-Chloro-4-methoxy-3-[2-(4-pyridyl)ethoxy]-N-(3-pyridylmethyl)dipbenylamine hhh) 3-[2-(4-Chlorophenyl)ethenyloxy]-4-methoxy-N-(3-pyridylmethyl)diphenylanine 00 iii) 3-Cyclopentyloxy-3 '-hydroxy-4-methoxy-N-(3-pyridylmethyl)diphenylamine jjj) 3-Cyclopentyloxy-4 '-hydroxy-4-methoxy-N-(3-pyridylmethyl)diphenylarnine kick) 4'-Cyclohexylethoxy-3-cyclopentyloxy-4-methoxy-N(3 pyridylmethyl)dipbenylamine 111) 3-Cyclopentyloxy-4-methoxy-4'-[2-( 1-methylpyrrolidiri-2-yI )ethoxy]-N-(3 pyridylmethyl)diphenylamine mmm) 3-Cyclopentyloxy-4-methoxy-4' 1-methylpiperidinyl)methoxyj-N-(3- pyridylrnethyl)diphenylamine nnn) 3-Cyclopentyloxy-4-rnethoxy-4 -methylpiperazin-4-yl)propoxy]-N-(3- pyridylmethyl)diphenylaniine ooo) 4-Methoxy-3-(2-phenoxyethoxy)-N-(3-pyridylmethyl)diphenylamine ppp) 3-Cyclopentyloxy-4-methoxy-4' -[2-(2-propanesul fonylarnino)ethoxyl-N-(3- pyridylmethyl)diphenylaniine qqq) 3 '-Cyano-3-cyclopentyloxy-4-methoxy-N-(3-pyridylmethyl)diphenylami ne rrr) 4'-Chloro-3-cyclopentyloxy-3 '-fluoro-4-rnethoxy-N-(3-pyridyhnethyl)diphenylanmine sss) 3-Cyclopropylxnethoxy-4-difluoromethoxy-N-(3-pyridylmethyl)diphenylamine ttt) 3-Cyclopentyloxy-4-methoxy-4' -(2-(tetrahydropyran-2-yI)-2H-tetraol-5-yl)-N-(3- pyridylmethyl)diphenylamine uuu) 3 -Cyclopentyloxy-4 '-methanesulfonylamino-4-methoxy-N-(3-pyridylmethyl)- diphenylamine vvv) 3-Cyclopentyloxy-4-methoxy-3 '-hydroxymethyl-N-(3- pyridylmethyl)diphenylamnine www) 3 -Cyclopentyloxy-4-methoxy-4' -hydroxymethyl-N- (3. pyridylmethyl)diphenylamine xxx) 4-Methoxy-3-[3-(4-pyridyl)prop- 1-yl~oxy-N-(3-pyridylmethyl)diphenylamine yyy) 3 '-Chloro-4-methoxy-3-(2-methoxyethoxy)-N-(3-pyridylmethyl)diphenylamine zzz) 3 -Cyclopropylmethoxy-4' -hydroxy-4-methoxy-N-(3- pyridylmethyl)diphenylamine P WPDOCSVADrSpuS\7H255 I51 dmc.3 IA)7fI2IX)7 -96- aaaa) 3-Cyclopentyloxy-4 '-(2-ethanesulfonylamino)ethoxy-4-methoxy-N-(3- pyridyfrnethyl)diphenylainine bbbb) 3-Cyclopentyloxy-4-methoxy-4' -propanesulfonylarnino)ethoxy]-N-(3- 00 pyridylmethyl)diphenylarnine cccc) 3 '-Chloro-3-cyclopentyloxy-4-methoxy-N-(3-pyridylmethyl)diphenylamidne dddd) 3 '-Chloro-4-methoxy-N-(3-pyridylmethyl)-3-(3- tetrahydrofuryloxy)diphenyLaxnine eee) 3' -Cyano-4-methoxy-N-(3-pyridylmethyl)-3 tetrahydrofuryloxy)diphenylamine iff f) 4-Difluoromethoxy-N-(3-pyridylmethyl)-3-(3 -tetrahydrofuryloxy)diphenylamine gggg) 3,4-Bis(difluoromethoxy)-N-(3-pyridylxnethyl)diphenylamine* hhhh) 4-Difluoromethoxy-N-!(3-pyridylmethyl)-3-((3R)- tetrah~ydrofuiryloxy)diphenylamine iii) 3.'-Cyano-4-difluoromethoxy-N-(3-pyridylrnethyl)-3-((3R)- tetrahydrofuryloxy)diphenylamine jjjj)3 '-Chloro-4-difluoromethoxy-N-(3-pyridylmethyl)-3-((3R)- tetrahydrofuryloxy)diphenylamine kkkk) 4'-tert-Butyldiuethylsilyloxy-3 -cyclopentyloxy-4-methoxy-N-(3- pyridyhnethyl)diphenylamine IIII)N(3-Cycopentyoxy-4-inethoxyphenyl)-N-(3-pyridylmethyl)-3-aminobenzoic acid nummm) N-(3-Cyclopentyloxy-4-methoxyphenyl)-N-(3 -pyridylmethyl)-4- aniinobeazoic acid nnnn) N-(3-Cyclopentyloxy-4-difluoromethoxyphenyl)-N-(3-pyridylmethyl)-3- aminobenzoic acid oooo) N-[4-Methoxy-3-(3 -tetrahydrofuryloxy)phenyl]-N-(3-pyridylmethyl)-3 aminobenzoic acid pppp) N-3,4-Bis(difluoromethoxy)phenyl)-N-(3-pyridylmethyl)-3-aminobenzoic acid qqqq) N-[4-methoxy-3-((3R)-tetrahydrofuryloxy)phenyl]-N-(3 -pyridyhnethyl)-3- aminobenzoic acid rrr) N-(3-Cyclopropylmethoxy-4-methoxyphenyl)-N-(3-pyridylmethyl)-4- aminobenzoic acid P \\PDOCSMDTlSp-\X255l53 do.-I110/712(X)7 -97- ;Z ssss) N-(3-Cyclopropylmethoxy-4-difluoromethoxyphenyl)-N-(3-pyridylethyl)-3- aminobenzoic acid tttt) N-[3-(4-Chlorophenyl)prop-1I-yloxy-4-methoxyphenyll-N-(3-pyridylmethyl)-3- 00 aninobenzoic acid uuuu) NV-(3-QClopropylmethoxy-4-methoxyphenyl)-N-(3-pyridylmethyl)-3- aminobenzoic acid vvvv) N-[3-(2-Indanyloxy)-4-methoxyphenyl]-N-(3-pyridylmethyl)-3- aminobenzoic acid wwww) N-[4-Methoxy-3-(3-tetrahydrofuryloxy)phenyll-N-(3-pyridylmethyl)-3 aminobenzoic acid xxxx) N-[4-Methoxy-3-((3R)-tetrahydrofuryloxy)pherlyl]-N-(3-pyridyhnethyl)-3- aminobenzoic acid yyyy) NV-[3-(2-Methoxyethoxy)-4-methoxyphenyl]-N-(3-pyridylmethyl)-3-aminobenzoic acid zzzz) 3-Cyclopropylmethyloxy-4-difluoromethoxy-N-(3 -pyridylmethyl)-4'-(2H- aaana) 3-Cyclopentyloxy-4-methoxy-N-(3 -pyridylmethyl)-4'-(2H-tetrazol.5- yl)diphenylamine bbbbb) 3-Cyclopentyloxy-4-methoxy-N-(3-pyridylrnethyl)-3 yl)diphenylamrine ccccc) 4-Methoxy-N-(3-pyridylmethyl)-3,-((3R)-tetrahydrofuryloxy)-4'-(2H-tetrazol-5- yl)diphenylamnine ddddd) 3-Cyclopropylniethyloxy-4-rnethoxy-N-(3-pyridylimethyl)-4'-(2H-tetrazol-5- yI)diphenylarnine eeeee) 4-Difluoromethoxy-N-(3-pyridylmethyl)-3 -((3R)-tetrahydrofuryloxy)-4' -(2H- fffff) 3-Cyclopentyloxy-4-difluromethoxy-N-(3-pyridylmethyl)-4'-(2H-teraol-5- yl)diphenylamne ggggg) 3-Cyclopropylmethyloxy-4-di fluoromethoxy-N-(3-pyridylrnethyl)-3 P MWPDOCSWM'pm.78255153 do .3 I A)7r2O)7 -98- hhhlih) Bis-3 ,4-difluoromethoxy-N-(3-pyridylmethyl)-4' yl)diphenylamine iiiii) N-(3 -Cyclopentyloxy-4-methoxyphenyl)-N-(3 -pyridyl)-N-(3-pyridylinethyI)amine 00 jjjj) N.(3-Cyclopentyloxy-4-difluorornethoxyphenyl)-N-(3 -pyridyl)-N-(3- pyridylmethyl)amine kkkkk). N-(3-Cyclopropylmethoxy-4-difluoromethoxyphenyl)-N(3-pyidyl)-N-(3- pyridylmethyl)arnine 11111) N-(4-Difluoromethoxy-3-(3R)-tetrahydrofuiryloxyphenyl)-N-(3-pyridyl)- N-(3-pyridylmethyl)amine mmmmm) 3-Gyclopentyloxy-3'-ethanesulfonylamino-4-methoxy-N-(3-. pyridylmethyl)diphenylamine nnnnn) 3-CycLopentyloxy-4-methoxy-3 -propanesulfonylamino)-N-(3- pyridylinethyl)diphenylamine 00000) 3-Cyclopentyloxy-4 '-ethanesulfonylamilno-4-rnethoxy-N-(3- pyridyhnethyl)diphenylaxnine PPPPP) 3-Cyclopentyloxy-4-methoxy-4' -propanesulfonylamino)-N-(3- pyridylmethy))diphenylamine qqqqq) 3-Cyclopropylmethoxy-3'-ethanesulfonylaxnino-4-methoxy-N-(3- pyridylmethyl)diphenylamine rrrrr) 4-Difluoromethoxy-3 '-ethanesulfonylamino-N-(3-pyridylmethyl)-3-[(3R)- tetrahydrofuyoxy]diphenylamnine sssss) 4-Methoxy-3-[2-(2-pyridyl)ethoxy]-N-(3-pyridylmethyl)diphenylamine ttttt) 4-Methoxy-N-(3-pyridylmethyl)-3-[(3R)-tetrahydrofuiryloxy]diphenylamine uuuuu) 3' -Chloro-4-methoxy-3-[2-(2-pyridyl)ethoxy]-N-(3 -pyridylmethyl)diphenylaxnine vvvvv) 3 '-Chloro-4-methoxy-N-(3-pyridylmethyl)-3-[(3R)- tetrahydrofuryloxy]diphenylamine wwwww) 3-Cyclopentyloxy-4-methoxy4'-[2-(5-oxopyrrolidiny1)methoxy]-N-(3. pyridylniethyl)diphenylamine; and pharmaceutically acceptable salts thereof, wherein if the compound exhibits chirality it can be in the form of a mixture of enantiomers such as a racemnate or a mixture of diastereomers, or can be in the form of a P \WPDOCS\MDPSpmXs78255151 dM-3 I ft1i2(K)7 -99- ;Z single enantiomer or a single diastereomer.
37. A compound according to claim 1, wherein said compound is selected from: 00 a) 3-Cyclopentyloxy-4-methoxy-N-(3-pyridylmethyl)diphenylanine b) 3-Cyclopentyloxy-4-methoxy-3 '-methyl-N-(3-pyridylmethyl)diphenylainine c) 3-Cyclopentyloxy-4-methQxy-4'-methyl-N-(3-pyridylnethyl)diphenjlamine d) 3-Cyclopentyloxy-4-methoxy-4'-nito-N-(3-pyridylnethyl)diphenylaniine e) 3-Cyclopentyloxy-3 ',4'-dichloro-4-methoxy-N-(3-pyridylmethyl)diphenylanine f) 3 '-Chloro-3-cyclopentyloxy-4'-fluoro-4-methoxy-N-(3-pyridymethyl)dipbenylamine g) 3-Cyclopentyloxy-N-(2,6-dichioro-4-pyridylmethyl)-4-methoxydiphenylanine h) 4-Methoxy-4'-methyl-N-(3-pyridylmethyl)-3-(3-tetrahydrofuiryloxy)diphenylaniine i) 4,4' -Dimethoxy-N-(3-pyridylmethyl)-3-(3-tetrahydrofuryloxy)diphenylamine j) 3-Indanyloxy-4-methoxy-N-(3-pyridylmethyl)diphenylanine k) N-[4-Methoxy-3-(2-(2-pyridyl)ethyl)oxyphenyl]-N-(3-pyridylmethyl)-3- aminobenzoic acid 1) N-(3-Cyclopentyloxy-4-methoxyphenyl)-N-(4-isoquinolinyl)-N-(3- pyridylmethyl)ainine mn) N-(3-Cyclopentyloxy-4-inethoxyphenyl)-N-(3-pyridylmethyl)-N-(5- pyrimidinyl)ainine n) N-(3-Cyclopentyloxy-4-methoxyphenyl)-N-(2-pyridyl)-N-(3 -pyridylmethyl)ainine o) N-(4-Methoxy-3-(3R)-tetrahydrofuryloxyphenyl)-N-(3-pyridyl)-N-(3- pyridylmethyl)aniine p) 3-Cyclopentyloxy-4-methoxyani lino-N-(3-pyridylrnethyl)-N-3-(4-pyridyl)benzanide qi) 3-Cyclopentyloxy-4-methoxy-3 '-(4-methylpiperazin- 1-ylcarbonyl)-N-(3- pyridylmethyl)diphenylaxnine r) 3-Cyclopentyloxy-4-difluoroinethoxy-4 '-(4-inethylpiperazin- I -ylcarbonyl)-N-(3- pyridylmethyl)diphenylainine s) 4-Methoxy-4' -(4-methylpiperazin- I -ylcarbonyl)-N-(3-pyridylmethyl)-(3-(3 tetrahydrofuryjoxy)diphenylainine t) 3 -Butanesulfonylamino)-3-cyclopentyloxy-4-methoxy-N-(3- pyridyhmethy)diphenylaxnine P X\VPDO>CS\MDT'5 5 33s\782551 53 d-~3 lfP7/(W~ -100- u) 3' -Acetamjdo-3-cyclopentyloxy-4-methoxy-N-(3 -pyridy~methyl)diphenylamine v) 4-Methoxy-N-(3-pyridylmethyl)-3-(3-tetrahydrofaryloxy)dipienylanine w) 4-Methoxy-3-[2-(4-pyridyl)ethoxyJ-N-(3-pyridylmethyl)diphenylamine 00 x) 4-Methoxy-3-(2-methoxyethoxy)-N-(3-pyridylmethyl)diphenylamine y) 3-Cyclopropylmethoxy-4-methoxy-N-(3-pyridylmethyl)diphenylamine z) 4-Methoxy-N-(3 -pyiidylrnethyl)-3-[(3S)-tetrahydrofuryloxy]diphenylamine aa) 3 '-Chloro-4-methoxy-3-[2-(4-pyridyl)ethoxy-N-(3-pyridylnethyl)diphenylanine bb) 3-[2-(4-Chlorophenyl)ethenyloxy] -4-methoxy-N-(3 -pyridylmethyl)diphenylamine cc) 3-Cyclopentyloxy-3 '-hydroxy-4-mcthoxy-N-(3-pyridylmethyl)diphenylamine dd) 3-Cyclopentyloxy-4'-hydroxy-4-methoxy-N-(3-pyridylnethyl)diphenylamine ee) 4' -Cyclohexylethoxy-3-cyclopentyloxy-4-methoxy-N-(3- pyridylmethyl)diphenylainine ff) 3-Cyclopentyloxy-4-metboxy-4' -[2-Cl -methylpyrrolidin-2-yl)ethoxy]-N-(3 pyridyhnethyl)diphenylamine gg) 3-Cyclopentyloxy-4-methqx y-4' 1-methylpiperidinyl)methoxy] pyridyhnethyl)diphenylamine hh) 3-Cyclopentyloxy-4-methoxy-4' I -methylpiperazin-4-yI)propoxy] pyridylmethyl)diphenylaxnine ii) 4-Methoxy-3-(2-phenoxyethoxy)-N-(3-pyridylmethyl)diphenylamine Ji) 3-Cyclopentyloxy-4-methoxy-4' -[2-(2-propanesulfonylamino)ethoxy]-N-(3- pyridylinethyl)diphenylarnine kk) 3 '-Cyano-3-cyclopentyloxy-4-methoxy-N-(3-pyridyimethyl)diphenylamine 11) 4'-Chloro-3-cyclopentyloxy-3 '-fluoro-4-methoxy-N-(3-pyridylmethyl)diphenylamine mm) 3-Cyclopropylmethoxy-4-difluoromethoxy-N-(3-pyridylMethyl)diphenylamine nn) 3-Cyclopentyloxy-4-methoxy-4 '-(2-(tetrahydropyran-2-yl)-2H-tetrazol-5 pyridylmethyl)diphenylamine oo) 3-Cyclopentyl'oxy-4 '-methanesulfonylamino-4-methoxy-N-(3 -pyridylmethyl)- diphenylamine pp) 3-Cyclopentyloxy-4-methoxy-3 '-hydroxymethyl-N-(3-pyridylmethyl)diphenylanune qq) 3-Cyclopentyloxy-4-methoxy-4'-hydroxymethyl-N-(3-pyridylmethyl)diphenylmine ff) 4-Methoxy-3-[3 -(4-pyridyl)prop-1I-ylloxy-N-(3 -pyridytmethyl)diphenylamine P \\hPDOICSU\tYI'Specuk782S5153 docI IA7/21c17 -101 ss) l '-Chloro-4-methoxy-3 -(2-methoxyethoxy)-N-(3-pyridylmethyl)diphenylamnine tt) 3-Cyclopropylinethoxy-4' -hydroxy-4-methoxy-N-(3 -pyridylrnethyl)diphenylamine uu) 3-Cyclopentyloxy-4 '-(2-ethanesulfonylamino)ethoxY-4-methoxy-N-(3- 00 pyridylmethyl)diphenylaxnine vv) 3-Cyclopentyloxy-4-metboxy-4 I-propancsulfonylamino)ethoxy]-N-(3- pyridylmethyl)diphenylamine ri ww) 3 '-Chloro-3-cyclopentyloxy-4-methoxy-N-(3-pyridylmethyl)diphenylamine xx) 3 '-Chloro-4-mettioxy-N-(3-pyridylmethyl)-3-(3-tetrahydrofuryloxy)diphenylamine yy) 3 '-Cyano-4-methoxy-N-(3-pyridylmethyl)-3 -((3R)-tetrahydrofiiryloxy)diphenylamine zz) 4-Di fluoromethoxy-N-(3-pyridylmethyl)-3-(3 -tetrahydrofuirylaxy)diphenylamine aaa) 3,4-Bis(difluorornethoxy)-N-(3-pyridylmetbyl)diphenylamine bbb) 4-Difluoromethoxy-N-(3-pyridylrnethyl)-3-((3R)- tetrahydrofur-yloxy)diphenylamine ccc) 3 '-Gyano-4-difluoromethoxy-N-(3-pyridylmethyl)-3-((3R)- tetrahydrofuiryloxy)diphenylarnine ddd) 3' -Chloro-4-difluoromethoxy-N-(3-pyridylmethyl)-3-((3R)- tetrahydrofuryloxy)diphenylamine eee) 4' -:ert-Butyldimethylsilyloxy-3 -cyclopentyloxy-4-methoxy-N-(3 pyridylmethyl)diphenylamine ffl) N-(3-Cyclopentyloxy-4-rnethoxyphenyl)-N-(3-pyridylmethyl)-3-aminobenzoic acid ggg) N-(3-Cyclopentyloxy-4-methoxyphenyl)-N-(3-pyridylmethyl)-4-aminobenzoic acid hhh) N-(3 -CycopentyIoxy-4-difluoromeffioxyphenyI)-N-(3-pyridymethy)-3- Sarninobenzoic acid iii) N-[4-Methoxy-3-(3-tetrahydrofuryloxy)phenyl]-N-(3 -pyridylmethyl)-3 -arninobenzoic acid jjj) N-3 ,4-Bis(difluoromethoxy)phenyl)-N-(3-pyridylmetbyl)-3-aminobenzoic acid kkk) N-[4-methoxy-3-((3R)-tetrahydrofuryloxy)phenyl -pyridylmethyl)-3 aminobeazoic acid 111) N-(3-.Cyclopropylmethoxy-4-methoxyphenyl)-N-(3-pyridylmethyl)-4-aminobenzoic acid P IV PDOCSIMDT\Spe-\782S55153 d..3 1A17/2(X)7 -102- ;Z mmm) N-(3-Cyclopropylmethoxy-4-difluoromethoxyphenyl)-N-(3-pyridylmethyl)- 3-aminobenzoic acid nnn) N-[3-(4-Chlorophenyl)prop-1I-yloxy-4-methoxyphenyl]-N-.(3-pyridylrnethyl)-3- 00 aminobenzoic acid ooo) N-(3-Cyclopropylmethoxy-4-methoxyphenyl)-N-(3-pyridylmethyl)-3- aminobeizoic acid ppp) N-[3-(2-Indanyloxy)-4-methoxyphenyl]-N-(3 -pyridylmethyl)-3-aniinobenzoic acid qqq) N-[4-Methoxy-3 -(3-tetrahydrofuryloxy)phenyl] -N-(3-pyridylmethyl).3 -aminobenzoic acid rrr) N-[4-Methoxy-3-((3R)-tetrahydrofuryloxy)phenyl]-N-(3 -pyridylmethyl)-3 aminobenzoic acid sss) N-[3-(2-Methoxyethoxy)-4-methoxyphenyl]-N-(3-pyridylmethyl)-3-aniinobenzoic acid ttt) 3-Cyclopropylmnethyloxy4-difluorornethoxy-N-(3-pyridylmethyl)-4 uuu) 3-Cyclopentyloxy-4-methoxy-N-(3-pyridylmethyl)-4 '-(2H-tetrazol-5 yl)diphenylarnine vv-v) 3 -Cyclopentyloxy-4-niethoxy-N-(3-pyridylmethyl)-3 '-(2H-tetrazol-5 yl)diphenylamine www) 4-Methoxy-N-(3 -pyridylmethyl)-3-((3R)-tetrahydrofuryloxy)-4' -(2H-tetrazol-5 YI)diphenylamine xxx) 3-Cyclopropyimnethyloxy-4-methoxy-N-(3 -pyridylmethyl)-4'-(2H-tetrazol-S- yI)diphenylaxnine yyy) 4-Difluoromethoxy-N-(3-pyridylmethyl)-3 -((3R)-tetrahydrofuryloxy)-4' -(2H- .zzz) 3-Cyclopentyloxy-4-difluromethoxy-N-(3-pyridylImethyl)-4 '-(2H-tetrazol-5 yl)diphenylamine aaaa) 3-Cyclopropylmethyloxy-4-difluoromethoxy-N-(3-pyridylmethyl)-3 P XWD0CSlMAflSp~k1S255 153 dxc.3 I A)7121X)7 -103- bbbb) Bis-3,4-difluoromethoxy-N.(3-pyridylmethyl)-4'-(2H-tetrazol-.5- yl)diphenylamine cccc) N-(3-Cyclopentyloxy-4-methoxyphenyl)-N-(3-pyridyl)-N-(3-pyridylmethyl)amine 00 dddd) N-(3-Cyclopentyloxy-4-difluoromethoxyphenyl)-N-(3-pyridyl)-N-(3- pyridylmethyl)amine eeee) N-(3-Cyclopropylmethoxy-4-difluoromethoxypheny)-N-(3-pyridyl)-N-(3- pyridyhnethyl)amine ffff) N-(4-Difluoromethoxy-3-(3R)-tetrahydrofiiryloxyphenyl)-N-(3 -pyridyl)-N-(3- pyfidylmethyl)amine gggg) 3-Cyclopentyloxy-3 ',-ethanesulfonylamino-4-methoxy-N-(3 pyridylmethyl)diphenylamine hhhh) 3-Cyclopentyloxy-4-methoxy-3 -propanesulfonylamino)-N-(3- pyridylniethyl)diphenylamirie iii) 3-Cyclopentyloxy-4 '-ethanesulfonylamino-4-methoxy-N-(3 pyridylmethyl)diphenylamine jj)3-Cyclopentyloxy-4-methoxy-4' -propanesulfonylaxnino)-N-(3- pyridylmethyl)diphenylamine kkkk) 3-Gyclopropylmethoxy-3 '-ethanesulfonylamnino-4.methoxy-N-(3- pyridylmethyl)diphenylamine 1111) 4-Difluoromethoxy-3 '-ethanesulfonylamino-N-(3-pyridylmethyl)-3-[(3R)- tetrahydrofuryloxy]diphenylamnine mrnmm) 4-Methoxy-3-(2-(2-pyridyl)ethoxy]-N-(3-pyridylmethyl)diphenylamine nnnn) 4-Methoxy-N-(3-pyridylmethyl)-3-[(3R)-tetrahydrofuryloxy~diphenylamine 0000) 3 '-Chloro-4-methoxy-3-[2-(2-pyridyl)ethoxy]-N-(3 -pyridylmethyl)diphenylaniine pppp) 3 '-Chloro-4-methoxy-N-(3-pyridylmethyl)-3-[(3R)- tetrahydrofuryloxy]diphenylamine qqqq) 3-Cyclopentyloxy-4-methoxy-4' -[2-(5-oxopyrrolidinyl)methoxy] pyridylmethyl)diphenylamine; and pharmaceutically acceptable salts thereof, wherein if the compound exhibits chirality it can be in the form of a mixture of enantiomers such as a racemate or a mixture of diastereomers, or can be in the form of a P W?DOCSW4D1'peW78255S3 d-3Ift)7/200)7 -104- ;Z single enantiomer or a single diastereomer.
38. A compounds according to claim 1, wherein said compound is selected from: 00 a) 3 '-Cyano-3-cyclopentyloxy-4-methoxy-N-(3-pyridylmethyl)diphenylainine M b) 4'-Chloro-3-cyclopentyloxy-3 '-fluoro-4-methoxy-N-(3-pyridylmethyl)diphenylaniine c) 3-Cyclopropylmethoxy-4-difluoromethoxy-N-(3-pyridylxnethyl)diphenylamine d) 3-Cyclopentyloxy-4-methoxy-4'-(2-(tetrahydropyran-2-y)-2H-tetrazol-5-yl)-N-(3 pyridylmethyl)diphenylamine e) 3-Cyclopentyloxy-4 '-methanesulfonylamino-4-methoxy-N-(3-pyridylmethyl)- diphenylamine f)3-Cyclopentyloxy-4-methoxy-3 '-hydroxymethyl-N-(3 -pyridylmethyl)diphenylamine g) 3-Cyclopentyloxy-4-methoxy-4 '-hydroxymethyl-N-(3-pyridylmethyl)diphenylamnine h) 4-Methoxy-3-[3-(4-pyridyl)prop-1I-yl]oxy-N-(3-pyridylmethyl)diphenylainine i) 3 '-Chloro-4-methoxy-3-(2-methoxyethoxy)-N-(3-pyridylmethyl)diphenylamine j) 3-Cyclopropylmethoxy-4'-hydroxy-4-methoxy-N-(3-pyridylmethyl)diphenylaznine k) 3-Cyclopentyloxy-4 '-(2-ethanesulfonylamino)ethoxy-4-methoxy-N-(3- pyridylmethyl)diphenylamine 1) 3-Cyclopentyloxy-4-methoxy-4' 1 -prop anesulfonylarnino)ethoxy] pyridylmethyl)diphenylamine rn) 3 '-Chloro-3-cyclopentyloxy-4-methoxy-N-(3-pyridylinethyl)diphenylamine n) 3 '-Chloro-4-inethoxy-N-(3-pyridylinethyl)-3-(3-tetrahydrofuryloxy)diphenylamine o) 3'-Cyano-4-methoxy-N-(3-pyridylmethyl)-3-((3R)-tetrahydrofuryloxy)diphenylaniine p) 4-Difluoromethoxy-N-(3-pyridylinethyl)-3-(3 -tetrahydrofuryloxy)diphenylainine q) 3,4-Bis(difluoroinetboxy)-N-(3-pyridylinethyl)diphenylamine r) 4-Difluoroinethoxy-N-(3-pyridylmethyl)-3-((3R)-tetrahydrofuryloxy)diphenylamine s) 3'-Cyano-4-difluoromethoxy-N-(3-pyridylmethyl)-3-((3R)- tetrahydrofuryloxy)diphenylainine t) 3' -Chloro-4-di fluoromethoxy-N-(3-pyridylmethyl)-3-((3R)- tetrahydrofuryloxy)diphenylainine u) 4'-tert-Butyldimethylsilyloxy-3-cyclopentyloxy-4-methoxy-N-(3- pyridylmethyl)diphenylamine P WPDOCS%)M1O1Sp-cX7X255153 dec-3 1/()7/2(X)7 -105- ;ZN( Ccoetlx--etoyhnl--3-yiymehl--mnbnocai w) N-(3-Cyclopentyloxy-4-rnethoxyphenyl)-N-(3-pyridylmrethyl)-4-aminobenzoic acid w) N-(3 -Cyclopentyloxy-4-dfrmethoxyphenyl)-N-(3-pyridylmethyl)- 3-noezicai x)00-ylpnyoy4dfurmthxpey)N(-yiymty)3 00 arinobenzoic acid y) N-[4-Methoxy-3-(3-tetrahydrofuryloxy)phenyl]-N-(3-pyridylmethyl)-3.aminobenzoic acid z) N-3,4-Bis(difluoromethoxy)phenyl)-N-(3 -pyfidylrnethyl)-3-amninobenzoic acid aa) N-[4.methoxy-3-((3R)-tetrahydrofuryloxy)phenyl]-N-(3 -pyfidylmethyl)-3 amninobenzoic acid bb) N-(3 -Cyclopropylmethoxy-4-methoxyphenyl)-N-(3-pyridylmethyl)-4-aminobenzoic acid cc) N-(3 .Cyclopropylmethoxy-4-difluoromethoxyphenyl)-N-(3-pyridylmethyl)-3- axninobenzoic acid dd) N-(3-(4-Chlorophenyl)prop-1I-yloxy-4-methoxyphenyl]-N-(3 -pyridylmethyl)-3- Saminobenzoic acid ee) N-(3-Cyclopropylmethoxy-4-methoxyphenyl)-N-(3-pyriciytmethyl)-3-aninobenzoic acid f)N-[3-(2-Indanyloxy)-4-methoxyphenyl]-N-(3-pyridylmethyl)-3-amninobenzoic acid gg) N-[4-Methoxy-3-(3-tetrahydrofuryloxy)phenyl]-N-(3-pyridylmethyl)-3-aminobenzoic acid hh) N-[4-Methoxy-3-((3R)-tetrahydrofuiryloxy)phenyl]-N-(3-pyridylmethyl)-3- aniinobenzoic acid ii) N-[3-(2-Methoxyethoxy)-4-methoxyphenyll-N-(3 -pyridylmethyl)-3 -aminobenzoic acid ii) 3-Cyclopropylxnethyloxy-4-difluoromethoxy-N-(3-pyridytmethyl)-4 '-(2H-tetrazol-5 yl)diphenylamine kk) 3-Cyclopentyloxy-4-methoxy-N-(3 -pyridylmethyl)-4 yI)diphenylamine 11) 3-Cyclopentyloxy-4-methoxy-N-(3-pyriylmethyl'-(2H-tetrazol-5 yl)diphenylamine P IWI'OCSW D? Mp W.78255 IS dmcS ID71(Dx7 -106- mm) 4-Methoxy-N-(3-pyridylmethyl)-3 -((3R)-tetrahydrofuryioxy)-4'-(2H-tetrazol-5- yl)diphenylamine nnl) 3-Cyclopropylmethyloxy-4-methoxy-N-(3 -pyridylmethyl)-4 00 yl)diphenylaxnine oo) 4-Difluoromethoxy-N-(3-pyridylmethyl)-3 -((3R)-tetrahydro Euryloxy)4' -(2H-tetrazol- pp) 3-Cyclopentyloxy-4-difluromethoxy-N-(3-pyridylmethyl)-4' yI)diphenylarnine qq) 3-Cyclopropylxnethyloxy-4-difluoromethoxy-N-(3-pyridylmethyl)-3 '-(2H-tetrazol.5 yl)diphenylamnine rr)) Bis-3 ,4-difluoromethoxy-N-(3-pyridylmethyl)-4'-(2H-tetrazo-5-y)dphenylamine ss) N-(3-Cyclopentyloxy-4-methoxyphenyl)-N-(3-pyridyl)-N-(3-pyridylmethyl)anine tt) N-(3-Cyclopentyloxy-4-difluoromethoxyphenyl)-N-(3-pyridyl)-N-(3- pyridylmethyl)amine uu) N-(3-Cyclopropylmethoxy-4-difluoromcthoxyphenyl)-N-(3-pyridyl)-N-(3 pyridylmethyl)armine vv) N-(4-Difluoromethoxy-3-(3R)-tetrahydrofuryloxyphenyl)-N-(3 -pyridyl)-N-(3- pyridylmethyl)amine ww) 3-Cyclopentyloxy-3 '-ethanesulfonylaxnino-4-methoxy-N-(3- pyridylmethyl)diphenylaxnine xx) 3 -Cyclopentylox y-4-methoxy-3 -propanesul fonylamino)-N-(3- pyridyhnethyl)diphenylaznine YY) 3-Cyclopentyl-oxy-4'-ethanesulfonylamino-4-methoxy-N-(3- pyridylmethyl)diphenylamine zz) 3-Cyclopentyloxy-4-methoxy-4' -propanesulfonylamino)-N-(3- pyridylmethyl)diphenylamine aaa) 3-Cyclopropylmethoxy-3 '-ethanesulfonylaxnino-4-rnethoxy-N-(3- pyridylmethyl)diphenylami ne bbb) 4-Difluoromethoxy-3 '-ethanesulfonylaxnino-N-(3-pyridylmethyl)-3-[(3R)- tetrahydrofuryloxy]diphenylamirie ccc) 4-Methoxy-3-[2-(2-pyfidyl)ethoxy]-N-(3-pyridylmethyl)diphenylamine P lWPDGCS\MDT\pcu\782S5153 dm 3 IA)712(X)7 -107- ddd) 4-Methoxy-N-(3-pyridylmethyl)-3-[(3R)-tetrahydrofurytoxy]diphenylamine eee) 3 '-Chloro-4-methoxy-3-[2-(2-pyridyl)ethoxy] -N-(3-pyridylmethyl)diphenylamine fff 3 '-Chloro-4-methoxy-N-(3-pyridylmethyl)-3-[(3R)- 00 tetrahydrofuryloxy]diphenylamine ggg) 3-Cyclopentyloxy-4-methoxy-4'-[2-(5-oxopyrrolidinyl)methoxy]-N-(3- pyridylmethyl)diphenylamine; and pharmnaceutically acceptable salts thereof, wherein if the compound exhibits chirality it can be in the form of a mixture of enantiomers such as a racemnate or a mixture of diastereomers, or can be in the form of a single enantiomer or a single diastereomer.
39. A compound according to claim 1, wherein said compound is selected from: a) 3' -Chloro-3-cyclopentyloxy-4-methoxy-N-(3-pyridylmethyl)diphenylamine. b) 3' -Chloro-4-methoxy-N-(3-pyridylmethyl)-3-(3-tetrahydrofuryloxy)diphenylamine c) 3 '-Cyano-4-methoxy-N-(3-pyridylmethyl)-3-((3R)-tetrahydrofiiryloxy)diphenylamine d) 4-Difluoromethoxy-N-(3-pyridylmethyl)-3 -(3-tetrahydrofuryloxy)diphenylamine e) 3,4-Bis(difluoromethoxy)-N-(3-pyridylmethyl)diphenylamine f) 4-Difluoromethoxy-N-(3-pyridylmethyl)-3-((3R)-tetrahydrofiuryloxy)diphenylamine g) 3 '-Cyano-4-difluoromethoxy-N-(3-pyridylinethyl)-3-((3R)- tetrahydrofuryloxy)diphenylamine h) 3 '-Chloro-4-difluoromethoxy-N-(3-pyridylmethyl)-3-((3R)- tetrahydrofuryloxy)diphenylamine i) 4'-terr-Butyldimethylsilyloxy-3-cyclopentyloxy-4-methoxy-N-(3- pyridylmethyl)diphenylamine j) N-(3-Cyclopentyloxy-4-methoxyphenyl)-N-(3-pyridylmethyl)-3-aminobenzoic acid k) N-(3-Cyclopentyloxy-4-methoxyphenyl)-N-(3-pyridylmethyl)-4-aminobenzoic acid 1) N-(3-Cyclopentyloxy-4-difluoromethoxyphenyl)-N-(3-pyridylmethyl)-3- aminobenzoic acid m) N-(4-Methoxy-3-(3-tetrahydrofuryloxy)phenyl]-N-(3-pyridylmethyl)-3-aminobenzoic acid n) N-3 ,4-Bis(difluoromethoxy)phenyl)-N-(3-pyridylmethyl)-3-axninobenzoic acid P MWPDOCSIMD~hpeuX\78255153 doc-3 IA3)712(K]7 -108- o) N-[4-methoxy-3-((3R)-tetrahydrofuryloxy)phenyl]-N-(3 -pyridylmethyl)-3- aminobenzoic acid p) N-(3-Cyclopropylmethoxy-4-methoxyphenyl)-N-(3 -pyridylmethyl)-4-amninobenzoic 00 acid q) N-(3-Cyclopropylmethoxy-4-difluoromethoxyphenyl)-N-(3 -pyridylmethyl)-3 aminobenzoic acid r) N-[3-(4-Chlorophenyl)prop- 1-yloxy-4-metlxoxyphenyl]-N-(3 -pyridylmethyl)-3- aniinobenzoic acid s) N-(3-Cyclopropylmethoxy-4-methoxyphenyD-N-(3 -pyridylmethyl)-3 -aminobenzoic acid t) N-(3-(2-lndanyloxy)-4-methoxyphenyl)-N-(3 -pyridylmethyl)-3 -aminobenzoic acid u) N-[4-Methoxy-3-(3-tetrahydrofiiryloxy)phenyl]-N-(3 -pyfidylmethyl)-3 -amninobenzoic acid v) N-[4-Methoxy-3-((3 R)-tetrahydrofuryloxy)phenyl]-N-(3-pyridylmethyl)-3- aniinobeazoic acid w) N-[3-(2-Methoxyethoxy)-4-methoxyphenyl]-N-(3-pyridylinethyl)-3 -aniinobenzoic acid x) 3-Cyclopropylmethyloxy-4-difluoromethoxy-N-(3 -pyridylmethyl)-4'-(2H-tetrazol-5- yl)diphenylamine y) 3 -Cyclopentyloxy-4-methoxy-N-(3 -pyridylmethyl)-4 yl)diphenylamine z) 3 -Cyclopentyloxy-4-methoxy-N-(3-pyridytmethyl)-3 '-(2H-tetrazol-5 yl)diphenylamine aa) 4-Methoxy-N-(3-pyridylmethyl)-3-((3R)-tetrahydrofuryloxy)-4' yl)diphenylamine bb) 3 -Cyclopropylmethyloxy-4-methoxy-N-(3 -pyridytrnethyl)-4 yl)diphcnylaniine cc) 4-Di fluoromethoxy-N-(3-pyridylmethyl)-3-((3R)-tetrahydrofuryloxy)-4' -(2H-tetrazol- -yl)diphenylamine P XWPDOCSW3OfSpca\7M255153 dom.3MIA7,2(X)7 -109- dd) 3-Cyclopentyloxy-4-difluromethoxy-N-(3 -pyridylmethyl)-4' -(2H-tetrazol-5 yI)diphenylamine ec) 3-Cyclopropylmethyloxy-4-difluoromethoxy-N-(3-pyridylniethyl)-3 00 yl)diphenylainine ff) Bis-3 ,4-di fluoromethoxy-N-(3 -pyridylniethyl)-4 gg) N-(3-Cyclopentyloxy-4-methoxyphenyl)-N-(3 -pyridyl)-N-(3 -pyridylmnethyl)amine hh) Nf-(3-Cyclopentyloxy-4-difluoromethoxyphenyl)-N-(3 -pyridy)-Ar-(3 pyridyLmethyl)amine ii) N-(3-Cyclopropylmethoxy-4-di fluoromethoxyphenyl)-N-(3 -pyridyl)-N-(3 pyridylmethyl)amine ii) N-(4-Difluoromethoxy-3 -(3R)-tetrahydrofuryloxyphenyl)-N-(3-pyridyl)-N-(3 pyridylmethyl)armine kk) 3 -Cyclopentyloxy-3 '-ethanesul fonylamino-4-methoxy-N-(3- pyridylmethyl)diphenylamine 11) 3-Cyclopentyloxy-4-methoxy-3 -propanesulfonylamino)-N-(3 pyridylxnethyl)diphenylamine 3 -Cyclopentyloxy-4 '-ethanesulfonylamino-4-methoxy-N-(3- pyridylmethyl)diphenylamine nn) 3-Cyclopentyloxy-4-inethoxy-4'-( 1-propanesulfonylamino)-N-(3 pyridylmethyl)diphenylamine oo) 3-Cyclopropylmethoxy-3 '-ethanesulfonylamino-4-methoxy-N-(3 pyridylmethyl)diphenylamine pp) 4-Difluoromethoxy-3 '-ethanesulfonylaniino-N-(3 -pyridylmnethyl)-3-[(3R)- tetrahydrof'uryloxy] diphenylamine qq) 4-Methoxy-3-[2-(2-pyridyl)ethoxy]-N-(3-pyridylmethyl)diphenylamine rr) 4-Methoxy-N-(3-pyridylmethyl)-3.[(3R)-tetrahydrofuryloxy]diphenylaniine ss) 3' -Chloro-4-methoxy-3-[2-(2-pyridyl)ethoxy] -N-(3-pyridylmethyl)diphenylamine tt) 3' -Chloro-4-methoxy-N-(3 -pyridylmethyl)-3-[(3R)- tetrahydrofuryloxy]diphenylamine uu) 3-Cyclopentyloxy-4-methoxy-4 '-(2-(5-oxopyrrolidinyl)methoxy] pyridylmethyl)diphenylaniine; and P kWPDOCSMDTrSp-cNl78255 15 do.3 IA)7/12lX7 0 -110- pharmaceutically acceptable salts thereof, 0 wherein if the compound exhibits chirality it can be in the form of a mixture of enantiomers such as a racemate or a mixture of diastereomers, or can be in the form of a single enantiomer or a single diastereomer. 0
40. A compound according to Formula I': R 1 R 3 X L R 3' R 2 I' wherein R' is methoxy, F, Cl, CHF 2 or CF 3 R 2 is alkyl having 1 to 12 carbon atoms, alkyl having 1 to 12 carbon atoms which is substituted one or more times by halogen, oxo, cyano, or combinations thereof, alkenyl having 2 to 12 carbon atoms, alkenyl having 2 to 12 carbon atoms which is substituted one or more times by halogen, oxo, cyano or combinations thereof, alkynyl having 2 to 12 carbon atoms, alkynyl having 2 to 12 carbon atoms which is substituted one or more times by halogen, oxo, cyano or combinations thereof, cycloalkyl having 3 to 10 carbon atoms, cycloalkyl having 3 to 10 carbon atoms substituted one or more times by halogen, oxo, alkyl, or combinations thereof, cycloalkylalkyl having 4 to 12 carbon atoms, P dWPDOCSVADTSp,-M255153doM.3IA7)M7 S- 111- cycloalkylalkyl having 4 to 12 carbon atoms which is substituted one or more times by halogen, oxo, alkyl or combinations thereof, 0 a partially unsaturated carbocyclic group having 5 to 14 carbon atoms, 00 Sa partially unsaturated carbocyclic group having 5 to 14 carbon atoms which is O 5 substituted one or more times by halogen, alkyl, alkyloxy, nitro, cyano, oxo, or N combinations thereof, Sarylalkyl having 7 to 26 carbon atoms arylalkyl having 7 to 26 carbon atoms which is substituted one or more times by halogen, alkyl, alkoxy, nitro, cyano, oxo, trifluoromethyl, or combinations thereof, heteroarylalkyl having 5 to 10 ring atoms in which at least 1 ring atom is a heteroatom, or substituted heteroarylalkyl having 5 to 10 ring atoms in which at least 1 ring atom is a heteroatom and which is substituted one or more times in the heteroaryl portion by halogen, aryl, alkyl, alkoxy, cyano, trifluoromethyl, nitro, amino, alkylamino, s1 dialkylamino or combinations thereof and/or substituted in the alkyl portion by halogen, oxo, cyano, or combinations thereof; X is O or S; R 3 is aryl having 6 to 14 carbon atoms, aryl having 6 to 14 carbon atoms which is substituted one or more times by halogen, alkyl, hydroxy, alkoxy, nitro, methylenedioxy, ethylenedioxy, amino, alkylamino, dialkylamino, hydroxyalkyl, hydroxyalkoxy, carboxy, cyano, acyl, alkoxycarbonyl, alkylthio, alkylsulfinyl, alkylsulfonyl, phenoxy, heteroaryl which is unsubstituted or substituted by halogen, alkyl or alkoxy, or combinations thereof, heteroaryl having 5 to 10 ring atoms in which at least 1 ring atom is a heteroatom, or P\ PDOCSMD1'Sp-c\k7H255 I5 dc.3 A7/2(IX) 0 -112- substituted heteroaryl having 5 to 10 ring atoms in which at least 1 ring atom is a heteroatom which is substituted one or more times by halogen, aryl, alkyl, alkoxy, cyano, trifluoromethyl, nitro, oxo, amino, alkylamino, dialkylamino or combinations thereof; 00 L is -NR 4 NR 4 CH 2 or -CH 2 NR4'-; and R 4 is alkyl having 1 to 12 carbon atoms, Salkyl having 1 to 12 carbon atoms which is substituted one or more times by halogen, oxo, cyano, or combinations thereof, aryl having 6 to 14 carbon atoms and which is unsubstituted or substituted one or more times by halogen, alkyl, hydroxy, alkoxy, nitro, methylenedioxy, ethylenedioxy, amino, alkylamino, dialkylamino, hydroxyalkyl, hydroxyalkoxy, carboxy, cyano, acyl, alkoxycarbonyl, alkylthio, alkylsulfinyl, alkylsulfonyl, phenoxy or combinations thereof, heteroaryl having 5 to 10 ring atoms in which at least 1 ring atom is a heteroatom, substituted heteroaryl having 5 to 10 ring atoms in which at least 1 ring atom is a heteroatom and which is substituted one or more times by halogen, aryl, alkyl, alkoxy, cyano, trifluoromethyl, nitro, oxo, amino, alkylamino, dialkylamino or combinations thereof, arylalkyl having 7 to 16 carbon atoms, arylalkyl having 7 to 16 carbon atoms which is substituted one or more times by halogen, alkyl, alkoxy, nitro, cyano, oxo, trifluoromethyl, or combinations thereof, heteroarylalkyl having 5 to 10 ring atoms in which at least 1 ring atom is a heteroatom, or substituted heteroarylalkyl having 5 to 10 ring atoms in which at least 1 ring atom is a heteroatom and which is substituted one or more times in the heteroaryl portion by halogen, aryl, alkyl, alkoxy, cyano, trifluoromethyl, nitro, oxo, amino, alkylamino, dialkylamino or combinations thereof and/or substituted in the alkyl portion by halogen, P \WPDOCS\MDTS s\7825515 dS3 oc/1 )7/2007 0 -113- oxo, cyano, or combinations thereof; and 0 pharmaceutically acceptable salts thereof, 00 wherein if the compound exhibits chirality it can be in the form of a mixture of Senantiomers such as a racemate or a mixture of diastereomers, or can be in the form of a single enantiomer or a single diastereomer.
41. A method for enhancing cognition in a patient in whom such enhancement C" is desired comprising administering to said patient an effective amount of a compound according to claim 1.
42. A method according to claim 41, wherein said compound is administered in to an amount of 0.01-100 mg/kg of body weight/day.
43. A method according to claim 41, wherein said patient is a human.
44. A method of treating a patient suffering from cognition impairment or decline comprising administering to said patient an effective amount of a compound according to claim 1. Is 45. A method according to claim 44, wherein said patient is a human.
46. A method according to claim 45, wherein said patient is suffering from memory impairment.
47. A method according to claim 44, wherein said compound is administered in an amount of 0.01-100 mg/kg of body weight/day.
48. A method according to claim 46, wherein said patient is suffering from memory impairment due to Alzheimer's disease, schizophrenia, Parkinson's disease, Huntington's disease, Pick's disease, Creutzfeldt-Jakob disease, depression, aging, head trauma, stroke, CNS hypoxia, cerebral senility, multiinfarct dementia, HIV or cardiovascular disease.
49. A method for treating a patient having a disease involving decreased cAMP P \WPDOCS\MDTnSpe\78255153 doc.-317/2()7 00 0 -114- levels comprising administering to said patient an effective amount of a compound according to claim
52. A composition according to claim 1.1, wherein said composition contains 0. 1-50 mg of said compound. A method of treainhibiting a patient suffering from memory imn a patient due to acomprising OO Sneurodegenerative disease comprising administering to said patient an effective amount of a compound according to claim 1. 51. A pharmaceutical composition comprising a compound according to claim
54. and a pharmaceutically acceptable carrient suffering from memory impairment due to an acute neurodegenerative disorder A composition according to claim 51, whinistering to said compositioent an effcntains 0.1-50 mgount of said compound according to claim 1. 53. A method of treating a patient suffering from an allmem ory impairment due inflammato a Sneurodegenerative disease comprising administering to said patient an effective amount of a compound a compound according to claim 1. 54. A method of treating a patient suffering from memory impairment due to an acute neurodegenerative disorder comprising administering to said patient an effective amount of a compound according to claim 1.
55. A method of treating a patient suffering from an allergic or inflammatory disease comprising administering to said patient an effective amount of a compound according to claim 1.
56. A compound of the Formula R 1 N/R3 R 2 R4 wherein: R' is H, tert-butyldimethylsilyl, 3 H 3 14CH 3 "CH 3 or a phenolic protective group; R 2 is alkyl having 1 to 12 carbon atoms, which is branched or unbranched and P \WPDOCS\MDTSpcc\78255 153 doc-.317/2XI)7 O -115- which is unsubstituted or substituted one or more times by halogen, hydroxy, cyano, CI-4- alkoxy, oxo or combinations thereof, and wherein optionally one or more -CH 2 CH 2 groups are replaced in each case by -CH=CH- or 00 cycloalkyl having 3 to 10 carbon atoms, which is unsubstituted or substituted one C s or more times by halogen, hydroxy, oxo, cyano, alkyl having 1 to 4 carbon atoms, alkoxy C having 1 to 4 carbon atoms, or combinations thereof, Scycloalkylalkyl having 4 to 16 carbon atoms, which is unsubstituted or substituted in the cycloalkyl portion and/or the alkyl portion one or more times by halogen, oxo, cyano, hydroxy, C 1 4 -alkyl, C -4-alkoxy or combinations thereof, aryl having 6 to 14 carbon atoms, which is unsubstituted or substituted one or more times by halogen, CF 3 OCF 3 alkyl, hydroxy, alkoxy, nitro, methylenedioxy, ethylenedioxy, cyano, or combinations thereof, arylalkyl in which the aryl portion has 6 to 14 carbon atoms and the alkyl portion, which is branched or unbranched, has 1 to 5 carbon atoms, which the arylalkyl radical is is unsubstituted or is substituted in the aryl portion one or more times by halogen, CF3, OCF 3 alkyl, hydroxy, alkoxy, nitro, cyano, methylenedioxy, ethylenedioxy, or combinations thereof, and wherein in the alkyl portion one or more -CH 2 CH 2 groups are each optionally replaced by -CH=CH- or and one or more -CH 2 groups are each optionally replaced by or -NH- and/or the alkyl portion is optionally substituted by halogen, oxo, hydroxy, cyano, or combinations thereof, a partially unsaturated carbocyclic group having 5 to 14 carbon atoms, which is unsubstituted or substituted one or more times by halogen, alkyl, alkoxy, hydroxy, nitro, cyano, oxo, or combinations thereof, a heterocyclic group, which is saturated, partially saturated or unsaturated, having to 10 ring atoms in which at least 1 ring atom is a N, O or S atom, which is unsubstituted or substituted one or more times by halogen, hydroxy, aryl, alkyl, alkoxy, cyano, trifluoromethyl, nitro, oxo, or combinations thereof, or P\WPDOCS\MDT1Spc\78255I 53 doc-31/0 7/2)7 S-116- a heterocycle-alkyl group, wherein the heterocyclic portion is saturated, partially saturated or unsaturated, and has 5 to 10 ring atoms in which at least 1 ring atom is a N, O or S atom, and the alkyl portion is branched or unbranched and has 1 to 5 carbon atoms, O the heterocycle-alkyl group is unsubstituted or substituted one or more times in the heterocyclic portion by halogen, OCF 3 hydroxy, aryl, alkyl, alkoxy, cyano, trifluoromethyl, nitro, oxo, or combinations thereof, wherein in the alkyl portion one or CN more -CH 2 CH 2 groups are each optionally replaced by -CH=CH- or and one or Smore -CH 2 groups are each optionally replaced by or -NH- and/or the alkyl portion is (N optionally substituted by halogen, oxo, hydroxy, cyano, or combinations thereof; R 3 is alkyl having 1 to 8 carbon atoms, which is branched or unbranched and which is unsubstituted or substituted one or more times with halogen, cyano, Ci-4-alkoxy, or combinations thereof, a partially unsaturated carbocycle-alkyl group wherein the carbocyclic portion has to 14 carbon atoms and the alkyl portion which is branched or unbranched has 1 to carbon atoms, and which is unsubstituted or substituted in the carbocyclic portion one or more times by halogen, alkyl, alkoxy, nitro, cyano, oxo, or combinations thereof, and the alkyl portion is optionally substituted by halogen, C 1 4 -alkoxy, cyano or combinations thereof, arylalkyl having 7 to 19 carbon atoms, wherein the aryl portion has 6 to 14 carbon atoms and the alkyl portion, which is branched or unbranched, has 1 to 5 carbon atoms, arylalkyl radical is unsubstituted or substituted, in the aryl portion, one or more times by halogen, trifluoromethyl, CF30, nitro, amino, alkyl, alkoxy, alkylamino, or dialkylamino and/or substituted in the alkyl portion by halogen, cyano or methyl, or heteroarylalkyl group, wherein the heteroaryl portion has 5 to 10 ring atoms in which at least 1 ring atom is a N, O or S atom, the alkyl portion, which is branched or unbranched, has 1 to 5 carbon atoms, the heteroarylalkyl group is unsubstituted or substituted one or more times in the heteroaryl portion by halogen, alkyl, alkoxy, cyano, trifluoromethyl, CF 3 0, nitro, oxo, amino, alkylamino, dialkylamino, or combinations thereof and/or substituted in the alkyl portion by halogen, cyano, or methyl or P \WPDOCSVMDT\Sp X78255 53 d.3 IA)7/f2(X)7 -117- combinations thereof; R 4 is aryl having 6 to 14 carbon atoms and which is unsubstituted or substituted one or more times by halogen, alkyl, alkenyl, alkynyl, hydroxy, alkoxy, alkoxyalkoxy, nitro, 00 methylenedioxy, ethylenedioxy, trifluoromethyl, OCF 3 amino, aminoalkyl, aminoalkoxy, dialkylamino, hydroxyalkyl, hydroxamic acid, tetrazole-5-yl, 2-(tetrahydropyranyl)- hydroxyalkoxy, carboxy, alkoxycarbonyl, cyano, acyl, alkylthio, alkylsulfinyl, alkylsulfonyl, phenoxy, trialkylsilyloxy, RS-L-, or combinations thereof, or heteroaryl having 5 to 10 ring atoms in which at least 1 ring atom is a heteroatom, which is unsubstituted or substituted one or more times by halogen, alkyl, hydroxy, alkoxy, io alkoxyalkoxy, nitro, methylenedioxy, ethylenedioxy, trifluoromethyl, amino, aminomethyl, aminoalkyl, aminoalkoxy dialkylamino, hydroxyalkyl hydroxamic acid, hydroxyalkoxy, carboxy, alkoxycarbonyl, cyano, acyl, alkylthio, alkylsulfinyl, alkylsulfonyl, phenoxy, trialkylsilyloxy R 5 dialkylamino-L-, or combinations thereof; R 5 is H, alkyl having 1 to 8 carbon atoms, which is unsubstituted or substituted one or more times with halogen, Ci. 4 -alkyl, C-4-alkoxy, oxo, or combinations thereof, alkylamino or dialkylamino wherein each alkyl portion has independently 1 to 8 carbon atoms, a partially unsaturated carbocycle-alkyl group wherein the carbocyclic portion has 5 to 14 carbon atoms and the alkyl portion has 1 to 5 carbon atoms, which is unsubstituted or substituted, preferably in the carbocyclic portion, one or more times by halogen, alkyl, alkoxy, nitro, cyano, oxo, or combinations thereof, cycloalkyl having 3 to 10 carbon atoms, which is unsubstituted or substituted one or more times by halogen, hydroxy, oxo, cyano, alkoxy, alkyl having 1 to 4 carbon atoms, or combinations thereof, cycloalkylalkyl having 4 to 16 carbon atoms, which is unsubstituted or substituted in the cycloalkyl portion and/or the alkyl portion one or more times by halogen, oxo, P WPDOCSMDpX\792551l dox-3 I A)12(X)7 0 -118- cyano, hydroxy, alkyl, alkoxy or combinations thereof, 0 aryl having 6 to 14 carbon atoms and which is unsubstituted or substituted one or more times by halogen, alkyl, hydroxy, alkoxy, alkoxyalkoxy, nitro, methylenedioxy, 00 ethylenedioxy, trifluoromethyl, amino, aminomethyl, aminoalkyl, aminoalkoxy dialkylamino, hydroxyalkyl, hydroxamic acid, tetrazole-5-yl, hydroxyalkoxy, carboxy, Calkoxycarbonyl, cyano, acyl, alkylthio, alkylsulfinyl, alkylsulfonyl, or combinations Sthereof, or arylalkyl having 7 to 19 carbon atoms, wherein the aryl portion has 6 to 14 carbon atoms and the alkyl portion, which is branched or unbranched, has 1 to 5 carbon atoms, arylalkyl radical is unsubstituted or substituted, in the aryl portion, one or more times by halogen, trifluoromethyl, CF 3 0, nitro, amino, alkyl, alkoxy, amino, alkylamino, dialkylamino and/or substituted in the alkyl portion by halogen, cyano, or methyl, a heterocyclic group, which is saturated, partially saturated or unsaturated, having to 10 ring atoms in which at least 1 ring atom is a N, O or S atom, which is unsubstituted or substituted one or more times by halogen, alkyl, hydroxy, alkoxy, alkoxyalkoxy, nitro, methylenedioxy, ethylenedioxy, trifluoromethyl, amino, aminomethyl, aminoalkyl, aminoalkoxy, dialkylamino, hydroxyalkyl, hydroxamic acid, hydroxyalkoxy, carboxy, alkoxycarbonyl, cyano, acyl, alkylthio, alkylsulfinyl, alkylsulfonyl, phenoxy, or combinations thereof; or a heterocycle-alkyl group, wherein the heterocyclic portion is saturated, partially saturated or unsaturated, and has 5 to 10 ring atoms in which at least I ring atom is a N, O or S atom, and the alkyl portion which is branched or unbranched and has 1 to 5 carbon atoms, the heterocycle-alkyl group is unsubstituted or substituted one or more times in the heterocyclic portion by halogen, alkyl, alkoxy, cyano, trifluoromethyl, CF 3 0, nitro, oxo, amino, alkylamino, dialkylamino, or combinations thereof and/or substituted in the alkyl portion by halogen, cyano, or methyl or combinations thereof; L is a single bond or a divalent aliphatic radical having 1 to 8 carbon atoms wherein one or more -CH 2 groups are each optionally replaced by -NR 6 P kWPDOCS\MDT\Spcc\78255153 doc.31)72(X)7 -119- S-SO 2 NH-, -NHSO 2 -NR 6 CO-, -CONR 6 -NHCONH-, -OCONH, -NHCOO-, -SCONH-, -SCSNH-, or -NHCSNH-; and R 6 is H, or alkyl having 1 to 8 carbon atoms, which is branched or unbranched and which is unsubstituted or substituted one or more times with halogen, C-4-alkyl, CI- 4 C 5 alkoxy, oxo, or combinations thereof; and CN pharmaceutically acceptable salts thereof, c wherein if the compound exhibits chirality it can be in the form of a mixture of enantiomers such as a racemate or a mixture of diastereomers, or can be in the form of a single enantiomer or a single diastereomer.
57. A compound of the Formula R 1 1 R2 R 4 wherein: R' is alkyl having 1 to 4 carbon atoms, which is branched or unbranched and which is unsubstituted or substituted one or more times by halogen; R 2 is H, tert-butyldimethylsilyloxy- or a phenolic protective group; R 3 is alkyl having 1 to 8 carbon atoms, which is branched or unbranched and which is unsubstituted or substituted one or more times with halogen, cyano, Ci-4-alkoxy, or combinations thereof, a partially unsaturated carbocycle-alkyl group wherein the carbocyclic portion has 5 to 14 carbon atoms and the alkyl portion which is branched or unbranched has 1 to carbon atoms, and which is unsubstituted or substituted in the carbocyclic portion one or more times by halogen, alkyl, alkoxy, nitro, cyano, oxo, or combinations thereof, and the alkyl portion is optionally substituted by halogen, Ci-4-alkoxy, cyano or combinations P WPDOCS IDT\Sp-c708235IS5ddc-3 Ift)7f(X)7 -120- thereof, O arylalkyl having 7 to 19 carbon atoms, wherein the aryl portion has 6 to 14 carbon atoms and the alkyl portion, which is branched or unbranched, has I to 5 carbon atoms, 00 arylalkyl radical is unsubstituted or substituted, in the aryl portion, one or more times by halogen, trifluoromethyl, CF 3 0, nitro, amino, alkyl, alkoxy, alkylamino, dialkylamino and/or substituted in the alkyl portion by halogen, cyano, or methyl, or heteroarylalkyl group, wherein the heteroaryl portion has 5 to 10 ring atoms in which at least I ring atom is a N, O or S atom, the alkyl portion, which is branched or unbranched, has 1 to 5 carbon atoms, the heteroarylalkyl group is unsubstituted or io substituted one or more times in the heteroaryl portion by halogen, alkyl, alkoxy, cyano, trifluoromethyl, CF 3 0, nitro, oxo, amino, alkylamino, dialkylamino, or combinations thereof and/or substituted in the alkyl portion by halogen, cyano, or methyl or combinations thereof; R 4 is aryl having 6 to 14 carbon atoms and which is unsubstituted or substituted one is or more times by halogen, alkyl, alkenyl, alkynyl, hydroxy, alkoxy, alkoxyalkoxy, nitro, methylenedioxy, ethylenedioxy, trifluoromethyl, OCF 3 amino, aminoalkyl, aminoalkoxy dialkylamino, hydroxyalkyl, hydroxamic acid, tetrazole-5-yl, 2-(tetrahydropyranyl)- hydroxyalkoxy, carboxy, alkoxycarbonyl, cyano, acyl, alkylthio, alkylsulfinyl, alkylsulfonyl, phenoxy, trialkylsilyloxy, R 5 or combinations thereof, or heteroaryl having 5 to 10 ring atoms in which at least 1 ring atom is a heteroatom, which is unsubstituted or substituted one or more times by halogen, alkyl, hydroxy, alkoxy, alkoxyalkoxy, nitro, methylenedioxy, ethylenedioxy, trifluoromethyl, amino, aminomethyl, aminoalkyl, aminoalkoxy dialkylamino, hydroxyalkyl hydroxamic acid, hydroxyalkoxy, carboxy, alkoxycarbonyl, cyano, acyl, alkylthio, alkylsulfinyl, alkylsulfonyl, phenoxy, trialkylsilyloxy RS-L-, dialkylamino-L-, or combinations thereof; is H, alkyl having 1 to 8 carbon atoms, which is unsubstituted or substituted one or more times with halogen, C 1 4 -alkyl, C 1 4 -alkoxy, oxo, or combinations thereof, P \WPDOCS\MDTSpecs\78255153 doc-3l )7/2(X)7 0D -121- alkylamino or dialkylamino wherein each alkyl portion has independently 1 to 8 carbon atoms, a partially unsaturated carbocycle-alkyl group wherein the carbocyclic portion has 00 to 14 carbon atoms and the alkyl portion has 1 to 5 carbon atoms, which is unsubstituted or substituted, preferably in the carbocyclic portion, one or more times by halogen, alkyl, Calkoxy, nitro, cyano, oxo, or combinations thereof, Scycloalkyl having 3 to 10 carbon atoms, which is unsubstituted or substituted one or more times by halogen, hydroxy, oxo, cyano, alkoxy, alkyl having 1 to 4 carbon atoms, or combinations thereof, cycloalkylalkyl having 4 to 16 carbon atoms, which is unsubstituted or substituted in the cycloalkyl portion and/or the alkyl portion one or more times by halogen, oxo, cyano, hydroxy, alkyl, alkoxy or combinations thereof, aryl having 6 to 14 carbon atoms and which is unsubstituted or substituted one or more times by halogen, alkyl, hydroxy, alkoxy, alkoxyalkoxy, nitro, methylenedioxy, ethylenedioxy, trifluoromethyl, amino, aminomethyl, aminoalkyl, aminoalkoxy, dialkylamino, hydroxyalkyl, hydroxamic acid, tetrazole-5-yl, hydroxyalkoxy, carboxy, alkoxycarbonyl, cyano, acyl, alkylthio, alkylsulfinyl, alkylsulfonyl, or combinations thereof, or arylalkyl having 7 to 19 carbon atoms, wherein the aryl portion has 6 to 14 carbon atoms and the alkyl portion, which is branched or unbranched, has 1 to 5 carbon atoms, arylalkyl radical is unsubstituted or substituted, in the aryl portion, one or more times by halogen, trifluoromethyl, CF 3 0, nitro, amino, alkyl, alkoxy, amino, alkylamino, dialkylamino and/or substituted in the alkyl portion by halogen, cyano, or methyl, a heterocyclic group, which is saturated, partially saturated or unsaturated, having to 10 ring atoms in which at least 1 ring atom is a N, O or S atom, which is unsubstituted or substituted one or more times by halogen, alkyl, hydroxy, alkoxy, alkoxyalkoxy, nitro, methylenedioxy, ethylenedioxy, trifluoromethyl, amino, aminomethyl, aminoalkyl, aminoalkoxy, dialkylamino, hydroxyalkyl, hydroxamic acid, P \WPDOCS\M DT\Spcc\78255153 doc.-3) 1)7/2r 0 -122- hydroxyalkoxy, carboxy, alkoxycarbonyl, cyano, acyl, alkylthio, alkylsulfinyl, alkylsulfonyl, phenoxy, or combinations thereof; or a heterocycle-alkyl group, wherein the heterocyclic portion is saturated, partially 00 saturated or unsaturated, and has 5 to 10 ring atoms in which at least 1 ring atom is a N, O or S atom, and the alkyl portion which is branched or unbranched and has 1 to 5 carbon C atoms, the heterocycle-alkyl group is unsubstituted or substituted one or more times in the Sheterocyclic portion by halogen, alkyl, alkoxy, cyano, trifluoromethyl, CF 3 0, nitro, oxo, C amino, alkylamino, dialkylamino, or combinations thereof and/or substituted in the alkyl portion by halogen, cyano, or methyl or combinations thereof; L is a single bond or a divalent aliphatic radical having 1 to 8 carbon atoms wherein one or more -CH 2 groups are each optionally replaced by -NR 6 -SO 2 NH-, -NHSO 2 -NR6CO-, -CONR 6 -NHCONH-, -OCONH, -NHCOO-, -SCONH-, -SCSNH-, or -NHCSNH-; and R 6 is H, oralkyl having 1 to 8 carbon atoms, which is branched or unbranched and which is unsubstituted or substituted one or more times with halogen, C-4-alkyl, C- 4 alkoxy, oxo, or combinations thereof; and pharmaceutically acceptable salts thereof, wherein if the compound exhibits chirality it can be in the form of a mixture of enantiomers sucy as a racemate or a mixture of diastereomers, or can be in the form of a single enantiomer or a single diastereomer.
58. A compound selected from: a) 3-tert-Butyldimethylsilyloxy-4-methoxy-N-(3-pyridylmethyl) diphenylamine; b) 3-tert-Butyldimethylsilyloxy-3'-chloro-4-methoxy-N-(3-pyridylmethyl) diphenylamine; c) Ethyl N-(3-tert-butyldimethylsilyloxy-4-methoxyphenyl)-N-(3- P PDGCSW~DTSp cV\T255 I5 d%.31 A 17121W7 -123- ;Z ~pyridylmethyl)-3 -am inobenzoate; d) 3 -Cyclopentyloxy-4-methoxydiphenylam ine; 00 e) 3-Hydroxy-4-methoxy-N-(3-pyridylmethyl)diphenylamine; f) 3'-Chloro-3-hydroxy-4-methoxy-N-(3-pyridylmethyl)diphenylamine; g) Ethyl N-(3-hydroxy-4-methoxyphenyl)-N-(3-pyridylmethyl)-3- aminobenzoate; h) 3'-(2-Bromoethoxy)-3-cyclopentyloxy-4-methoxy-N-(3- pyridylmethyl)diphenylamine; i) 1 -Bromopropyl)oxy]-3-cyclopentyloxy-4-methoxy-N-(3- pyridylmethyl)diphenylamine; and j) 4-hydroxy-3-cyclopentyloxy-N-(3-pyridylmethyl)diphenlamine wherein if the compound exhibits chirality it can be in the form of a mixture of enantiomers such as a racemnate or a mixture of diastereomers, or can be in the form of a single enantiomer or a single diastereomer.
59. A compound according to claim 1, wherein said compound is N-3,4- bis(difluoromethoxy)phenyl-N-(3-pyridylmethyl)-3-aminobenzoic acid or a pharmaceutically acceptable salt thereof. A compound according to claim 1, wherein said compound is N-(3- cyclopentyloxy-4-methoxyphenyl)-N-(3-pyridylmethyl)-3-aminobenzoic acid or a pharmaceutically acceptable salt thereof.
61. A method according to claim 43, wherein said compound is N-3,4- bis(difluoromethoxy)phenyl-N-(3-pyridylmethyl)-3-aminobenzoic acid or a pharmaceutically acceptable salt thereof.
62. A method according to claim 49, wherein said compound is N-3,4- P \WPDOCS\MDTp\SDpc\78255 153 doc-3 A)7r2 O -124- bis(difluoromethoxy)phenyl-N-(3-pyridylmethyl)-3-aminobenzoic acid or a pharmaceutically acceptable salt thereof.
63. A method according to claim 62, wherein said disease is depression. 00
64. A method according to claim 43, wherein said compound is N-(3- cyclopentyloxy-4-methoxyphenyl)-N-(3-pyridylmethyl)-3-aminobenzoic acid or a C pharmaceutically acceptable salt thereof. A composition according to claim 51, wherein said compound is N-3,4- bis(difluoromethoxy)phenyl-N-(3-pyridylmethyl)-3-aminobenzoic acid or a pharmaceutically acceptable salt thereof.
66. A composition according to claim 51, wherein said compound is N-(3- cyclopentyloxy-4-methoxyphenyl)-N-(3-pyridylmethyl)-3-aminobenzoic acid or a pharmaceutically acceptable salt thereof.
67. A composition according to any one of claims 51, 65 or 66, wherein said composition further comprises an additional pharmaceutical agent selected from calcium channel blockers, cholinergic drugs, adenosine receptor modulators, ampakines, NMDA-R modulators, mGluR modulators, cholinesterase inhibitors, or any combination thereof.
68. Compounds of formula I, as claimed in any one of claims 1 to 40, 59 or methods for their synthesis, compositions containing same and/or uses thereof, substantially as herein described with reference to the examples.
69. A method according to claim 55, wherein the disease is asthma. A method according to claim 55, wherein the disease is chronic obstructive pulmonary disease (COPD).
AU2002303078A 2001-01-22 2002-01-22 Aniline derivatives useful as phosphodiesterase 4 inhibitors Ceased AU2002303078B2 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US26265101P 2001-01-22 2001-01-22
US60/262,651 2001-01-22
US26719601P 2001-02-08 2001-02-08
US60/267,196 2001-02-08
US30614001P 2001-07-19 2001-07-19
US60/306,140 2001-07-19
PCT/US2002/001508 WO2002074726A2 (en) 2001-01-22 2002-01-22 Aniline derivatives useful as phosphodiesterase 4 inhibitors

Publications (2)

Publication Number Publication Date
AU2002303078A1 AU2002303078A1 (en) 2003-03-27
AU2002303078B2 true AU2002303078B2 (en) 2007-08-30

Family

ID=27401532

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002303078A Ceased AU2002303078B2 (en) 2001-01-22 2002-01-22 Aniline derivatives useful as phosphodiesterase 4 inhibitors

Country Status (23)

Country Link
EP (1) EP1353907A2 (en)
JP (1) JP4223287B2 (en)
KR (1) KR100856622B1 (en)
CN (1) CN100378075C (en)
AU (1) AU2002303078B2 (en)
BG (1) BG108003A (en)
BR (1) BR0206943A (en)
CA (1) CA2435847A1 (en)
CL (1) CL2004001165A1 (en)
CZ (1) CZ20031986A3 (en)
EE (1) EE05362B1 (en)
HR (1) HRP20030662A2 (en)
HU (1) HUP0302793A3 (en)
IL (1) IL156958A0 (en)
MA (1) MA25996A1 (en)
MX (1) MXPA03006519A (en)
NO (1) NO329548B1 (en)
NZ (1) NZ527081A (en)
PL (1) PL373301A1 (en)
SK (1) SK9152003A3 (en)
WO (1) WO2002074726A2 (en)
YU (1) YU57603A (en)
ZA (1) ZA200305623B (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003256616B2 (en) * 2002-07-19 2009-08-27 Memory Pharmaceuticals Corporation Phosphodiesterase 4 inhibitors, including N-substituted aniline and diphenylamine analogs

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7153871B2 (en) 2001-01-22 2006-12-26 Memory Pharmaceuticals Corporation Phosphodiesterase 4 inhibitors, including aminoindazole and aminobenzofuran analogs
MXPA03007261A (en) * 2001-02-14 2006-03-09 Abbott Lab Glucocorticoid receptor modulators.
DE60325984D1 (en) 2002-07-19 2009-03-12 Memory Pharmaceutical Corp 4-AMINOBENZOFURAN COMPOUNDS AS PHOSPHODIESTERASE-4 INHIBITORS
CA2506297A1 (en) * 2002-11-19 2004-06-03 Memory Pharmaceuticals Corporation Pyridine n-oxide compounds as phosphodiesterase 4 inhibitors
AU2003286024A1 (en) * 2002-11-22 2004-06-18 Daniel Dube Use of phosphodiesterase-4 inhibitors as enhancers of cognition
ES2282701T3 (en) * 2002-12-27 2007-10-16 H. Lundbeck A/S USEFUL 1,2,4-TRIAMINOBENCENE DERIVATIVES TO TREAT CENTRAL NERVOUS SYSTEM DISORDERS.
FR2856595B1 (en) * 2003-06-27 2008-05-30 Exonhit Therapeutics Sa METHODS AND COMPOSITIONS FOR TREATING COGNITIVE DEFICITS.
JP2007504201A (en) 2003-09-05 2007-03-01 アルタナ　ファルマ　アクチエンゲゼルシャフト Use of PDE4 inhibitors for the treatment of diabetes mellitus
MY141255A (en) * 2003-12-11 2010-03-31 Memory Pharm Corp Phosphodiesterase 4 inhibitors, including n-substituted diarylamine analogs
MX2007000480A (en) 2004-07-15 2007-03-29 Japan Tobacco Inc Fused benzamide compound and vanilloid receptor 1 (vr1) activity inhibitor.
US20070287716A1 (en) * 2004-10-28 2007-12-13 Hu Essa H Pyrimidine and Quinoline Potentiators of Metabotropic Glutamate Receptors
EP1874308A1 (en) 2005-03-08 2008-01-09 Nycomed GmbH Roflumilast for the treatment of diabetes mellitus
JP2008543781A (en) * 2005-06-10 2008-12-04 メモリー・ファーマシューティカルズ・コーポレイション Phosphodiesterase 4 inhibitor
AR057455A1 (en) * 2005-07-22 2007-12-05 Merck & Co Inc INHIBITORS OF HIV REVERSE TRANSCRIPTASE AND PHARMACEUTICAL COMPOSITION
US7906508B2 (en) 2005-12-28 2011-03-15 Japan Tobacco Inc. 3,4-dihydrobenzoxazine compounds and inhibitors of vanilloid receptor subtype 1 (VRI) activity
CA2676715A1 (en) 2007-02-12 2008-08-21 Merck & Co., Inc. Piperazine derivatives for treatment of ad and related conditions
EP2110375A1 (en) * 2008-04-14 2009-10-21 CHIESI FARMACEUTICI S.p.A. Phosphodiesterase-4 inhibitors belonging to the tertiary amine class
EP2291181B9 (en) 2008-04-18 2013-09-11 University College Dublin National University Of Ireland, Dublin Captodiamine for the treatment of depression symptoms
WO2010041449A1 (en) * 2008-10-09 2010-04-15 国立大学法人 岡山大学 Anti-allergic agent comprising rxr agonist as active ingredient
HRP20191460T1 (en) * 2009-06-12 2019-11-15 Abivax COMPOUNDS USEFUL FOR TREATMENT OF CANCER
US10253020B2 (en) 2009-06-12 2019-04-09 Abivax Compounds for preventing, inhibiting, or treating cancer, AIDS and/or premature aging
SI2440547T1 (en) 2009-06-12 2023-05-31 Abivax New chemical molecules that inhibit the splicing mechanism for the treatment of diseases resulting from splicing defects
JP6023926B2 (en) 2010-02-12 2016-11-09 株式会社ＡｓｋＡｔ 5-HT4 receptor agonists for the treatment of dementia
WO2013118855A1 (en) 2012-02-09 2013-08-15 塩野義製薬株式会社 Heterocyclic ring and carbocyclic derivative
CN102603676B (en) * 2012-02-20 2014-02-12 徐江平 A phosphodiesterase 4 inhibitor that avoids the vomiting response
CA2859842C (en) * 2012-03-14 2016-11-08 Sinochem Corporation Substitute diphenylamine compounds use thereof as antitumor agents
EP2757161A1 (en) 2013-01-17 2014-07-23 Splicos miRNA-124 as a biomarker of viral infection
CN105530938B (en) 2013-07-05 2019-10-22 Abivax公司 Compounds for the treatment of diseases caused by retroviruses
AU2014307803A1 (en) 2013-08-16 2016-03-10 Universiteit Maastricht Treatment of cognitive impairment with PDE4 inhibitor
EP2974729A1 (en) 2014-07-17 2016-01-20 Abivax Quinoline derivatives for use in the treatment of inflammatory diseases
EP3669873A1 (en) 2018-12-20 2020-06-24 Abivax Quinoline derivatives for use ine the traeatment of inflammation diseases
CN121609673A (en) * 2026-02-02 2026-03-06 五邑大学 PDE4 inhibitor and preparation method and application thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996021435A1 (en) * 1995-01-10 1996-07-18 Euro-Celtique, S.A. Compounds for and method of inhibiting phosphodiesterase iv

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6971894A (en) * 1993-05-27 1994-12-20 Smithkline Beecham Laboratoires Pharmaceutiques Anti-arrhythmic n-substituted 3-benzazepines or isoquinolines
JPH07206789A (en) * 1993-09-01 1995-08-08 Taisho Pharmaceut Co Ltd Combretastatin analogs
FR2729142A1 (en) * 1995-01-06 1996-07-12 Smithkline Beecham Lab New heterocyclic amine derivs.
CA2295106C (en) * 1997-06-24 2007-03-13 Nikken Chemicals Co., Ltd. 3-anilino-2-cycloalkenone derivatives
JP4649046B2 (en) * 1999-05-21 2011-03-09 ブリストル−マイヤーズ スクイブ カンパニー Pyrrotriazine inhibitor of kinase
EP1116711B1 (en) * 1999-12-18 2005-12-14 Wella Aktiengesellschaft 2-aminoalkyl-1,4-diaminobenzene derivatives and dye composition containing these compounds

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996021435A1 (en) * 1995-01-10 1996-07-18 Euro-Celtique, S.A. Compounds for and method of inhibiting phosphodiesterase iv

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003256616B2 (en) * 2002-07-19 2009-08-27 Memory Pharmaceuticals Corporation Phosphodiesterase 4 inhibitors, including N-substituted aniline and diphenylamine analogs

Also Published As

Publication number Publication date
KR20040064606A (en) 2004-07-19
YU57603A (en) 2006-08-17
CA2435847A1 (en) 2002-09-26
HUP0302793A2 (en) 2003-11-28
MXPA03006519A (en) 2004-10-15
CL2004001165A1 (en) 2005-04-15
EE05362B1 (en) 2010-12-15
CZ20031986A3 (en) 2003-12-17
BG108003A (en) 2004-09-30
SK9152003A3 (en) 2004-04-06
IL156958A0 (en) 2004-02-08
CN1498211A (en) 2004-05-19
HUP0302793A3 (en) 2006-01-30
HRP20030662A2 (en) 2005-06-30
HK1066215A1 (en) 2005-03-18
EP1353907A2 (en) 2003-10-22
NO20033288L (en) 2003-09-22
JP2005507365A (en) 2005-03-17
NO329548B1 (en) 2010-11-08
WO2002074726A3 (en) 2003-03-13
ZA200305623B (en) 2005-01-26
EE200300347A (en) 2003-12-15
BR0206943A (en) 2006-01-24
NZ527081A (en) 2006-03-31
MA25996A1 (en) 2003-12-31
PL373301A1 (en) 2005-08-22
KR100856622B1 (en) 2008-09-03
JP4223287B2 (en) 2009-02-12
WO2002074726A2 (en) 2002-09-26
CN100378075C (en) 2008-04-02
NO20033288D0 (en) 2003-07-21

Similar Documents

Publication Publication Date Title
AU2002303078B2 (en) Aniline derivatives useful as phosphodiesterase 4 inhibitors
US7405230B2 (en) Phosphodiesterase 4 inhibitors, including N-substituted aniline and diphenylamine analogs
AU2002303078A1 (en) Aniline derivatives useful as phosphodiesterase 4 inhibitors
RS57603B1 (en) Composition and method for diagnosis and treatment of diseases associated with neurite degeneration
US20050222207A1 (en) Phosphodiesterase 4 inhibitors, including N-substituted diarylamine analogs
US7087625B2 (en) Phosphodiesterase 4 inhibitors
US6699890B2 (en) Phosphodiesterase 4 inhibitors
US20030149052A1 (en) Phosphodiesterase 4 inhibitors
US7205320B2 (en) Phosphodiesterase 4 inhibitors
US20090048255A1 (en) Phosphodiesterase 4 inhibitors, including n-substituted aniline and diphenylamine analogs
KR20050019904A (en) Phosphodiesterase 4 inhibitors, including n-substituted aniline and diphenylamine analogs
HK1066215B (en) Aniline derivatives useful as phosphodiesterase 4 inhibitors

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired